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12Abstract
Neuropilin-1 (NRP1) is a co-receptor required for neuronal and vascular development,
which binds to class 3 semaphorins and VEGFs. NRP1 has been strongly implicated in
VEGF-induced endothelial cell migration. VEGF has been shown to regulate vascular
smooth muscle cell (VSMC) function in vitro. Evidence from mutant mice also suggests
that NRP1 disruption in vivo can aect VSMC as well as endothelial function. I there-
fore investigated the role of NRPs in VSMC biological functions and more particularly in
their migration. Western blotting showed that NRP1 and the related molecule, NRP2,
were strongly expressed in human coronary artery SMC (HCASMC), whereas the major
VEGF signalling receptor VEGFR2/KDR was not detectable. A high molecular weight
NRP1-immunoreactive band (>250 kDa) was also strongly expressed in HCASMC, but
was not detected either in cognate Human coronary artery endothelial cells (HCAEC) or in
Human umbilical vein EC. The high molecular weight species was decreased signicantly
by treating the SMCs with chondroitinase, an enzyme that specically chondroitin sul-
phate (CS) residues found in CS proteoglycan. Treatment with heparitinase, an enzyme
that specically heparan sulphate (HS) residues also resulted in a decrease of the high
molecular weight band but to a lesser extent than chondroitinase. Finally, treatment of
SMC with both enzymes caused the complete disappearance of the high molecular weight
species. Hence, in SMCs, in addition to the known NRP1 species at 130 kDa, NRP1
exists as a glycosaminoglycan containing either chondroitin sulphate or heparan sulphate
polysaccharide chains.
Mutational analysis of candidate O-linked glycosylation sites in the NRP1 extracellular
domain showed that glycosylation occurred at serine 612. The importance of this gly-
cosaminoglycan (GAG) modication was assessed by generating a construct of NRP1
lacking this GAG modication, called S612A. This was done by generation of an aden-
ovirus NRP1 mutant with an alanine residue instead of the serine found in the wild-type
13species, however, the over-expression of the S612A NRP1 mutant in VSMC caused no
signicant dierence in PDGF-induced HCASMC migration.
VEGF was able to bind signicantly to ECs and SMCs but did not induce a signicant
migratory response of SMCs in contrast to PDGF-AA and PDGF-BB. PDGF-BB-induced
HCASMC migration in transwell assays was inhibited by EG3287, a NRP1-specic an-
tagonist, which blocks the ability of VEGF-A165 to bind to NRP1. Furthermore, the
migratory response to PDGF-BB was signicantly decreased by siRNA-mediated knock-
down of NRP1, NRP2 or a neuropilin interacting protein (NIP1 or synectin), and by
pre-treatment with soluble NRP1 or NRP1 b1 domain (NRP1 VEGF binding domain).
NRP1 knockdown also inhibited the migratory response to PDGF-AA.
NRP1 was found to physically interact with PDGFR, but not with PDGFR, as de-
termined by co-immunoprecipitation. PDGFR, but not PDGFR, phosphorylation was
decreased in response to PDGF-AA and PDGF-BB when NRP1 was knocked down in
HCASMC.
Intracellular signalling in response to PDGF-BB stimulation was investigated in HCASMCs
with NRP1 knockdown. PDGF-BB stimulated tyrosine phosphorylation of the adapter
protein p130Cas, which has been stronlgy implicated in cellular and molecular processes
involved in cell migration. NRP1 knockdown reduced p130Cas phosphorylation, but had
little eect on signalling pathways, such as ERK1/2, Akt, colin, Hsp27 and FAK. To
investigate the contribution of the NRP1 intracellular domain in PDGF-induced migra-
tion and signalling, I generated a NRP1 construct lacking the intracellular domain by
introducing a stop codon after the transmembrane domain. Overexpression of NRP1 lack-
ing its C-terminus in HCASMC resulted in a decrease of PDGF-induced migration and
activation of phospho-p130Cas. Furthermore, p130Cas knockdown also inhibited PDGF-
induced HCASMC migration, thus reinforcing the importance of p130Cas phosphorylation
in NRP1-dependent cell migration.
The ndings that NRP1 is strongly expressed in HCASMC in a CS-GAG and a HS-GAG
modied form and plays a role in the chemotactic response to PDGF-BB, highlight the
possible involvement of NRPs in neotintima formation in vasculoproliferative diseases.
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26Chapter 1
Introduction
The formation of the vascular system and the function of the adult vasculature are com-
plex processes that involve many cell types and are regulated by many factors, their
receptors and eectors. During early embryonic vascular development, the dierentiation
of angioblasts from the mesoderm and the formation of primitive blood vessels from an-
gioblasts are the two distinct steps which occur at the onset of vascularisation and dene
vasculogenesis (Risau and Flamme, 1995). Later, the primitive vascular system undergoes
a complex process of remodelling of the primary vascular plexus with formation of new
vessels from pre-existing ones: this process is known as angiogenesis (Risau, 1997; ten
Dijke and Arthur, 2007) (Figure 1.1).
1.1 Vasculogenesis and development of the primary
vascular plexus
In both avian and mammalian embryos, blood vessels are rst observed in the yolk sac
and it was initially thought that they arose from extraembryonic tissues. However, histo-
logical analysis later indicated that endothelial cells can also be observed in the embryo,
suggesting that blood vessels come from an intraembryonic source. It is now commonly
accepted, that endothelial cell progenitors exclusively arise from the mesoderm (Fergu-
son et al., 2005). The pluripotency of vascular precursors has also proved a complex
issue to clarify. Indeed, colocalisation of endothelial and hematopoietic precursors (in the
so-called blood islands) within the yolk-sac has been recognised since the beginning of
the 20th century (Sabin, 2002) and is induced by signals from the endoderm (Ferguson
et al., 2005). This raised the possibility that both cell types originate from a common
precursor, the hemangioblast. The existence of this common precursor was suggested by
defects in both cell lineages in embryos lacking the vascular endothelial growth factor re-
ceptor 2 (VEGFR2) (Shalaby et al., 1995). Also recent evidence indicates that cells with
hemangioblast properties are present transiently in the posterior segment of the primi-
27tive streak during gastrulation and are dened by the co-expression of VEGFR2 and the
mesodermal T-box gene brachyury (Huber et al., 2004). Nevertheless, in some cases, he-
mangioblasts do not seem to be an essential step for all endothelial development, and
direct dierentiation of angioblasts from mesoderm is also thought to occur (Drake and
Fleming, 2000; Pardanaud and Dieterlen-Livre, 1993). Moreover, the denitive isolation
and localisation of the hemangioblasts within the embryo is still awaited. Drake (2003)
described the following as essential steps in vasculogenesis: 1) the birth of angioblasts;
2) angioblast aggregation; 3) elongation of angioblasts into cord-like structures; 4) the
organisation of isolated vascular segments into capillary-like-networks and, concomitant
with step four; 5) endothelialisation and lumenisation. Targeted gene deletion established
the vascular endothelial growth factor A165 (VEGF-A165) gene and its related receptor
Flk-1/KDR/VEGFR2 as major regulators of the vasculogenesis process (Carmeliet et al.,
1996; Ferrara et al., 1996; Fong et al., 1995). These regulatory systems are conserved
amongst species especially in mammals and birds, reptiles and amphibians (Figg and
Folkman, 2008).
281.2 Angiogenesis
1.2.1 Sprouting and non-sprouting angiogenesis
After the embryo has formed the primary vascular plexus, further blood vessels are formed
through a process called angiogenesis. Angiogenesis can be of two types, sprouting and
intussusceptive. Intussusception involves the splitting of pre-existing vessels in situ by
transcapillary pillars or extracellular matrix (Patan et al., 1996) and is commonly found
in the yolk sac and the developing lungs (Short, 1950) and during tumour vascularisation.
By contrast, in sprouting angiogenesis, endothelial cells proliferate behind the tip cell
of a growing branch in response to cytokines such as vascular endothelial growth factor
(VEGF) and lumens form by vacuole fusion. Tip cells are specialised endothelial cells
situated at the leading edge of vascular sprouts. They are lumenless and characterised by
lipodia extensions that integrate directional cues from their environment (Gerhardt et al.,
2003). Sprouting angiogenesis involves proteolytic degradation of the extracellular matrix
followed by chemotactic migration towards an unvascularised region and proliferation of
endothelial cells, formation of a lumen and nally functional maturation of the endothelium
(Risau, 1997). In both forms of angiogenesis, the nal step of the angiogenic process
is to stabilise the newly-formed vessels through the recruitment of mural cells such as
smooth muscle cells (SMCs) and pericytes (Gerhardt and Betsholtz, 2003; Hellstrom et al.,
1999), and the integration of the vessel into the surrounding matrix. The endpoint of
angiogenesis is a network that meets the nutritional and functional requirement of an
organ i.e. transportation of oxygen and nutrients to, and removal of waste products from,
the tissues.
1.2.2 Regulation of angiogenesis
Physiological angiogenesis occurs mainly during development. In the adult, this process
is infrequent and occurs mostly in repair processes such as wound, fracture healing, and
in the female reproductive system during the menstrual cycle and pregnancy. In these
contexts, angiogenesis is transient and tightly regulated. By contrast, pathological and of-
ten uncontrolled or poorly regulated angiogenesis occurs in many diseases such as cancer,
diabetic retinopathy, retinal vein occlusion, rheumatoid arthritis, psoriasis and cardiovas-
cular diseases. In the majority of these diseases, the common characteristics of pathological
vascularisation include abnormal vascular permeability, defective vascular remodelling and
29Figure 1.1: Vasculogenesis and angiogenesis
This illustration shows the processes of vasculogenesis corresponding to the de novo for-
mation of blood vessels from endothelial cell precursors, the angioblasts and angiogenesis
corresponding to the formation of blood vessels from pre-existing one, Figure from ten
Dijke and Arthur (2007).
30maturation leading to leakage, haemorrhaging and inammation (Gerhardt and Betsholtz,
2003).
The rst characterised endothelial specic growth factor, VEGF, is the most potent and
critical vascular regulator, as it is required for vasculogenesis and angiogenesis during
development as well as in the adult. Its expression must be tightly regulated in a spatial,
temporal and quantitative manner to avoid profound vascular defects (Yancopoulos et al.,
2000). This is illustrated by the disruption of both VEGF alleles in mice which mimics
knockout of VEGFR2, resulting in the almost complete absence of a vasculature and death
in utero between days 8.5 and 9.5. Even loss of a single VEGF allele leads to embryonic
lethality due to severe vascular abnormalities between day 11 and 12, which constitute
probably the most severe autosomal phenotype due to heterozygous deciency known to
date (Carmeliet et al., 1996; Ferrara et al., 1996).
Other growth factors such as angiopoietin-1 (Ang1) and ephrin-B2, are required for the
maturation of the primary plexus, with ephrin-B2 and its receptor, ephrin receptor B4
(EphB4), having an important role in segregating developing blood vessels. Ang1 plays
a role in the maintenance of a quiescent and stable mature vasculature. Disruption of
this stabilising signal or its receptor Tie2 leads to embryonic lethality at E9.5 to E12.5
but does not impair the formation of the primary vascular plexus. However, vascular
remodelling is compromised as the endothelial cells fail to form appropriate contact with
their supporting cells, suggesting a role for mediating reciprocal interactions between the
endothelium (expressing Tie2) and surrounding matrix and mesenchyme (expressing Ang1)
(Suri et al., 1996). Deletion of ephrin-B2 and EphB4 genes result in fatal defects in early
angiogenic remodelling that resemble those seen in mice lacking Ang1 or Tie2 (Wang
et al., 1998; Adams et al., 1999). Ephrin-B2 is expressed by the endothelium of primordial
arterial vessels while EphB4 marks the endothelium of primordial venous vessels (Gerety
et al., 1999), indicating a role for both in the establishement of arterial-venous identity.
311.3 Biology of endothelial cells
All blood and lymphatic vessels are lined by endothelial cells and form a layer called
the endothelium. First thought to be only a static physical barrier, the endothelium is
now regarded as a dynamic and heterogeneous organ that possesses secretory, synthetic,
metabolic, and immunologic functions (Aird, 2004).
1.3.1 Structure
Being composed of a single layer of at scale-like cells that are all in contact with a
basement membrane, the endothelium is described as a squamous epithelium. Endothelial
cells are very at, between 135 m in diameter and up to 5 m in depth (Limaye and Vadas,
2007). The cytoplasm is relatively simple with few organelles, mostly concentrated in the
perinuclear zone. Another prominent feature of ECs is the presence of many pinocytotic
vesicles which are involved in the process of transport of substances from one side of the
cell to the other.
1.3.2 Function
Endothelial cells are involved in many aspects of vascular biology, including:
 Vasoconstriction and vasodilation, and hence the control of blood pressure,
 Coagulation (thrombosis & brinolysis),
 Atherosclerosis,
 Formation of new blood vessels (angiogenesis),
 Inammation and oedema,
 Filtering and tracking funtions, particularly in the renal glomerulus and in the
blood-brain barrier to allow transit of white blood cells in and out of the bloodstream.
Several of these essential functions will be briey reviewed below.
32Control of blood pressure
ECs regulate vascular ow and basal vasomotor tone, and therefore blood pressure, by the
tightly controlled release of vasodilators, eg. nitric oxide (NO) and prostacyclin (PGl2) and
vasoconstrictors eg. endothelins and platelet activating factor (PAF), NO and endothelins,
being the main regulators of basal vascular tone (Limaye and Vadas, 2007).
NO is synthetised by the constituvely active endothelial NO synthase that can be further
induced by receptor dependent agonists such as thrombin or shear stress (Topper et al.,
1996; Venema et al., 1994). NO has multiple eects in the vasculature, causing not only
SMC relaxation by binding to guanylyl cyclase and hence maintaining basal vasomotor
tone, but also inhibiting platelet aggregation (Mendelsohn et al., 1990), and inhibiting
SMC proliferation (Zuckerbraun et al., 2007).
The endothelins (ETs) are a family of 21 amino acid peptides, of which ECs and SMCs
produce mainly the ET-1 isoform. Production of ET-1 is induced by hypoxia, ischaemia
and shear stress, which induce the transcription of ET-1 mRNA, with rapid secretion of
ET-1 within minutes. The majority of ET-1 secretion is towards the abluminal side of
the EC and thus it acts in a paracrine manner by binding to ETA receptors on smooth
muscle cells, to cause vasoconstriction. It also has some autocrine eects through the
ETB receptor on endothelial cells, activation of which causes NO and prostacyclin release
(Rosendor, 1997).
Coagulation
The quiescent endothelium possesses anticoagulant activity by providing an anti-thrombotic
surface which inhibits the coagulation cascade. One of the major strategies used by ECs
to maintain anticoagulant activity is to prevent activation of thrombin which, if acti-
vated, converts soluble brinogen into insoluble strands of brin, stimulates coagulation
by causing platelet activation and the activation of several coagulation factors (Limaye
and Vadas, 2007). ECs express heparan sulphate proteoglycan (HSPG), which along
with glycosaminoglycans in the ECM, is able to stimulate antithrombin-III (Rosenberg,
1985). They also express tissue factor pathway inhibitor (TFPI) that prevents thrombin
formation, and express thrombomodulin (Dielis et al., 2008). Therefore in the healthy en-
dothelium, the balance is towards the expression of anticoagulant factors to ensure smooth
uninterrupted blood ow in the vessels.
33Angiogenesis
Angiogenesis corresponds to the formation of new blood vessels from pre-existing ones.
This process involves the degradation of ECM by ECs, as well as their migration, prolifer-
ation and the formation of tubes in association with mural cells. To ensure the successful
outcome of vessel formation, it is essential for ECs to carry out ecient cell-matrix at-
tachments and cell-cell contacts.
Attachments between the EC and surrounding ECM are mediated by the integrin group
of cell surface adhesion receptors. Integrins provide adhesive and signalling functions
between ECs and the ECM, and this interaction is critical in maintaining EC polarity
and alignment along the vasculature. The integrins link the cell with the ECM at focal
adhesion points and interact with the actin cytoskeleton. This interaction stimulates cell
contraction, thus allowing cell movement on adhesive contacts. This is reviewed later in
this introduction (see 1.5.3.6).
In addition to interaction with the ECM, ECs must form cell-cell contacts in order to
produce viable capillary like networks. This cell-cell adhesion is mediated by cell adhesion
molecules, including vascular endothelial cadherin (VE-cadherin) and platelet endothelial
cell adhesion molecule-1 (PECAM-1).
PECAM-1 (cluster of dierentiation 31, CD31) is a 130 kDa member of the immunoglob-
ulin superfamily and is highly expressed on the vasculature (Newman et al., 1990). It
is able to form homophilic interactions on adjacent cells via its domains 1 and 2 (New-
ton et al., 1997). Moreover, heterophilic ligands for PECAM-1 include V 3 (Piali et al.,
1995), glycosaminoglycans (Muller et al., 1992) and CD38 (Horenstein et al., 1998). Hence,
PECAM-1 is thought to act as a docking molecule, which allows other proteins (including
integrins) to form additional cell-cell and cell-matrix interactions.
The transmembrane protein, VE cadherin, forms homophilic interactions in a calcium de-
pendent manner (Dejana, 1996). VE cadherins further interact with catenins, intracellular
proteins linking the cadherins to the actin cytoskeleton. VE-cadherin is abundantly ex-
pressed at adherens-type cell junctions where it plays roles in the control of endothelium
permeability and angiogenesis.
34Inammation and oedema
Endothelial cells are responsive to local agents such as histamine, which is released when
local tissues are damaged. Consequently, the endothelial cells open up their intercellular
junctions and allow the passage of large amounts of uid from blood plasma so that the
surrounding tissues become engorged with uid and swollen, a condition called oedema.
The endothelium also plays a critical function in regulating the tracking of leucocytes
from the intravascular space to extravascular sites of inammation. The rst step in leuco-
cyte transmigration is the arrest of leucocytes and contact with the ECs. This is mediated
by the selectins, which allow the rolling and docking of the leucocyte on the endothelium
(Vestweber, 2007). During the second step of the transmigration process, the leucocytes
atten and migrate along the endothelium, a process known as diapedesis. Finally, ex-
travasation occurs by leucocyte migration through EC junctions and their subsequent
attachment/migration on ECM components (collagen and bronectin) (Vestweber, 2007).
The main families of molecules involved in this tracking process are the selectins, in-
tegrins, immunoglobulin supergene family and variants of the CD44 family (Limaye and
Vadas, 2007).
351.4 Biology of vascular smooth muscle cells
1.4.1 Structure
Smooth muscle is a type of non-striated muscle, found within the tunica media layer of
large and small arteries and veins (Figure 1.2), and around hollow organs such as the
bladder, the uterus, the reproductive, gastrointestinal and respiratory tracts, the ciliary
muscle, and the iris of the eye. Smooth muscle is fundamentally dierent from skeletal
muscle and cardiac muscle in terms of structure, function and mechanism of contraction.
Smooth muscle bres are smaller (2-10 m in diameter) than skeletal muscle bres (10-100
m) and are assembled in a dierent manner. Smooth muscle bres making up the single-
unit muscle are gathered into dense sheets or bands. The bres run approximately parallel
to each other, packed together, most often so that the narrower portion of one bre lies
against the wider portion of its neighbour. These bres are connected by gap junctions
between their cytoplasmic membrane (sarcolemma), which act as a low resistance pathway
for the rapid spread of electrical signals throughout the tissue. In contrast, multi-unit
smooth muscle bres have no interconnecting bridges and are combined with surrounding
connective tissue.
Smooth muscle cells are spindle-shaped, and, like striated muscle, can contract and relax.
Their actin and myosin chains are not arranged into distinct sarcomeres that form orderly
bands throughout the muscle cell; hence, the most striking feature of smooth muscle is the
lack of visible cross striations. Nonetheless, there is an organised cytoskeleton consisting
of the intermediate lament proteins vimentin and desmin, along with actin laments.
Moreover, dierences can be observed between SMC types, for example vascular SMCs
(VSMCs) dier from other smooth muscle cells with a predominance of vimentin laments
and a specic -type actin.
1.4.2 Function
Smooth muscle controls slow, involuntary movements such as the contraction of the smooth
muscle tissue in the walls of the intestines, of the uterus during labour and of the arteries
to regulate blood ow. SMCs are coupled to one another by adherens junctions, and
therefore, cells are mechanically linked to one another such that contraction of one cell
triggers the contraction of its neighbour (Eddinger et al., 2005). Gap junctions couple
adjacent cells chemically and electrically, facilitating the spread of molecules such as Ca2+
36Figure 1.2: Anatomy of a muscular artery
This illustration shows the anatomy of a muscular artery with, from the lumen to the out-
side of the vessel: the endothelium, the tunica intima, tunica media and tunica adventitia,
Figure adapted from Fox (2007).
37or action potentials between SMCs. Moreover, smooth muscle may contract spontaneously
or be induced by a number of physiochemical agents (e.g. oxytocin triggers contraction
of the uterus, histamine contracts the SMC of airways in asthma), and also mechanical
stimulation (such as stretch).
As mentionned before, SMC are essential for function of the vasculature as their con-
tration/relaxation state is responsible for alterations of the luminal diameter and allows
the maintenance of an adequate blood pressure. However, in addition to their contractile
abilities, SMCs can also perform synthetic functions and the modulation between the two
phenotypes are characterised by changes in morphology, proliferation, migration rates and
expression of dierent marker proteins (Rensen et al., 2007). Contractile SMCs are elon-
gated, spindle-shaped cells and contain contractile laments. They exhibit a very low rate
of synthetic activity and express a unique repertoire of contractile proteins, ion channels
and signalling molecules which are required to fulll its contractile function (Owens et al.,
2004). In contrast, synthetic SMCs are usually associated with vasculo-proliferative disor-
ders involving abnormal neointimal SMC accumulation (see below) and with cell culture
of SMCs. Synthetic SMCs are less elongated and have a morphology which is referred to
as epithelioid or rhomboid (see Figure 1.3) (Hao et al., 2002). Synthetic SMCs contain a
large number of organelles involved in protein synthesis and exhibit higher proliferative
and migratory activities than contractile SMCs (Hao et al., 2002). Nevertheless, it is not
really accurate to reduce the number of SMCs functions to either contractile or synthetic
as a whole range of phenotypes between these two end states can be observed in vivo
(Owens et al., 2004). Moreover, even in adult organisms, SMCs are not terminally dier-
entiated and are capable of major changes in their phenotypes in response to their local
environment such as injury and inammation (Owens et al., 2004).
The protein markers most commonly used to dierentiate the contractile and synthetic
phenotypes are -smooth muscle actin (-SMA), smooth muscle-myosin heavy chain (SM-
MHC) and smoothelin. The relevance of these markers is illustrated by the fact that, in
the case of SM-MHC, its expression has never been detected in non-SMCs in vivo, and
is the only marker protein that is also SMC specic during embryogenesis (Miano et al.,
1994). Another relevant marker, smoothelin has a more uniform expression and is rapidly
downregulated in cultured vascular SMCs switching towards a synthetic phenotype (Chris-
ten et al., 1999). Moreover, both SM-MHC and smoothelin are absent in myobroblasts
in models of arterial injury which are known to be highly synthetic (Christen et al., 2001).
38As stated before, SMCs are able to alter their phenotype in response to local cues in their
environment, such as the growth factor PDGF. PDGF-BB is able to downregulate -SMA
expression in rat aortic SMCs and stimulate proliferation and migration of SMCs of pig
coronary SMCs (Hao et al., 2002; Li et al., 1997). Moreover, PDGFs are strongly impli-
cated in mediating neointima formation in vivo as indicated by the fact that inhibition of
both PDGF isoforms, PDGF-AA and PDGF-BB, decreased neointima formation in the
rat model of aterial injury (Deguchi et al., 1999; Kotani et al., 2003). On the contrary,
TGF- seem to play an essential role in the induction of the contractile phenotype. Treat-
ment of cultured SMCs with TGF- increases the expression level of protein markers of
the contractile phenotype such as -SMA, SM-SMH and SM-calponin (Hautmann et al.,
1997). Other environmental cues that dictate the behaviour of SMCs are the components
of the ECM, mainly collagen, elastin and proteoglycans. One example is the eect of
the proteoglycan heparin which has been shown to be important for the maintenance of
the contractile phenotype and is also able to decrease SMC proliferation. Treatment of
porcine SMCs with heparin reduced proliferation of both contractile and synthetic SMCs
and increased the expression of the contractile markers desmin and smoothelin (Hao et al.,
2002). Other examples are hyaluronan and versican, ECM proteoglycans that are present
in low amounts in normal blood vessels, but increase dramatically in vasculo-proliferative
disease. They are particularly upregulated in neointimal hyperplasia following balloon
angioplasty and provide a permissive environment for arterial smooth muscle cell (ASMC)
proliferation, migration, and macrophage adhesion (Wight, 2008). Moreover, physical fac-
tors also inuence the phenotype of SMCs: the level of mechanical stress can either drive
SMCs towards a contractile or a synthetic phenotype.
1.4.3 Role in atherosclerosis
1.4.3.1 Denition of atherosclerosis
Atherosclerosis is a disease aecting arterial blood vessels. It is generally regarded as a
chronic, excessive, inammatory and broproliferative response to various forms of damage
to the endothelium and also the smooth muscle cell layer of the artery wall (Ross, 1993).
Atherosclerosis, the principal underlying cause of myocardial and cerebral infarction or
stroke and gangrene of the extremities, is responsible for the majority of deaths in western
Europe, the USA and Japan (Ross, 1993). Briey, atherosclerosis is thought to be initiated
by injury which is likely to involve some form of oxidative stress, including free radical ox-
39Figure 1.3: Structural character-
istics of synthetic and contrac-
tile SMCs
This illustration shows the struc-
tural dierences between the con-
tractile and the synthetic SMCs. G:
Golgi complex, M: Mitochondria,
ER: Endoplasmic reticulum, ECM:
Extracellular matrix, N: Nucleus,
DB: Dense body, DP: Dense plaque,
C: Caveolae, CF: Contractile la-
ments. Figure adapted from Rensen
et al. (2007).
idation of low-density lipoprotein molecules (LDL) carrying cholesterol. In veins, the lack
of oxygen probably limits the development of atherosclerosis. When oxidized LDL comes
into contact with an artery wall, a series of reactions occur to repair the damage to the
artery wall caused by oxidized LDL. The body's immune system responds to the damage
to the artery wall by sending macrophages and T-lymphocytes (Faggiotto et al., 1984) and
the rst lesion type of atherosclerosis appears by accumulation of lipid-lled macrophages
(or foam cells): "the fatty streak". These can be found randomly through the arterial
tree but are commonly found at sites where the ow is decreased (bifurcations, curves)
(Wissler and Vesselinovitch, 1983). The second category of lesions are the intermediate
or "brofatty lesions" (Ross, 1993), consisting of layers of lipid-lled macrophages and T
cells that alternate with layers of smooth muscle cells surrounded by a relatively poorly
developed connective tissue matrix with collagen, elastic bres and proteoglycans. As the
lesions progress, the cells undergo a rearrangement that may lead to the nal, advanced
lesion or "brous plaque". The brous plaque is characteristically covered by a cap of
connective tissue that contains smooth muscle cells surrounded by more connective tissue,
consisting of collagen with some elastic bres. The brous cap containing macrophages
and T lymphocytes (Faggiotto and Ross, 1984) may provide stability to the lesion. More
recently, the importance of SMC apoptosis was identied as a a critical process determin-
ing plaque stability and thus the nal and dramatic step of the atherosclerotic process,
plaque rupture and the triggering of the accute thrombotic events causing myocardial or
cerebral infarction (Clarke and Bennett, 2006).
401.4.3.2 Role of vascular smooth muscle cells in atherosclerosis
SMCs are known to have an important role in the initiation and early progression of
atherosclerosis (Doran et al., 2008) and also in plaque stability (Clarke and Bennett, 2006).
Very early, intimal thickening containing SMCs and the proteoglycans they produce, are
found in regions of the vascular tree with turbulent blood ow such as bifurcations and
branch points and are present in all humans at 1 year of age (Stary et al., 1992; Velican
and Velican, 1976, 1985). This focal-type of intimal thickening correlates with sites of
advanced atherosclerotic lesions observed later in life (Stary et al., 1992). Moreover, SMCs
present in these intimal thickenings dier greatly from those found in the media. They
switch from a "contractile" state to a "synthetic" state, express lower levels of proteins
involved in contraction (such as -SMA) and synthesise more extracellular matrix as well
as proteases and cytokines (Owens et al., 2004; Worth et al., 2001). The SMCs found in
the atherosclerotic lesions are also able to take up lipids (Stary et al., 1994) and to interact
with monocytes and macrophages (Stary et al., 1994).
As stated previously, SMC apoptosis is now thought to have an important role in plaque
destabilisation (Clarke and Bennett, 2006). The advanced atherosclerotic plaque consists
of an SMC-rich brous cap overlying a lipid- and macrophage-rich necrotic core and those
which are more prone to rupture contain a higher proportion of lipids and a preponderance
of monocyte/macrophages with fewer SMCs in the cap (Davies et al., 1993).
411.5 Cytokines regulating angiogenesis and intra-cellular
pathways involved
In the past several years, genetic manipulation of the mouse genome and identication of
several molecules have provided insights into the molecular mechanisms that govern vessel
formation. This complex process is tightly controlled by several pro-angiogenic cytokines
in balance with other inhibitory factors, and their identication is important not only
for understanding normal development but also for the generation of novel therapies for
cancer and neovascular diseases generally. Clinically, the promotion of new blood vessel
formation is desirable in situations of severe tissue ischemia such as ischemic heart or
peripheral disease, often resulting from underlying atherosclerosis. In contrast, there is
an increasing interest in the development of inhibitory molecules to block the initiation of
angiogenesis in cancer and ocular diseases. Factors that have been implicated in the regu-
lation of angiogenesis include vascular endothelial growth factor (VEGF), platelet-derived
growth factor (PDGF), basic broblast growth factor (bFGF), transforming growth factor
beta-1 (TGF-1), the Tie-1 and Tie-2 receptors, the angiopoietins, integrins and several
coagulation factors (Beck and D'Amore, 1997).
1.5.1 VEGF
1.5.1.1 VEGF structure
The rst VEGF member to be identied was VEGF-A, initially called vascular permeabil-
ity factor (VPF) because of its ability to render microvessels hyperpermeable to plasma
proteins at sites where it was over-expressed along with its receptors (Leung et al., 1989;
Dvorak et al., 1991). Other early research established a clear role for VEGF-A as a po-
tent mitogen for endothelial cells and was also able to induce their survival and migration
(Connolly et al., 1989). The VEGF family of growth factors comprises a group of ho-
modimeric glycoproteins most of which are implicated in the formation and modelling of
the vascular system, and belong to a super-family of growth factors also including the
PDGFs. Both growth factors consist of antiparallel homodimers covalently linked by two
interchain disulphide bonds and possessing a characteristic cysteine knot structure that
confers important binding properties (Keyt et al., 1996).
The VEGF family includes VEGF-A, -B, -C, -D , the related placental growth factor gene
PlGF, the orf virus-encoded factor, VEGF-E, and VEGF-F found in snake venom. In
42humans, six isoforms of VEGF-A are generated by alternate splicing: 121, 145, 165, 189
and 206 amino acids long, with VEGF-A121 and VEGF-A165 being the most abundant
isoforms (Neufeld et al., 1996; Tischer et al., 1991) (Figure 1.4). VEGF-A121 is readily
diusible and does not bind to heparin, while the larger isoforms, such as VEGF-A206, bind
heparin and are sequestered by the extracellular matrix. Heparin binding activity is due
to the presence or absence of exons 6 and/or 7 that encode for heparin binding domains
(Robinson and Stringer, 2001). The heparin binding, but also diusible isoform, VEGF-
A165, is regarded as the most abundant and biologically active isoform and is able to induce
proliferation and migration of endothelial cells in vitro and blood vessel permeabilisation
in vivo (Neufeld et al., 1999). Moreover, VEGF-A165 is regulated by oxygen availability
(Shweiki et al., 1992), and VEGF-A165 production in response to hypoxia is an important
regulator of abnormal angiogenesis in several diseases such as diabetic retinopathy (Adamis
et al., 1994), psoriasis (Detmar et al., 1994) and cancer (Shweiki et al., 1995). Gene
targetting in mice further conrmed a pivotal role for VEGF-A in angiogenic processes,
with the absence of only one VEGF-A allele causing severe disruption of the developing
vasculature (Carmeliet et al., 1996; Ferrara et al., 1996).
VEGF-B is expressed in a wide range of tissue and particularly in the heart and skeletal
muscle. Studies from two separate groups shown dierent results in VEGF-B knockout
mice. The rst group observed that knockout mice did not display any abnormal phe-
notype but had smaller hearts with conduction abnornalities suggesting that VEGF-B is
required for normal heart function in adult animals but is not required for proper devel-
opment of the cardiovascular system during development (Aase et al., 2001). The other
group found that, despite appearing normal, hearts of VEGF-B =  mice were reduced in
size and displayed vascular dysfunction after coronary occlusion and impaired recovery
from experimentally induced myocardial ischemia (Bellomo et al., 2000).
VEGF-C plays an essential role in the development of the lymphatic system as VEGF-
C =  mice die during late embryogenesis due to a defect in lymph vessel formation
(Karkkainen et al., 2001). On the contrary, VEGF-D =  mutant mice are viable and
do not display any abnormal phenotype, but both high levels of VEGF-C and VEGF-
D are a prognostic factor for cancer patients as lymphatic growth around tumors may
facilitate metastatic spread of malignant cells (Alitalo and Carmeliet, 2002).
VEGF-E is a VEGF-related molecule found to be encoded in the Orf virus, a parapox
virus infecting sheeps, goats and sometimes human and inducing a transient angiogenesis
43Figure 1.4: VEGF-A isoforms result from alternative splicing
VEGF-A isoforms are generated by alternative splicing and are 121, 145, 165, 189 and
206 amino acids long. The larger isoforms contain an heparin binding domain granting
anity to the ECM, Neuropilin 1 and HSPG. Domains 1 to 5 are conserved between all
VEGF-A isoforms and are the VEGFR1 and VEGFR2 binding domains, Figure modied
from Eming and Krieg (2006).
44in the skin (Lyttle et al., 1994).
1.5.1.2 VEGF regulation
Up-regulation of VEGF-A by hypoxia is mediated via the binding of hypoxia inducible
factor-1 (HIF-1) to the hypoxia response element (HRE) in the VEGF promoter. HIF-1 is
composed of a 120 kDa HIF-1 subunit complexed with a HIF-1 subunit. Under phys-
iological conditions, HIF-1 undergoes rapid degradation. Two key prolines within its
oxygen degradation domain (ODD) are hydroxylated by one of a three member family of
prolyl-hydroxylase domain-containing proteins (PHDs 1-3), the activity of these enzymes
being oxygen dependent (Semenza, 2001). Their action allows HIF-1 interaction with
ubiquitin ligase thus promoting the formation of a larger complex which is rapidly de-
stroyed by proteasome activity. Under hypoxia, the hydroxylation of HIF-1 is reduced,
allowing HIF-1 and HIF-1 to combine at nuclear HREs of target genes such as VEGF,
thereby allowing gene transcription. Not only hypoxia is able to increase the production
of VEGF but it also allows stabilisation of its mRNA (Ikeda et al., 1995), and these two
mechanisms provide a system by which ischemic tissues can increase VEGF production
and secretion, so attracting the growth of new blood vessels (Shweiki et al., 1992).
1.5.1.3 VEGF receptors
VEGFs bind to three major receptor tyrosine kinases (RTK): VEGFR1/Flt-1 (fms-like ty-
rosine kinase-1), VEGFR2/KDR/Flk-1 (fetal liver kinase-1) and VEGFR3/Flt-4 (Neufeld
et al., 1999) and also to accessory or co-receptors, the neuropilins (Soker et al., 1996). The
three VEGFRs comprise an extracellular domain of seven immunoglobulin-like (Ig-like) do-
mains containing ligand binding activity, a single hydrophobic transmembrane domain and
a cytoplasmic region containing a bipartite tyrosine kinase domain divided into two parts
by an insert sequence. Analysis of mutant and chimeric forms of VEGFR1 and VEGFR2
have shown that ligand binding occurs primarily to the second and third immunoglobulin-
like domains (Barleon et al., 1997; Davis-Smyth et al., 1996). Figure 1.5 summarises the
interactions between the dierent VEGF isoforms and their receptors. Briey, VEGF-A165
binds to VEGFR1 and VEGFR2 (Neufeld et al., 1999). VEGF-C and -D also recognise
VEGFR2 with lower anity and bind to a third receptor, VEGFR3. PlGF and VEGF-B
bind with high anity only to VEGFR1, and VEGF-E only to VEGFR2. VEGFR1 has a
10-fold higher anity for VEGF-A165, than VEGFR2 (Petrova et al., 1999). Nevertheless,
VEGFR1 undergoes little detectable phosphorylation and weak signalling when bound
45to VEGF-A165, whereas, VEGF-A165 binding to VEGFR2 results in autophosphorylation
on several major sites and is followed by the activation of multiple downstream signalling
pathways. All three VEGF receptors possess a similar overall structure, the tyrosine kinase
domains being 80% identical at the amino acid level in the three receptors.
VEGFR1 is a 180 kDa protein which binds VEGF and can be alternatively spliced to
generate a soluble, secreted form, sFlt1 (Kendall et al., 1996). VEGFR1 =  mice die
in utero from vascular defects at E8.5 (Fong et al., 1999). It was found that, increased
hemangioblast commitment, is the primary defect in VEGFR1 knock-out mice. Mice
expressing only the extracellular region of VEGFR1 develop normally (Hiratsuka et al.,
1998); it is therefore thought that, at least during embryonic angiogenesis, VEGFR1
act primarily as a decoy that negatively regulates VEGFR2-mediated actions of VEGF.
Nevertheless, the mechanisms by which VEGFR1 mediates its biological functions are only
partially elucidated, especially in the adult. Although VEGFR1 may not be essential for
mediating eects of VEGF in ECs, it is able to bind other members of the VEGF family
and also may play a more signicant role in other cell types, such as monocytes (Clauss
et al., 1990). Moreover, some experiments suggested a role for VEGFR1 phosphorylation
by VEGF in increasing the potency of VEGFR2 signalling (Autiero et al., 2003).
VEGFR2 is a 230kDa protein and is responsible for the transduction of most biological
eects of VEGFs including EC migration, proliferation, survival and vascular permeability
(Quinn et al., 1993; Waltenberger et al., 1994). Mice decient for VEGFR2 die in utero at
embryonic day 8.5 to 9.5. Their phenotype resembles that observed in mice lacking VEGF
and results from an early defect in the development of haematopoietic and endothelial cells
(Shalaby et al., 1995) and is characterised by a lack of EC development. Originally thought
to be exclusive to the vascular endothelium, VEGFR2 has since been found to be expressed
on neuronal precursor cells in the retina (Yang and Cepko, 1996). Moreover, VEGF was
shown to have direct eects on neurons and glial cells, and stimulate their growth, survival
and axonal outgrowth (Carmeliet and Storkebaum, 2002), indicating important roles for
VEGF and its receptor in the nervous system.
Finally, VEGFR3 is expressed only in venous endothelial cells in the embryo, and is con-
ned to the lymphatic system in the adult (Iljin et al., 2001). It has roles in cardiovascular
development in the embryo, particularly lymphangiogenesis, and binds to VEGF-C and
VEGF-D. In VEGFR3 decient mice, large vessels become abnormally organised with de-
fective lumens, leading to uid accumulation in the pericardial cavity and cardiovascular
46failure at embryonic day 9.5 (Dumont et al., 1998).
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Figure 1.5: VEGF family ligands and their receptors
The RTKs that specically recognise VEGF-A, Flt-1 (VEGFR1) and KDR (VEGFR2),
possess an extracellular domain containing seven Ig-like loops (red ovals), a single hy-
drophobic membrane-spanning domain, and a cytoplasmic domain comprising a single
kinase domain (yellow ovals) that is interrupted by a non-catalytic region, called the ki-
nase insert. The extracellular domain of Flt-1 is also independently expressed as a soluble
protein. VEGFs C, D and E also bind to KDR, while PlGF and VEGF-B bind to Flt-1
only. Flt-4 (VEGFR3) is a related receptor for VEGFs C and D that undergoes prote-
olytic processing to yield 120 and 75 kDa polypeptides with a disulphide bridge in the
fth Ig domain. Neuropilin 1 is a non-RTK receptor for VEGF-A165, the PlGF-2 isoform,
VEGF-B and VEGF-E. NRP1 comprises an extracellular region with two complement
binding domains (CUB), two coagulation factor domains, one MAM (meprin, A5,  ty-
rosine phosphatase) domain, a transmembrane region and a short cytoplasmic domain,
Figure adapted from Pellet-Many et al. (2008).
471.5.1.4 VEGF signal transduction
Most biologically relevant VEGF signalling occurs through VEGFR2 which is also thought
to be primarily responsible for endothelial functions of VEGF, vasculogenesis and an-
giogenesis (Zachary, 2005). Indeed, in contrast to VEGFR1, autophosphorylation of
VEGFR2 is easily detected in endothelial cells and several phosphorylated tyrosine residues
have been identied and found important for binding to eector molecules and propaga-
tion of intracellular signalling. Tyr 1054 and Tyr1059 are required for maximal kinase
activity (Dougher and Terman, 1999).
Survival signalling
Phosphorylation of Tyr1175 by VEGF has been shown to activate phosphatidylinosi-
tol 3'-kinase (PI3K) (Dayanir et al., 2001) which in turn activates anti-apoptotic Ser-
ine/Threonine kinase Akt/PKB to mediate survival of endothelial cells (Gerber et al.,
1998b). Akt then phosphorylates Bad and caspase-9 which are pro-apoptotic proteins
(Brunet et al., 1999; Cardone et al., 1998), while long-term survival eects of VEGF may
be mediated through the upregulation of anti-apoptotic proteins that inhibit caspase func-
tion, such as Bcl-2, a1 (Gerber et al., 1998a), survivin and XIAP (X-linked inhibitor of
apoptosis) (Tran et al., 1999)(see Figure 1.6).
The integrity of cell junctions is also important in survival as it regulates the balance
between the proliferative and conuent/quiescent phenotypes of the endothelial cells (De-
jana, 2004). Deciency or truncation of VE-cadherin, the calcium-dependent cell-cell
adhesion glycoprotein, major component of the adherens junction, induces endothelial
apoptosis and abolishes transmission of the endothelial survival signal by VEGF-A to Akt
kinase and Bcl2 via reduced complex formation with VEGF receptor-2, beta-catenin, and
phosphoinositide 3 (PI3)-kinase (Carmeliet et al., 1999).
Mitogenic signalling
VEGF strongly activates the extracellular signal-regulated kinases (ERKs) 1 and 2 through
VEGFR2. Activation of the raf-1/MEK/ERK 1/2 cascade, rather than involving growth
factor receptor-bound protein 2 (GRB2) phosphorylation pathway, and subsequent Sos (a
guanylnucleotide exchange factor) and ras activation, occurs via a ras-independent path-
way mediated through phospholipase C (PLC)- and protein kinase C (PKC) (Takahashi
et al., 2001; Gliki et al., 2001). PLC- binds to phosphorylated Tyr1175 and mediates
48the generation of diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3) leading to
PKC activation and an increase in intracellular Ca2+ (Takahashi et al., 2001; Cunning-
ham et al., 1999). Activated PKC then activates ERKs 1/2 via Raf-1 and MEK which is
a major pathway leading to cell mitogenesis and proliferation (see Figure 1.6).
Chemotactic signalling
Chemotaxis corresponds to the directional response of a cell towards a gradient of chemoat-
tractant in a uid phase. This process is called haptotaxis when the chemoattractant
molecules are attached to a support, like the surface of a dish or the extracellular ma-
trix. Necrotaxis is a special type of chemotaxis which occurs when the chemoattractant
molecules are released from necrotic or apoptotic cells. Finally, chemokinesis is the re-
sponse of a cell to a chemical that causes the cell to make some kind of change in its
movement by speeding it up, slowing it down or changing its direction (see Figure 1.7).
VEGF is strongly involved in endothelial cell migration by activating many proteins in-
volved in chemotaxis. As the extracellular matrix (ECM) plays an essential role in stabil-
ising blood vessels through interactions with endothelial and SMC sheathed in a basement
membrane, breakdown of the later is a prerequisite for endothelial cell migration and for-
mation of new vessels during development and disease (Zachary, 2005). This is triggered
by the induction of matrix-degrading metalloproteinases (MMPs). MMP-2 and MMP-9
seem to play an important role in promoting angiogenesis and are upregulated along with
VEGF and VEGFR2 in angiogenic lesions in a model of tumour angiogenesis (Bergers
et al., 2000). Little is known of the link between VEGFR2 activation by VEGF and
induction of MMPs.
The VEGF receptor-associated protein (VRAP) also called Tsad (T cell-specic adapter
protein), binds to the phosphorylated Tyr951 of VEGFR2 and has been shown to mediate
endothelial cell migration, as indicated by the reduced vascularisation and tumour growth
seen in VRAP =  mice (Matsumoto et al., 2005). VRAP forms a complex with Src
upon VEGF activation, indicating that it might regulate Src activation and permeability
downstream of VEGFR2.
Focal adhesion kinase (FAK) is a key transducer of signals converging from RTKs and
integrins important for migration (Zachary and Gliki, 2001). Both FAK and its substrate
paxillin are phosphorylated in response to VEGF, and they are both known to be in-
volved in focal adhesion turnover during cellular migration (Abedi and Zachary, 1997).
49Figure 1.6: Functional VEGF signalling in endothelial cells
Activation of VEGFR2 occurs through ligand-induced dimerisation and autophosphoryla-
tion at several tyrosine residues in the intracellular domain. VEGF-induced cell survival
is mediated in part via PI3K activation of Akt, which in turn inhibit the pro-apoptotic
proteins Bad and capases activity. Caspases are also inhibited by the anti-apoptotic pro-
tein Bcl2, survivin and XIAP. Increased tyrosine phosphorylation of FAK is a converging
point for diverse endothelial cell survival stimuli, including VEGF, matrix-integrin inter-
actions, and uid shear stress. FAK and its substrate, paxillin, may also be important
for endothelial cell migration and, hence, angiogenesis. Interactions between the inte-
grin v3 and VEGFR2 may also play a role in survival functions of VEGF. Short-term
NO production induced by VEGF is mediated via increased cytosolic Ca2+, resulting
from activation of PLC- and subsequent generation of IP3. Activation of Akt leads to
phosphorylation and activation of endothelial NO synthase, providing a mechanism for
sustained Ca2+-independent NO synthesis which might be a pathway important for mi-
gration. The activity of the RTK also trigger the activation of the small GTPases ras and
rac1 important for migration. PLC--mediated production of DAG leads to activation of
PKC, and this pathway plays an important role in mediating VEGF-induced activation
of ERKs and EC proliferation. In turn, ERK activation mediates cPLA2-mediated PG
synthesis. Increased cytosolic Ca2+ also stimulates the cellular release of PGI2. Figure
modied from Zachary (2005).
50Figure 1.7: Representation of the dierent types of chemotaxis and chemokinesis
This picture represents several chemotaxis processes and chemokinesis. Chemotaxis as
such is the attraction of a cell towards a gradient of chemokine present in a uid phase;
necrotaxis a type of chemotaxis when the chemokine is released by a dying cell; and
haptotaxis when the chemokine instead of being in a uid phase is attached to a surface or
in the ECM. Finally chemokinesis is the locomotory response of a cell in a non-directional
manner. Figure from Khidai (1999).
51Phospohrylation of FAK in response to VEGF occurs at Tyr397 and Tyr861, the latter
being phosphorylated via a Src-dependent pathway (Abu-Ghazaleh et al., 2001).
The importance of Src in the migration of endothelial cells was demonstrated using a spe-
cic Src inhibitor that led to a decrease in migration of ECs (Abu-Ghazaleh et al., 2001).
Furthermore, a dominant negative Src construct selectively inhibited VEGF-induced an-
giogenesis and reduced VEGF anti-apoptotic eects in the chick CAM model (Eliceiri
et al., 2002). Src also participates in the formation of a complex between FAK and in-
tegrin V 5 stimulated by VEGF (Eliceiri et al., 2002). Although there is no evidence
for vascular defects in mice lacking individual Src kinases, the previous results indicate an
important role for Src in VEGF induced migration of EC for FAK signalling.
Phosphorylation of Tyr1214 on VEGFR2 is required for the VEGF-induced actin reorgan-
isation and EC migration through the sequential activation of cell division cycle protein 42
(CDC42) and p38 MAP kinase (Lamalice et al., 2004). The major p38 substrate, MAPK-
activated protein kinase-2 (MAPKAPK-2), is able to phosphorylate heat-shock-protein 27
(Hsp27) at serines 15, 78 and 82 (Landry et al., 1992; Stokoe et al., 1992). Hsp27 is a
molecular chaperone known to positively regulate actin reorganisation and VEGF-induced
migration of endothelial cells. It was recently found that serine 82 could also be activated
via protein kinase D (PKD), independently of p38 kinase to stimulate EC migration and
tubulogenesis (Evans et al., 2008). Indeed, while p38 kinase may contribute to signalling
pathways involved in EC migration, and cell migration more generally, p38 kinase alone
may not play a key role in the endothelial migratory response to VEGF, and a PKC/PKD
pathway acting at least in part via Hsp27 phosphorylation is a more important contributor
to VEGF chemotactic signalling (Evans et al., 2008).
IQ motif containing GTPase activating protein (IQGAP1) is a scaolding protein that
controls cellular motility by interacting directly with cytoskeletal, cell adhesion, and small
G proteins, including Rac1, which it activates by inhibiting its intrinsic GTPase activ-
ity (Hart et al., 1996). It is strongly expressed in ECs and is able to bind directly to
VEGFR2. IQGAP co-localises with phosphorylated VEGFR2 at the leading edges of
migrating endothelial cells and its knock down by siRNA decreased VEGF-induced EC
migration (Yamaoka-Tojo et al., 2004).
Finally, small GTPases of the Rho family play an important role in cell migration as well
as other cellular functions such as the regulation of endothelial phenotype and perme-
ability (Wojciak-Stothard and Ridley, 2002). RhoA and Rac1 are activated by VEGFR2
52phosphorylation at Tyr951 in response to VEGF and are required for KDR-mediated HU-
VEC migration (Zeng et al., 2002). Rac1 is required for the assembly and maturation
of endothelial junctions and its activity increases during junction formation (Lampugnani
et al., 2002), whereas RhoA destabilises endothelial junctions (van Nieuw Amerongen and
van Hinsbergh, 2002).
Vascular tone/permeability
Nitric oxide (NO) is a multifunctional gaseous molecule and a highly reactive free radi-
cal. It is synthesized from L-arginine, NADPH and oxygen by NO synthase (NOS). In
the cardiovascular system, NO signalling has several important physiological functions.
NO produced by the constitutive endothelial nitric oxide synthetase (eNOS also called
NOS3) diuses into the vessel wall and relaxes VSMCs in arteries, thereby increasing
vessel diameter, lowering resistance and enhancing blood ow to tissues (Isenberg et al.,
2009). Endothelial cell-derived NO mediates acute local self-regulation of arterial tone
in response to changes in mechanical shear sensed by the endothelium and to circulating
factors such as VEGF, VEGFR2 being the major mediator for the hypotensive eect of
VEGF (Li et al., 2002). NO also diuses into the lumen of vessels, where it regulates
haemostasis by limiting platelet aggregation. Finally, NO acts in an autocrine manner to
regulate endothelial permeability and angiogenesis. These vascular responses to NO oc-
cur over dierent timescales: haemostasis and vessel tone are regulated acutely, whereas
angiogenesis requires a sustained increase of NO levels, see Figure 1.8.
Prostacyclin (prostaglandin I2, PGI2) is another well-known key regulator of vascular
tone that is also produced upon VEGF stimulation (Gliki et al., 2001; Wheeler-Jones
et al., 1997). VEGF-induced PGI2 production results from PKC-mediated ERK1/2 ac-
tivation, ERK-mediated phosphorylation and activation of cytosolic phospholipase A2
(cPLA2) (Wheeler-Jones et al., 1997). Cyclooxygenase 2 (Cox2) catalyses the biosyn-
thesis of prostaglandins from arachidonic acids. Prostaglandin H2 is transformed into
the primary prostanoids PGE2, PGF2, PGD2, PGI2 and thromboxane A2 (TXA2) that
directly stimulate endothelial cell migration and angiogenesis in vivo (Vane et al., 1998).
VEGF is therefore a major regulator of endothelial cell function and is able to promote EC
proliferation, migration, survival as well as regulating vascular tone: the major pathways
involved are summarised in Figure 1.6.
53Figure 1.8: Role of nitric oxide (NO) signalling in angiogenesis, vascular tone
and haemostasis
VEGF binding to its receptor VEGFR2 on endothelial cells activates endothelial nitric
oxide synthase (NOS3, eNOS) to produce the diusible signalling molecule NO. NO acts
in an autocrine manner to stimulate endothelial cell growth and motility leading to angio-
genesis. VEGF signalling through NO also contributes to increasing vascular permeability.
NO diuses into vessel walls, causing arterial vessels to relax and increase blood ow. NO
also acts in a paracrine manner to prevent thrombosis by inhibiting platelet adhesion and
aggregation. These dierent vascular activities of NO occur on dierent timescales. Figure
modied from Isenberg et al. (2009).
541.5.2 PDGF
1.5.2.1 PDGF structure
Platelet-derived growth factor (PDGF) was rst described as a platelet-dependent serum
factor that stimulates the proliferation of arterial smooth muscle cells in vitro (Ross et al.,
1974). Further studies revealed that PDGF is also produced by many other cell types such
as neurons, endothelial and epithelial cells (Heldin and Westermark, 1999), which are in
close contact with mesenchymal cells expressing PDGF receptors (PDGFR) suggesting an
involvement in paracrine signalling for PDGF (Ataliotis and Mercola, 1997; DiCorleto and
Bowen-Pope, 1983). Moreover, knock-out experiments showed that paracrine signalling
appears to be the common route of signalling by PDGFs in embryogenesis, allowing cross-
talk between dierent cell types to form a viable vascular system, brain, kidney and lungs
(reviewed in Betsholtz et al., 2001). It is also clear now that in addition to its mitogenic
role, PDGF also plays an important role in cell migration and survival (Claesson-Welsh,
1994).
Structurally, PDGFs and VEGFs belong to the same family of growth factors, charac-
terised by eight conserved cysteine residues with similar spacing between the two cys-
teines. The A- and B-chains of PDGF are 126 and 110 amino acids long respectively and
show 60% sequence homology. Two of the cysteine residues are involved in cysteine bonds
between the two subunits in the PDGF dimer, and the other six are engaged in intrachain
disulphide bonds (Haniu et al., 1994, 1993). More recently, two new members were added
to the PDGF family: PDGF-C and PDGF-D which form a separate subfamily (Bergsten
et al., 2001; Li et al., 2000). The four homodimers PDGF-AA, PDGF-BB, PDGF-CC
and PDGF-DD and the heterodimer PDGF-AB have all been demonstrated to exist as
endogenous cell products. PDGF-C and PDGF-D do not appear to heterodimerise with
PDGF-A or PDGF-B as their core domains seem to be rather distantly related. Although
PDGF-C and PDGF-D are closely structurally related, it remains to be established if they
can form heterodimers with each other. Both the A-chain and the B-chain of PDGF are
synthesised as precursor molecules that undergo proteolytic activity in their NH2 termini
and, in the case of the B-chain, also in its COOH terminus (Ostman et al., 1991). PDGF-C
and PDGF-D possess a novel N-terminal motif referred to as a CUB domain (with homolo-
gies to the complement binding factors C1s/C1r, sea urchin bropellins, called Uegf and
Bone Morphogenetic Protein 1, BMP1) (Bergsten et al., 2001; Li et al., 2000). In contrast
to the N-terminal pro-peptides of PDGF-A and PDGF-B, the CUB domains of PDGF-C
55and PDGF-D do not appear to be obligatorily removed by proteolytic processing prior
to secretion, and remain on the secreted PDGF-CC and PDGF-DD molecules (Bergsten
et al., 2001; Li et al., 2000). Nevertheless, proteolytic removal of the CUB domain is
necessary for binding of PDGF-CC and PDGF-DD to PDGF receptors (Figure 1.9).
1.5.2.2 PDGF receptors
PDGF isoforms trigger their eects on target cells by activating two structurally related
protein kinase receptors. Because all isoforms are dimeric molecules, they bind two recep-
tor molecules simultaneously and thus trigger their dimerisation upon binding (Bishayee
et al., 1989; Seifert et al., 1989). While the  receptor binds the A-, -B and -C chains
of PDGF with high anity, the -receptor binds only the -B chain and -D chain with
high anity. Thus, PDGF-AA and PDGF-CC induce the formation of  receptor ho-
modimers, PDGF-DD induces  receptor homodimer formation, PDGF-AB, -receptor
homodimers or -receptor heterodimers, and PDGF-BB induces all three dimeric com-
binations of - and -receptors (Figure 1.9).
The PDGF -receptor contains 1063 amino acid residues and the -receptor 1067. The
receptor precursors are converted in the endoplasmic reticulum to mature forms of 170,000
and 190,000 Da, respectively. Both receptor types are glycosylated through N-linked
and 0-linked sugar groups (Daniel et al., 1987) and their level of glycosylation varies
among dierent cell types (Heldin et al., 1988). A broad spectrum of cells express the
PDGF receptors, their common target, the broblasts and SMC of several species express
both PDGF receptor isoforms, with the  isoform being the most abundantly expressed,
though there are dierences in expression between SMC of dierent species and arterial
types. Other cell types exclusively express the  receptors, such as platelets (Vassbotn
et al., 1994), or exclusively the  isoform, such as pericytes or myoblasts (Jin et al., 1990;
Sundberg et al., 1993; Heldin and Westermark, 1999). More recently, Greenberg et al.
(2008) found that there is an interaction between PDGFR and VEGFR2 (KDR) and
that this complex formation through heterodimerisation is implicated in the suppression
of pericyte function and therefore negatively regulates tumour angiogenesis.
561.5.2.3 PDGF signal transduction
PDGF receptors
The dierent PDGFRs trigger overlapping, but not identical intracellular signals. Both 
and  receptors are able to transduce a potent mitogenic signal (Heldin et al., 1985) and
induce intracellular Ca2+ (Diliberto et al., 1992) mobilisation, whereas there is stimula-
tion of migration through activation of the  receptor and a cell-type dependent migration
through activation of the  receptor (Heldin and Westermark, 1999). Like other tyrosine
kinase receptors, ligand binding induces receptor dimerisation, which allows autophos-
phorylation in trans of tyrosine residues in the intracellular domain (Heldin and Ostman,
1996). The PDGFR extracellular domains contains ve Ig-like domains, the three most N-
terminal ones joined through a disulphide bond and involved in ligand binding (Heidaran
et al., 1990). Similarly to VEGFRs, PDGFRs possess a split tyrosine kinase domain, the
two parts separated by a 100-amino acid residue hydrophilic stretch that does not possess
any catalytic properties.
Autophosphorylation induced by ligand binding and receptor dimerisation has two im-
portant functions. Firstly, phosphorylation on tyrosine residues within the kinase domain
(Tyr849 for the  receptor and Tyr857 for the  receptor) leads to an increase in the
kinase eciency and a suppression of phosphatase activity (Kazlauskas and Kovalenko,
2004). Secondly, tyrosine phosphorylation outside the kinase domain creates docking sites
for transduction molecules containing Src homology domain 2 (SH2) domains, such as
PI3K, PLC-, the Src family of tyrosine kinases, the tyrosine phosphatase SHP2 and a
GTPase activating protein (GAP) for Ras.
Downstream eector molecules
PI3K has a central role in intracellular signalling transduction downstream of PDGFRs. It
is activated by association of its SH2 domains with the tyrosine phosphorylated PDGFR,
and mediates several cellular responses. It phosphorylates phosphatidylinositol 4,5-biphos-
phate (PIP2) to form phosphatidylinositol 3,4,5-triphosphate (PIP3). PIP3 is an upstream
regulator of Rac/Rho activity, either by stimulation of GTP/GDP exchange activity
or by inhibition of GAP activity (Hawkins, 1995), and Rac activation will in turn en-
courage lamellipodia extension and rue formation, hence playing a role in migration
(Hooshmand-Rad et al., 1997). Moreover, PI3K will have anti-apoptotic eects through
the serine/threonine kinase Akt/PKB (Dudek et al., 1997).
57Figure 1.9: Processing and receptor specicity of PDGF isoforms
A, B, C and D chains of PDGF are synthesised as precursor molecules that form disulphide-
bonded dimers and undergo proteolytic processing. While the A and B chain are secreted
in their active forms, the C and D chain are still linked to their CUB domain. Dierent
PDGF isoforms bind to and dimerise - and -receptors with dierent specicities. PDGF-
CC and PDGF-DD must be released of their CUB domain to be able to bind to the PDGF
receptors. Receptors are drawn to illustrate that extracellular parts consist of 5 Ig-like
domains; ligands bind to 3 outermost Ig-like domains, and domain 4 is involved in direct
receptor-receptor interactions. Intracellular parts of receptors contain two tyrosine kinase
domains. Adapted from Betsholtz et al. (2001) and Heldin and Westermark (1999).
58PLC- catalyses the hydrolysis of membrane PIP2 to form IP3 and diacylglycerol (DAG).
The rst increases intracellular Ca2+ and the second activates certain members of the
PKC family. Interestingly, full activation of PLC- is dependent upon PI3K as the PIP3
formed by the latter binds to PLC- and may help to anchor the enzyme to the membrane
(Falasca et al., 1998). The importance of PLC- in cell mitogenesis seems to be dependent
upon cell type (Kamat and Carpenter, 1997).
Phosphorylation of tyrosine residues situated in the juxtamembrane domain of PDGFR
(Kypta et al., 1990), leads to the dephosphorylation of the Src Tyrosine in position 530, in
the COOH-terminus which, in turn, leads to a change in conformation allowing substrate
interaction, translocation of Src to the membrane and phosphorylation of other tyrosines
within the molecule. Although Src is thought to be important for the cell mitogenic
response, it was discovered that binding of Src to PDGFR is not necessary for mitogenic
signalling via this receptor (Hooshmand-Rad et al., 1998). Indeed, a mutant PDGFR
missing the two tyrosine residues responsible for Src binding was unable to associate
with or activate Src family tyrosine kinases but was able to trigger mitogenicity, actin
reorganisation and chemotaxis similar to the wild-type receptor (Hooshmand-Rad et al.,
1998).
SH2 domain-containing tyrosine phosphatase 2 (SHP2) is a ubiquitous phosphatase that
is activated by the binding of both its SH2 domains to phosphorylated tyrosine residues
(Pluskey et al., 1995). Firstly, it is known to inhibit PDGFR signalling as it is able to
dephosphorylate autophosphorylated receptors and its substrates (Klinghoer and Ka-
zlauskas, 1995). Alternatively, it may be involved in positive downstream signalling by
acting as an adaptor that binds to Grb2/Sos and therefore activate Ras (Li et al., 1994),
and also through its ability to dephosphorylate, thus activate, Src (Stokoe and McCormick,
1997).
GTPase activating proteins (GAP) bind to PDGFR and initiate the conversion of Ras-
GTP to Ras-GDP (Heidaran et al., 1990), and therefore have a modulatory role in Ras
activation by PDGF receptors (van der Geer et al., 1997).
Grb2 is an adaptor protein that possess one SH2 and two SH3 domains. The SH2 domain
is able to bind directly to the phosphorylated PDGFR or indirectly with the help of other
molecules such as SHP2. The SH3 domains are involved in binding with Sos, a nucleotide
exchange factor for Ras that converts inactive Ras-GDP to active Ras-GTP. Consequently,
Ras activates Raf-1, which in turn, initiates the activation of the extracellular-signal reg-
59ulated kinases (ERK) cascade to stimulate cell growth and migration (reviewed in Sch-
lessinger, 1993 and Klinghoer and Kazlauskas, 1995).
Regulation of PDGFR signalling
As mentioned earlier, several proteins, such as SHP2 and GAP, are involved in negative
feedback which may in turn inhibit signal transduction from PDGF receptors (van der
Geer et al., 1997). Another example is ERK that phosphorylates and thus inactivate Sos.
Sos inactivation will in turn result in a decrease of Ras activation (Porri and McCormick,
1996).
PDGFR versus PDGFR
In vitro data show that there are some dierences in signal transduction between PDGFR
and  and these can be explained by dierential interaction with SH2 domain eector
proteins (Rosenkranz and Kazlauskas, 1999). For example, GAP binds only to the 
receptor (Heidaran et al., 1990). Another example is the importance of PI3K in PDGFR
signalling, whereas it does not seem to be an important eector for PDGFR (Rosenkranz
and Kazlauskas, 1999). In vascular smooth muscle cells, the signalling mechanisms of the
 and  receptors are dierent and the  receptor promotes cellular hypertrophy whereas
the  receptor mediates mitogenesis (Inui et al., 1994). This was discovered by selectively
stimulating rat vascular SMC that express both  and  receptors with PDGF-AA or
PDGF-BB (Inui et al., 1994). In this cell type, PDGF-BB elicited a mitogenic response;
however, PDGF-AA increased only protein synthesis without activating DNA synthesis.
There is a clear dierence in the phenotypes of knockout mice that lack either the  (So-
riano, 1997) or the  receptor (Soriano, 1994). Both mutants die in utero, but whereas
PDGFR decient mice exhibit incomplete cephalic closure and alterations in mutant
vertebrae, ribs and sternum (Soriano, 1997), PDGFR decient mice are hemorrhagic,
thrombocytopenic, and severely anemic and exhibit a defect in kidney glomeruli because
of a lack of mesangial cells (Soriano, 1994). The defective development of blood ves-
sels, with characteristic bleeding, has been correlated to the lack of microvessel pericyte
recruitment, subsequent aneurysm formation and capillary rupture at late gestation (Lin-
dahl et al., 1998). Nevertheless, the major vessels and the heart appear normal in the
absence of PDGFR; this indicates that whereas it is essential in certain cell types during
embryonic development, its complete role may be underestimated because of compensation
by PDGFR (Soriano, 1994).
601.5.2.4 Role of PDGF in development
Targeted disruption of the genes encoding the PDGF B-chain or the PDGFR gave similar
phenotypes in mice. Both mutants show an impared kidney and blood vessels development
with leaking microvessels that failed to attract supporting cells. However, in contrast to the
-receptor knock-out, the B-chain knock-out mice showed heart defects with an increased
size and trabeculation of the myocardium. The fact that this defect is not seen in the
-receptor knock-out animals suggests that during normal development it is compensated
by PDGF-BB acting via -receptors (Leveen et al., 1994; Soriano, 1994).
Knock-out of the A-chain gene led to defective development of the lung alveoli, leading
to death of the mice at around three weeks of age (Bostrm et al., 1996). PDGF-A = 
mice also lack lung alveolar SMC, exhibit reduced deposition of elastin bres in the lung
parenchyma, and develop lung emphysema due to complete failure of alveogenesis (Lindahl
et al., 1997).
The patterns of PDGF A- and B-chains and PDGF receptors expression during embryoge-
nesis are complex and dynamic and suggest that signalling can be autocrine or paracrine,
depending on the particular tissue and the stage of development (reviewed in Ataliotis
and Mercola, 1997).
1.5.3 Other molecules involved in angiogenesis
1.5.3.1 Fibroblast growth factor (FGF)
The FGF family comprises at least 22 members in humans, of which FGF-1 (acidic FGF),
FGF-2 (basic FGF) and FGF-4 play a role in angiogenesis in vivo (Fernig and Gallagher,
1994). Basic broblast growth factor (bFGF) has been shown to stimulate vessel growth
(Cross and Claesson-Welsh, 2001) and bFGF decient mice, although viable, present neu-
ronal defects and also impaired regulation of their blood pressure (Dono et al., 1998).
The redundancy among the various FGF family members may explain the absence of a
stronger phenotype and makes it dicult to dene a clear role for FGF-2 (bFGF). There
are four structurally related FGF receptors (FGFR), all possess an extracellular binding
region with three Ig-like domains, a single transmembrane domain and an intracellular
domain with a split kinase domain (Jaye et al., 1992). FGF-2 binds as a monomer to
FGFR1 and FGFR2 with high anity and requires heparin or heparan sulphate proteo-
glycan (HSPG) to promote receptor dimerisation and signalling (Plotnikov et al., 1999).
61FGF-2 is a strong activator of the ERK cascade, but it is unclear if it is able to stimulate
the PI3K/Akt pathway. A recent report has shown that FGF-2 can stimulate the activa-
tion of Akt through FGFR1 but this is also dependent on the presence of the non-receptor
tyrosine kinase Src (Sandilands et al., 2007).
1.5.3.2 Transforming growth factor-Beta (TGF-)
In humans, the TGF-s are a large family of 35 homodimeric peptides implicated in the
regulation of proliferation, migration, survival, dierentiation, and extracellular matrix
synthesis in EC and VSMC (reviewed in Bertolino et al., 2005). In mammals, seven
type I receptors, also termed activin receptor-like kinases (ALKs) 1 to 7 and ve type
II receptors have been identied for TGFs. Gene-targeting studies revealed the crucial
role of TGF- and its signaling components in angiogenesis. Targeted inactivation of
TGF-1 caused embryonic lethality (E10.5) due to defects in the yolk sac vasculature
and in the hematopoietic system (Dickson et al., 1995). TGF-1 mutant embryos have
decreased wall integrity, with defective dierentiation resulting in an inadequate capillary
tube formation and a lack of SMC recruitment at the periphery of the newly formed vessel.
A similar phenotype is exhibited by mice lacking the receptor TRII (Bertolino et al.,
2005). Moreover, mutations in two TGF- receptors, endoglin (a co-receptor for TGF-
type II receptor, lacking intracellular enzymatic function) and activin receptor-like kinase
1 have been linked to a vascular dysplasia named hereditary hemorrhagic telangiectasia
(Johnson et al., 1996; McAllister et al., 1994).
1.5.3.3 Angiopoietins and Tie receptors
Four members of the angiopoietin family of growth factors have been isolated: Ang1
to Ang4 (Jones et al., 2001). All of them seem to bind exclusively to the Tie2 (also
known as Tek) receptor tyrosine kinase, whereas the ligand for the related Tie1 receptor
remains unknown to date. Interestingly, Angiopoietins have dierent eects on endothelial
cells. While Ang1 and Ang4 both activate Tie2, Ang2 and Ang3 behave as competitive
antagonists for this receptor (Davis et al., 1996; Maisonpierre et al., 1997; Valenzuela
et al., 1999). The Tie receptors consist of one extracellular domain with one complete and
one incomplete immunoglobulin (Ig)-like domain that are separated by three epidermal
growth factor (EGF)-like cysteine repeats. These are followed by three bronectin type
III homology domains, a single transmembrane domain and an intracellular region with a
split kinase domain. Embryos lacking Tie2 die between embryonic day E9.5 and E12.5 as
62a consequence of insucient remodeling and maintenance of the primary vascular plexus
and resemble to the phenotype observed in Ang1 =  mice (Maisonpierre et al., 1997;
Sato et al., 1995; Suri et al., 1996). Both embryos present severe malformations in the
heart, and also display vascular haemorrhage. The vasculature appears simplied with
few supporting cells which suggests a role for Ang1 in mediating interactions between
the endothelium (expressing Tie2) and surrounding matrix and mesenchyme (expressing
Ang1) (Suri et al., 1996). Embryos lacking Tie1 also show defects in vascular maintenance
due to impaired endothelial cell integrity and die later in development, between E13.5 and
birth (Puri et al., 1995; Sato et al., 1995).
1.5.3.4 FAK
Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase localised at the cell mem-
brane where it mediates signals between the ECM and the cytoskeleton. FAK plays a
prominent role in the mediation of signalling by integrins or growth factor receptors, hence
controlling several crucial cell functions such as growth, survival, migration and dierenti-
ation (Parsons, 2003). Upon activation, FAK is phosphorylated at Tyrosine 397, creating
a high-anity binding site for signalling molecules carrying SH2 domains, which in turn
phosphorylate FAK within its kinase and C-terminal domain resulting in its complete ac-
tivation (Parsons, 2003). FAK has been found to play an important role in angiogenesis
and has been implicated in the migration of endothelial cells in response to VEGF-A165
(Abu-Ghazaleh et al., 2001) through its association with p130Cas, Pyk2, and Src (Cary
et al., 1998).
1.5.3.5 p130Cas
The Cas family of adaptor protein comprises of p130Cas (Crk-associated substrate), HEF1
(Human enhancer of lamentation), Efs/Sin (embryonal fyn substrate/ Src interacting)
and recently identied HELP (HEF1-Efs-p130Cas-like) (Singh et al., 2008), which have
structural homology with several domains for protein-protein interactions and share similar
eector proteins (Delippi et al., 2006), but with dierent functional role and tissue dis-
tribution. The 130-kDa Crk-associated substrate, p130Cas, was originally identied as a
protein highly tyrosine-phosphorylated in cells transformed by v-Src and v-Crk oncogenes
(Sakai et al., 1994a). It was found to be ubiquitously distributed and particularly highly
expressed in smooth muscle cells (Tang, 2009). p130Cas is composed of an SH3 domain
that interacts with proteins containing a proline-rich motif such as FAK, a proline-rich
63domain, a cluster of SH2-binding motifs and a bipartite C-terminus domain for interaction
with both SH2 and SH3 motifs (Sakai et al., 1994a). p130Cas plays an important role
in the formation of signalling complexes through its association with focal adhesion pro-
teins, such as FAK, paxillin, and SH2 domain-containing signalling molecules, such as Crk
(Sakai et al., 1994a; Polte and Hanks, 1995). Its activation is initiated after stimulation
with various growth factors, such as endothelin-1 (ET) and PDGF, and also during cell
adhesion (Casamassima and Rozengurt, 1997; Kodama et al., 2003).
1.5.3.6 Integrins
Vessel development requires the migration of EC, a process that involves cell adhesion
molecules such as integrins to interact with the extracellular matrix (ECM). Integrins are
heterodimeric transmembrane proteins that comprise a large family of over 15  and 8 
subunits that can heterodimerise in over 20 combinations.
1 subunits form dimers with at least 12 distinct  subunits. They are found on almost
all vertebrate cells: 51, for example, is a bronectin receptor, 61 a laminin receptor
and 11 a collagen receptor on many types of cells (Shimaoka et al., 2002).
The 2 subunits form dimers with at least four types of  subunit. They are expressed
on the surface of white blood cells (leucocytes and macrophages) and have an essential
role in enabling these cells to ght infection. The 2 integrins present on white blood
cells mediate cell-cell rather than cell-matrix interactions, binding to specic ligands on
another cell, such as an endothelial cell, to attach rmly to ECs at sites of infection and
migrate out of the bloodstream into the infected site (Shimaoka et al., 2002).
3 subunits are expressed by several dierent cells, including platelets, and bind several
matrix proteins, including brinogen. Another integrin, named V 3, has been identi-
ed as having an interesting expression pattern among vascular cells during angiogenesis
and vascular remodelling. Integrin-mediated adhesion triggers a number of downstream
signals, including activation of the Ras/MAPK pathway (Eliceiri et al., 1998), thus induc-
ing proliferation and cell survival by activating NF-B (Scatena et al., 1998). A major
pathway stimulated by integrin-dependent cell adhesion is activation of the FAK pathway
(Sieg et al., 1999), implicated in cell survival and migration. Furthermore, V 3 is able
to stimulate migration via matrix metalloproteinases (MMPs)-induced degradation of the
ECM (Leavesley et al., 1993). In ECs, V 3 not only stimulates MMP-2 production, but
interacts with it, to further activate the newly synthesised enzyme (Brooks et al., 1996).
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to integrin V 3 inhibits angiogenesis and tumor growth in vivo (Silletti et al., 2001).
Integrin V 3 is a receptor for a wide variety of ECM ligands including vitronectin, -
bronectin, brinogen, von Willebrand factor, osteopontin and peptides with an exposed
RGD (Arginine-Glycine-Asparagine) sequence. Finally, V 3 activation promotes its as-
sociation with VEGFR2 and augments its signalling by doing so (Soldi et al., 1999).
651.6 Proteoglycans
Proteoglycans are glycoproteins that are heavily glycosylated. They have a core protein
with one or more covalently attached glycosaminoglycan (GAG) chain(s). The chains
are long, linear carbohydrate polymers that are negatively charged under physiological
conditions, due to the addition of sulphate and uronic acid groups. Proteoglycans can be
categorised depending upon the nature of their glycosaminoglycan chains. These chains
may be: chondroitin sulphate and dermatan sulphate, heparin and heparan sulphate, or
keratan sulphate (Varki et al., 2008).
Chondroitin sulfate (CS) and heparan sulphate (HS) chains are linked to hydroxyl groups
on serine residues of certain proteins. Exactly how proteins are selected for attachment of
glycosaminoglycans is not understood. Glycosylated serines are often followed by a glycine
and have neighbouring acidic residues, but this motif does not always predict glycosylation.
Both CS and HS synthesis initiates with the transfer of xylose by xylosyltransferase to
specic serine residues within the protein core. Attachment of two galactose residues by
galactosyltransferases I and II and glucuronic acid by glucuronosyltransferase I completes
the formation of a core protein linkage tetrasaccharide. Each sugar is attached by a specic
enzyme, allowing for multiple levels of control over GAG synthesis. Xylose is attached to
proteins in the endoplasmic reticulum, while the rest of the sugars are attached in the Golgi
apparatus. The pathways for HS/heparin or CS and dermatan sulphate (DS) biosynthesis
diverge after the formation of this common linkage structure (Varki et al., 2008).
1.6.1 Chondroitin sulphate
CS chains are unbranched polysaccharides of variable length containing two alternat-
ing monosaccharides: D-glucuronic acid (GlcA) and N-acetyl-D-galactosamine (GalNAc)
(Varki et al., 2008). Some examples of proteoglycans containing CS are aggrecan, versican,
brevican, and neurocan, collectively termed the lecticans. Another example are syndecans,
single transmembrane domain proteins that are thought to act as coreceptors, especially
for G protein-coupled receptors. These core proteins carry three to ve heparan sulfate
and chondroitin sulfate chains which allow for interaction with a large variety of ligands
including FGF, VEGF, TGF, bronectin and antithrombin-1.
66Figure 1.10: Repeating disaccharide units composing CS
Chondroitin sulphate (CS) chains are unbranched polysaccharides of variable length
containing two alternating monosaccharides: D-glucuronic acid (GlcA) and N-acetyl-D-
galactosamine (GalNAc). The most common for of CS are sulphated on the GalNAc
residue in position 4 or 6.
671.6.2 Heparan sulphate
Heparan sulphate (HS) chains are unbranched polysaccharides of variable length con-
taining two alternating monosaccharides: GlcA and N-acetyl-glucosamine (GlcNAc). HS
binds to a variety of protein ligands and regulates a wide variety of biological activities,
including developmental processes, angiogenesis, blood coagulation and tumour metasta-
sis (Tumova et al., 2000). Attachment of the rst N-acetylglucosamine (GlcNAc) residue
to the tetrasaccharide linker is continued by the stepwise addition of GlcA and GlcNAc
residues. These are transferred from their respective UDP-sugar nucleotides. This is car-
ried out by one or more related enzymes whose genes are members of the exostoses (EXT)
gene family of tumour suppressors.
Figure 1.11: Repeating disaccharide units composing HS
Chondroitin sulphate (HS) chains are unbranched polysaccharides of variable length
containing two alternating monosaccharides: D-glucuronic acid (GlcA) and N-acetyl-
glucosamine (GlcNAc).
1.6.3 Role for heparan sulphate proteoglycan in angiogenesis
Endothelial-targeted deletion in N-acetylglucosamine N-deacetylase/N-sulfotransferase 1
(Ndst1), a biosynthetic enzyme catalysing the N-sulfation of specic glucosamine residues,
results in in decreased tumor angiogenesis, and angiogenesis in vitro in response to FGF-2
and VEGF-A165, altered growth factor binding to isolated endothelial cells and heparan
sulfate, and attenuation of ERK1/2 signalling (Fuster et al., 2007). Ndst1-decient em-
bryos die perinatally in a condition resembling respiratory distress syndrome (Fan et al.,
2000). Both these ndings suggest an important role for heparan sulphate proteoglycan
(HSPG) in development and particularly in angiogenesis.
Several angiogenic growth factors, such as vascular endothelial growth factor (VEGF-A),
broblast growth factor (FGF-2), and platelet-derived growth factor (PDGF-BB), depend
on HS/heparin for full biological eect (Gitay-Goren et al., 1992; Rolny et al., 2002; Yayon
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polysaccharide backbone, creating a multitude of protein binding domains (Kreuger et al.,
2005). In addition to their role in binding growth factors and presenting them to their
receptors in a cis conrmation, a study by Jakobsson et al. (2006) show that VEGF-A165-
induced signalling is potentiated by HSPGs presented in trans to the receptor. Transacti-
vation of VEGFR2 by HSPGs presented by perivascular cell types, or alternatively by the
extracellular matrix/basement membrane, traps the receptor complexes at the surface of
the cell, and hence, internalisation and degradation of activated receptor complexes are
delayed, sustaining activation and downstream signalling (Jakobsson et al., 2006).
691.7 Neuropilins
1.7.1 Introduction
Neuropilin-1 (NRP1) was originally identied as the antigen of a specic monoclonal an-
tibody called A5, raised against neuronal cell surface proteins presumed to be involved in
neuronal recognition between the visual centres and the optic nerve bres of Xenopus lae-
vis (Takagi et al., 1991, 1987). It was subsequently named neuropilin because A5 bound to
the supercial neuropile of the tadpole optic tectum (Fujisawa et al., 1995). Further work
demonstrated an essential role of NRP1 in development of the embryonic nervous and
cardiovascular systems (Gu et al., 2003; Kawasaki et al., 1999; Kitsukawa et al., 1997; Lee
et al., 2002). NRP1 and the structurally-related molecule, NRP2, are receptors both for
class 3 semaphorins, a family of secreted polypeptides with key roles in axonal guidance,
and for various members of the VEGF family of angiogenic cytokines, but are thought to
transduce functional responses only when co-expressed with other receptors: plexins in the
case of semaphorins and VEGFR2 for VEGFs. NRPs are also highly expressed in diverse
tumour cell lines and human neoplasms and have been implicated in tumour growth and
vascularisation in vivo (Gagnon et al., 2000; Klagsbrun et al., 2002; Liang et al., 2007; Pan
et al., 2007b). More recently, NRP1 was also found to be a novel mediator of the primary
immune response (Bruder et al., 2004; Tordjman et al., 2002; Wulng and Rupp, 2002).
These ndings suggest that NRPs are multi-functional co-receptors essential for neuronal
and cardiovascular development, and potentially with additional roles in other physiologi-
cal and disease-related settings. However, despite the wealth of information regarding the
likely biological functions of these molecules, many aspects of the regulation of cellular
function via NRPs remain uncertain, and little is known concerning the molecular mecha-
nisms through which NRPs mediate the functions of their various ligands in dierent cell
types.
1.7.2 NRP structure
NRP1 and NRP2a are transmembrane glycoproteins of up to 923 and 926 amino acids,
respectively, sharing a similar domain structure and an overall amino acid homology of
44% (Chen et al., 1997). NRPs comprise large extracellular regions with a multi-domain
structure, a single transmembrane domain and small cytoplasmic domains (44 amino acids
for NRP1 and 43 for NRP2). The carboxy-terminal three amino acids, SEA, present in
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association with a PDZ domain protein called NIP-1 (neuropilin interacting protein-1),
also known as GIPC (RGS-GAIP-interacting protein) or synectin (Cai and Reed, 1999).
The NRP extracellular region comprises two CUB (a1/a2) domains, two Factor V/VIII
homology (b1/b2) domains (Takagi et al., 1991), and a single MAM (c) domain (Figure
1.12).
The CUB (a1/a2) domains share homology with the complement binding factors C1s/C1r,
sea urchin bropellins (called Uegf) and Bone Morphogenetic Protein 1 (BMP1). CUB do-
mains comprising approximately 110 amino acid residues are found in functionally diverse,
often developmentally regulated proteins, including the dorso-ventral patterning protein
tolloid, BMP1, a family of spermadhesins (Bork and Beckmann, 1993). Most CUB do-
mains contain four conserved cysteines which probably form two disulphide bridges and
are predicted to form a beta-barrel structure similar to that of immunoglobulins. In NRPs,
the CUB domains contain the major ligand-binding site for semaphorins.
The b1/b2 domains consist of two tandem regions each of approximately 150 amino acids,
sharing homology with the C-terminal (C1/C2) domains of blood coagulation factors V
and VIII. In factors V and VIII, C1/C2 domains are part of a larger functional domain,
which promotes binding of membrane phospholipids on the surface of platelets and en-
dothelial cells. The NRP1 b1 domain is essential for VEGF-A165 binding, though the b2
domain is also required for optimal binding. In addition, the b1/b2 domains contribute
to semaphorin binding.
The c or MAM domain is a 170 amino acid region, found in the extracellular domains of
diverse proteins, including meprin (a cell surface glycoprotein), A5 antigen, and receptor
tyrosine protein phosphatase  (hence MAM). MAM domains are thought to mediate
homophilic protein-protein associations important for homodimerisation or oligomerisation
(Chen et al., 1998; Nakamura et al., 1998), and have also been implicated in regulating
protein stability.
71Figure 1.12: Neuropilins domain structure homology
This gure shows the protein structure of full-length and soluble neuropilins. Full-lenght
NRPs are composed of two complement binding domains (CUB), two blood coagulation
factors V and VIII homology domains (FV/VIII), one meprin-A5-phosphatase  domain
(MAM), a transmembrane domain and a cytoplasmic domain containing a PDZ binding
domain (for NRP1 and NRP2a). Soluble forms do not include the MAM, transmembrane
and cytoplasmic domains. Percentage homology between NRP1 and NRP2a and between
NRP2a and NRP2b are displayed on the gure. On the top part are represented the
genomic DNA structure of NRP1 as well as the cDNA composed of 17 exons. Figure
adapted from Pellet-Many et al. (2008).
721.7.3 Genomic organisation and expression
NRPs are present in all vertebrates so far examined, including mammals, chicken Gallus
gallus and the zebrash Danio rerio and are highly conserved between species. Though
homologues of the VEGFs and semaphorins have been found in Drosophila, Caenorhabditis
elegans and other invertebrates, NRPs have not so far been identied in lower (non-
vertebrate) organisms. Human NRP1 and NRP2 genes are located on chromosomes 10p12
and 2q34, respectively (Rossignol et al., 1999, 2000), and both encode full-length proteins
with apparent molecular weights of 130-140 KDa (923 aa for NRP1 and 926 aa for NRP2a).
The NRP1 gene spans over 120 Kb and is composed of 17 exons (Rossignol et al., 2000)
while the NRP2 gene spans over 112 Kb and also comprises 17 exons (Rossignol et al.,
2000). The strong similarities in the exon-intron organisation of the NRP1 and NRP2
genes, their exon and intron sizes, and positions of many of the splices sites suggests that
they may have originated from a gene duplication event.
1.7.3.1 NRP1 isoforms
Alternative splicing results in the generation of several soluble isoforms forms of NRP1
and NRP2. One membrane-associated NRP1 isoform has been identied, called NRP1
(exon16), which lacks the 51 nucleotides corresponding to exon 16 (Rossignol et al.,
2000; Tao et al., 2003). NRP1 (exon16) does not dier from the common full-length
NRP1 in its binding to VEGF165, dimerisation with VEGFR2 or regulation of VEGF165
signalling (Tao et al., 2003). Four NRP1 mRNA isoforms have so far been reported
(see Figure 1.12), all predicted to encode soluble proteins containing the CUB (a1/a2)
and b1/b2 domains but lacking the MAM (c), transmembrane and cytoplasmic domains.
These isoforms vary in size from 551 to 704 amino acid residues due to alternative splicing.
However, only two soluble NRP1 isoforms, s12NRP1 (NRP1 isoform b) and sIV NRP1
(NRP1 isoform c), have so far unambiguously been shown to be expressed in protein
form and are found in protein databases. sIIINRP1 contains a1/a2 and b1/b2 domains
missing 48 aa at the C terminus of the b2 domain, but contains 13 extra amino acids
resulting from a shift in the reading frame of exon 12 (Cackowski et al., 2004). Soluble
isoforms s12NRP1 (644 aa) and s11NRP1 (704aa) are secreted by a variety of tissues,
including kidney tubules and hepatocytes, where their role is currently unknown, but not
by endothelial cells. Both bind to VEGF165 and Sema3a (Gagnon et al., 2000). sIIINRP1
(551 aa) and sIV NRP1 (609 aa) occur in both normal and cancerous human tissues.
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as VEGF165 and Sema3a, and therefore negatively regulating functions mediated by these
cytokines. For example, sNRP1 triggers tumour cells apoptosis mimicking the eect of
VEGF165 withdrawal (Benjamin and Keshet, 1997; Gagnon et al., 2000). However, the
eects of sNRP1s may be more complex than suggested by a simple decoy role. Thus,
whereas an sNRP1 monomer sequesters VEGF165 and inhibits its activity, sNRP1 dimers
appear to deliver VEGF165 to endothelial cell VEGFR2, thereby promoting angiogenesis
(Yamada et al., 2001).
1.7.3.2 NRP2 isoforms
Membrane-bound NRP2 exists in two major isoforms, NRP2a which shares 44% overall
homology at the amino acid level with NRP1, and NRP2b which is identical to NRP2a in
its extra-cytoplasmic domain, but exhibits only 11% homology with NRP2a in its trans-
membrane and cytoplasmic regions (see Figure 1.12). In the mouse, a total of four NRP2a
isoforms are generated by alternative splicing resulting in insertion of 0, 5, 17 and 22
(17+5) amino acids after residue 808, situated between the MAM and the transmem-
brane domain (Chen et al., 1997). In the human, only two forms of NRP2a have been
cloned, NRP2a(17) and NRP2a(22), homologous to the corresponding mouse isoforms. The
NRP2a(22) isoform (931 amino acids) results from the insertion of the ve amino acids
GENFK within the 17 amino acid insertion of NRP2a(17) (926 amino acids). So far,
NRP2a(0) and NRP2a(5) isoforms have not been found in human tissues. These isoforms
do not appear to dier in their ligand binding properties, but insertion of residues be-
tween the MAM and transmembrane domains might potentially alter its ability to form
complexes with VEGFR2 or homodimerise. NRP2b displays little homology with NRP2a
from residue 808 (Rossignol et al., 2000) with a distinct cytoplasmic domain lacking the
carboxy-terminal PDZ domain recognition sequence, SEA, required for interaction with
synectin (Cai and Reed, 1999). Similar to NRP2a, NRP2b(0) and NRP2b(5) isoforms re-
sult from alternative splicing and the insertion of none or ve amino acids after amino
acid 808. The marked dierences in their cytoplasmic domains suggest that NRP2a and
NRP2b isoforms may have divergent functions, a possibility supported by their dieren-
tial tissue expression. NRP2a and NRP2b are both highly expressed in the brain, but
NRP2a is preferentially expressed in the liver, lung, small intestine, kidney and heart,
while NRP2b is present in heart and skeletal muscle (Rossignol et al., 2000). A soluble
NRP2 isoform is also generated by alternative splicing (Figure 1.12), s(9)NRP2 (1785 bp,
74555 aa, 62.5 kDa) consisting of the two a1/a2 domains the b1 domain and a truncated
b2 domain followed by the 8 amino acids VGCSWRLPL encoded by intron 9 (Rossignol
et al., 2000).
1.7.4 Ligands for neuropilins
NRPs have the ability to bind with high anity two structurally unrelated classes of
ligands with distinct biological functions, the class 3 semaphorins and VEGFs (see Figure
1.13).
1.7.4.1 Semaphorins
Semaphorins constitute a large protein family including both transmembrane and secreted
species expressed in diverse Metazoans (worms, insects, crustaceans, shes, vertebrates)
and also in viruses but not in plants or protozoans (Raper, 2000; Yazdani and Terman,
2006). The class 3 semaphorins are secreted proteins, most of which require NRP1 or 2
as obligate co-receptors. The major ligand for NRP1 is Sema3a (also named collapsin-1),
a factor that induces collapse of the growth cone in selected sensory and sympathetic
neurons, e.g. dorsal root ganglia, also repels DRG axons, and is essential for neurogenesis
in development (Luo et al., 1993). NRP1 also binds Sema 3F with lower anity and
several other secreted class 3 semaphorins (see Figure 1.13), though the functional roles
of these interactions are not clear in each case. The binding of Sema3a to the CUB
domains of NRP1 is mediated by the sema domain, a conserved extracellular domain of
500 amino acids forming a -sheet propeller structure held together by four disulphide
bonds (Gherardi et al., 2004), while a carboxy-terminal region of Sema3a rich in basic
residues interacts with the b1b2 domains (Gu et al., 2002; He and Tessier-Lavigne, 1997;
Taniguchi et al., 2005). The most well-characterised ligands for NRP2 are Sema3c and 3f,
and NRP2 also recognises Semas3b and 3g, but does not bind Sema3a. There is evidence
that several NRP2 ligands (Sema3b, c and f) may act as antagonists of Sema3a (Chen
et al., 1997; Tamagnone et al., 1999). The members of the class 3 semaphorins have
dierent anities for NRPs 1 and 2 and require distinct plexins to transduce their signal.
Therefore dierent complexes combinations can be formed and allow a ne tuning of the
downstream signal of plexins.
751.7.4.2 VEGFs
The most active and abundant isoform, VEGF-A165 contains exon 7 but lacks exon 6, and
is able to bind to both NRP1 and 2, indicating a key role for the domain encoded by exon 7
in NRP binding (Soker et al., 1996). However, VEGF-A145 lacks exon 7 and binds only to
neuropilin 2 (Gluzman-Poltorak et al., 2000). Though VEGF-A165 was originally believed
uniquely able to bind to NRPs with high anity through its exon 7-encoded carboxy-
terminal domain, it now appears that the residues encoded by exon 8 are crucial for NRP
recognition. Peptides corresponding to exon 8 inhibit VEGF binding to NRP1 (Jia et al.,
2006), and a naturally-occurring peptide, Tuftsin, with homology to exon 8 also binds
NRP1 (von Wronski et al., 2006). Antibodies specically blocking VEGF-A165 binding to
NRP1 also inhibited endothelial cell migration induced by VEGF-A121 (Pan et al., 2007b).
VEGF-A121, lacking exon 7 but containing exon 8, was found to bind NRP1 in vitro using
surface plasmon resonance, but was unable to promote complex formation between NRP1
and VEGFR2 (Pan et al., 2007b). These ndings are consistent with a model in which
initial VEGF binding to NRP1 is mediated via the extreme carboxy-terminal residues
encoded by exon 8. NRP1 is either stabilised by further interactions between NRP1 and
exon 7-encoded residue and/or the exon 7 domain functions as a bridge between NRP1
and VEGFR2. The larger isoforms, VEGF-A189 and VEGF-A206, bind heparin, are not
readily diusible, and are thought to remain sequestered by the extracellular matrix. A
novel isoform, VEGF-A165b, has a distinct carboxy-terminus, RSLTRKD, encoded by an
alternative exon 8 and is unable to stimulate endothelial cell proliferation, angiogenesis
or other biological activities (Bates et al., 2002). Possibly, the weaker biological activity
of VEGF-A165b is due to its inability to bind NRP1 and thereby to promote productive
signalling complexes with VEGFR2. VEGF-B and VEGF-E have been shown to bind to
NRP1 (Makinen et al., 1999; Wise et al., 1999), while VEGF-C and VEGF-D interact with
NRP1 and NRP2 (Karkkainen et al., 2001; Karpanen et al., 2006). PlGF-2 also binds to
NRP1 (Migdal et al., 1998). Whether binding of other VEGFs to NRPs results in complex
formation with the respective receptor tysine kinases, VEGFR1/Flt-1, VEGFR2/KDR, or
VEGFR3/Flt-4, and the biological relevance of these interactions, remains unclear. Also,
the role of VEGF-A binding to NRP2 is not clear.
76Figure 1.13: Neuropilins, their ligands and co-receptors
This gure shows the two dierent families of neuropilin ligands: Class 3 Semaphorins and
VEGFs. Both comprise dierent isoforms and are classied in function of their binding
properties to NRP1 and/or NRP2. Also, the neuropilin co-receptors are represented:
Plexin A1/2 which participates to the binding module for Semaphorins and VEGFR2
(Vascular endothelial growth factor receptor 2 also called KDR for kinase insert domain-
containing receptor) and VEGFR3 (Vascular endothelial growth factor receptor 3 also
called Flt-4 for fms-related tyrosine kinase receptor 4) which participate to the formation
of binding modules with NRP1 or NRP2 for VEGFS. Under the NRP1 and NRP2 symbols
are indicated their biological functions in relation to the family of ligands (Semaphorins
or VEGFs). Figure from Pellet-Many et al. (2008).
771.7.5 Neuropilin function in development
Targeted disruption of NRP genes has demonstrated an essential dual role of these molecules
in neurogenesis and cardiovascular development (Table 1.1). NRP1 null mice die between
E12 and E13.5 with a spectrum of cardiovascular and neuronal defects. Both the central
nervous system (CNS) and peripheral nervous system (PNS) are severely aected with
severe abnormalities in the trajectory and connection of eerent bres of the PNS (Kit-
sukawa et al., 1997). Vessels of the yolk sacs are disorganised and the capillary network
sparse. Aberrant embryonic macrovascular development is characterised by lack of devel-
opment of the branchial arch, related great vessels and dorsal aorta, by a transposition
of the aortic arch, and insucient septation of the Truncus arteriosus (Kawasaki et al.,
1999). NRP1 over-expression also results in embryonic lethality with excess capillary
growth, haemorrhage in the head and neck and a malformed heart, in addition to anarchic
sprouting and defasciculation of nerve bres (Kitsukawa et al., 1995). These transgenic
embryos also appear redder than normal, suggesting that the blood vessels are leaky per-
haps due to an enhanced vascular permeability activity of VEGF-A165. In contrast to
NRP1 mutant mice, NRP2 null mice survive to adulthood with no obvious cardiovascular
abnormalities, but exhibit a severe reduction of small lymphatic vessels (Yuan et al., 2002)
and capillaries, as well as abnormal guidance and fasciculation of cranial and spinal nerves
(Chen et al., 2000; Giger et al., 2000). Doubly decient NRP1 = /NRP2 =  mice exhibit
earlier embryonic mortality than the single NRP1 knock out (E8 versus E12-13.5) and
have a more severe vascular phenotype resembling the VEGF-A165 and VEGFR2 knock-
outs (Takashima et al., 2002), marked by large avascular areas in the yolk sacs, and head
and trunk regions, and a lack of connections between blood vessel sprouts.
An essential role of NRP1 in vascular development has also been demonstrated in other
vertebrate species. Morpholino NRP1 knock down in the developing zebrash (Bovenkamp
et al., 2004; Lee et al., 2002; Yu et al., 2004) produced a severe vascular phenotype char-
acterised by a loss, or anarchic sprouting, of new capillaries from pre-existing intersomitic
vessels, but had no eect on the formation of the major axial vessel, suggesting that, in
zebrash, NRP1 is not implicated in vasculogenesis (Lee et al., 2002). Defects were also
observed in the developing zebrash nervous system after NRP1 knockdown, characterised
by aberrant migration and branching of motor neurons (Feldner et al., 2005).
Important insights into the relationship between the vascular and neural functions of NRPs
have been yielded by analysis of tissue-specic knock-outs and mutant knock-in mice. An
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the generation of endothelial-specic NRP1 knock out mice. These mice exhibit mid-to-
late embryonic lethality, a poorly-branched vasculature and multiple defects in the major
arteries and failure of septation of the major cardiac outow tract (Gu et al., 2003). In
contrast, knock-in mice expressing a mutant NRP1 with a 7 amino acid deletion in the
CUB (a1) domain required for Sema 3A binding but retaining the ability to bind VEGF-
A165, survive to birth, possess no obvious cardiovascular defects, but exhibit aberrant
pathnding of sensory aerent nerves to synapses in the CNS and defasciculation of spinal
and cranial nerves, most of the mice dying by P7. Specically, the Semaphorin/NRP1 sig-
nalling axis is essential for formation of cranial and spinal nerve projections, guidance of
peripheral projections of bipolar neurons of the vestibular ganglion and the central projec-
tions of a subset of axons of cutaneous sensory neurons, and for basal cortical neuron den-
drite development (Gu et al., 2003). These ndings indicate a critical role for Semaphorin
binding to NRP1 in axonal pathnding, but also demonstrate the compartmentalisation
of the neuronal and vascular roles of NRP1. The importance of Semaphorin-Neuropilin in-
teractions in axonal homing is further emphasised by the close similarities of the neuronal
pathnding defects in NRP1 and Sema 3A mutant mice (Gu et al., 2003; Kitsukawa et al.,
1997; Taniguchi et al., 1997), and in mice lacking NRP2 (Chen et al., 2000; Giger et al.,
2000; Huber et al., 2005; Sahay et al., 2005; Tran et al., 2007). The guidance of motor
axons from the spinal cord during vertebrate limb bud development serves as a striking
illustration of how the expression pattern of NRPs and their specic semaphorin ligands
exquisitely choreographs the homing of specic subsets of axons. These ndings indicate
that in key respects the cardiovascular and neuronal guidance functions of NRP1 are not
reliant on mutual dependence or cross-talk between the development of these networks,
mediated by ligands for a shared receptor, but result from spatially distinct and divergent
functions of NRP1 expressed in the vasculature or neurons. However, there is some co-
operation between Sema 3A and VEGF binding in cardiovascular development because
knock-in NRP1 mice decient in Sema 3A binding and also null for NRP2 (Table 1.1),
mice in which VEGF is only able to bind to NRP1, exhibit cardiovascular defects similar
to those in endothelial-specic NRP1 null mice (Gu et al., 2003).
NRP expression may also play an important role in the early specication of arterial and
venous fate during vascular development. In one day old chick embryos, NRP1 and NRP2
are co-expressed in the early extra-embryonic blood islands, but by the 13 somite stage
expression of NRP1 and NRP2 has become restricted to, respectively, the arterial and
79venous regions of the primary vascular plexus before blood has started to ow (Herzog
et al., 2005). In 26-somite embryos, which have a functioning vasculature, NRP1 and
NRP2 are dierentially expressed in arteries and veins, while the NRP2 ligand, Sema 3F,
was bound to NRP2-expressing cells (Coultas et al., 2005; Herzog et al., 2005). Similar
to the expression patterns in the chicken embryo, NRP1 is preferentially expressed in the
dorsal aorta of zebrash embryos, and NRP2 transcripts are localised to the posterior
cardinal vein (Coultas et al., 2005). It is unclear at present whether dierential NRP
expression is crucial for the early embryonic segregation of arterial and venous cells in
mammalian embryos, though the mild phenotype in NRP2-decient mice (Table 1.1),
suggests that NRP2 expression may be less important in this respect.
1.7.6 Cellular functions
The most characteristic biological function mediated by NRPs in neuronal cells is chemore-
pulsion. NRP1 is essential for mediating Sema 3A stimulation of growth cone collapse and
axon repulsion in DRG neuronal cultures (He and Tessier-Lavigne, 1997; Kolodkin et al.,
1997), while NRP2 is responsible for Sema 3F-induced repulsion of superior cervical gan-
glia (Chen et al., 1997; Giger et al., 1998). Sema 3A and 3F have also been reported to
promote chemorepulsion in porcine aortic endothelial (PAE) cells expressing, respectively,
NRP1 and NRP2 (Bielenberg et al., 2004; Miao et al., 1999), though other investigators
failed to nd an inhibitory eect of Sema 3A on EC migration (Pan et al., 2007a). Sema
3A also appears to be required for the correct orientation and chemoattraction of cortical
apical dendrites (Polleux et al., 2000). This chemoattracatant role of Sema 3A is mediated
at least in part via NRP1, as judged by the eects of function-blocking NRP1 antibody.
Remarkably, the conversion of the Sema 3A/NRP1 axis from chemorepulsion to chemoat-
traction is determined by the distribution of soluble guanylate cyclase: guanylate cyclase
is localised to the dendrite, and inhibition of either guanylate cyclase or protein kinase G
disrupted dendrite outgrowth in response to Sema 3A (Polleux et al., 2000; Song et al.,
1998).
Most evidence points to a role of NRP1 in endothelial cell migration and adhesion. Co-
expression of NRP1 and VEGFR2 in PAE cells enhances VEGF binding and chemotaxis
(Soker et al., 1998), and NRP1 mediates endothelial cell attachment to extracellular matrix
(Murga et al., 2005). VEGF-A165 also stimulates morphogenetic responses in renal epithe-
lial cells, including sheet migration and tubulogenesis, through a mechanism dependent
on VEGFR2 and which is also blocked by either neutralising antibody to NRP1 or by the
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81chemorepulsive NRP1 ligand, Sema 3A (Karihaloo et al., 2005). Antibodies which specif-
ically block VEGF binding to NRP1 inhibited the migratory response to VEGF, in vitro
endothelial cell sprouting, and neovascularisation in vivo (Pan et al., 2007a). Interestingly,
the same study reported that blocking NRP1 antibodies prevents pericyte recruitment to
new vessels in mouse neonatal retinal vascularisation and tumour vascularisation models,
suggesting a role of endothelial NRP1 in the maturation and stabilisation of developing
vessels. The cellular mechanism underlying such a role of NRP1 is unclear, but could
occur via one or both of two mechanisms, one in which endothelial NRP1 is important for
adhesion or chemoattraction of pericytes to developing vessels, and/or a role for pericyte
NRP1 in adhesion and migration of immature VSMC (Pan et al., 2007a). The fact that
NRP1 is expressed in some mature VSMC cell types suggests a role for this molecule in
migratory and adhesive functions of these cells (Shintani et al., 2006).
Analysis of vascularisation in the developing hindbrain of NRP1 =  mice shows that this
molecule plays a key role in the guidance of specialised endothelial tip cells in newly
sprouting vessels. Tip cells extend long lopodia, which sense gradients of VEGF, and
undergo a stereotypic series of movements during development. In NRP =  mice, tip cell
lopodia remain associated with radial glia in the subventricular zone of the hindbrain and
fail to move laterally across this region, forming characteristic tufts (Gerhardt et al., 2004).
These ndings indicate that NRP1 may not be essential for endothelial cell migration per
se, or for elaboration of the cellular migratory apparatus, but rather for determining
the trajectories of migrating cells, similar to its pathnding and homing role in neuronal
patterning.
Several studies indicating a role for NRP1 in cell adhesion to extracellular matrix, are
suggestive that such a role of NRP1 may be independent of known ligand interactions
(Murga et al., 2005; Shimizu et al., 2000). Shimizu et al. (2000) found that recombinant
NRP1 proteins supported adhesion of a variety of cell lines, including L cells, HEK293T,
COS-7, HeLa, p19, KB and NIH3T3, and identied specic regions in the NRP1 b1 and b2
domains for adhesion, but showed that neither Sema 3A nor VEGF-A165 interfered with
this activity. Furthermore, siRNA-mediated NRP1 knockdown disrupted endothelial cell
adhesion to bronectin, laminin or gelatin, while silencing of VEGFR2 had little eect,
suggesting that an NRP1-mediated adhesive function is independent of VEGF-A signalling
through VEGFR2 (Murga et al., 2005). Blocking NRP1 antibodies appeared to have no
eect on adhesion of endothelial cells to bronectin (Pan et al., 2007a), consistent perhaps
82with the independence of any adhesive function from VEGF binding.
1.7.7 Receptors and signalling mechanisms
NRPs are not thought to be able to transduce a biological signal or response in the absence
of another signalling receptor, but to function as co-receptors that bind extracellular lig-
ands with high anity and complex with other transmembrane molecules (e.g. VEGFR2
or plexins) to form a holoreceptor. However, this model does not fully explain all the
evidence relating to the functions of NRPs in endothelial cells and other cell types. Fur-
thermore, NRP1 has been demonstrated to associate with at least one intracellular PDZ
protein, synectin, raising the possibility that NRPs despite having a small cytoplasmic
domain may be able to modulate intracellular signalling through protein-protein interac-
tions.
1.7.7.1 Plexins
NRP1 mediates the chemorepulsive eects of Sema 3A, but does so by acting as the ligand-
binding module of a complex or holoreceptor between NRP1 and specic members of a
family of transmembrane receptors called plexins (Rohm et al., 2000; Takahashi et al.,
1998; Tamagnone et al., 1999). NRP1 and 2 form complexes with several plexins inde-
pendently of the presence of their ligand Sema 3A, including plexin A1, plexin A2, plexin
A3 and B1 (Cheng et al., 2001; Rohm et al., 2000; Tamagnone et al., 1999). The human
plexin gene family comprises nine members divided into four subfamilies: four plexin As
(1 to 4), three plexin Bs (1 to 3), plexin C1 and plexin D1 [30]. Plexins are large trans-
membrane receptors with extracellular regions comprising a Sema domain (homologous
to sema domains in Semaphorins), two or three plexin-cysteine-rich regions called Met-
related sequences (MRS) domains also found in the MET oncogene family, and three or
four immunoglobulin-like domains shared by plexins and transcription factors (IPT), a
transmembrane domain, and an intracellular region containing two conserved regions, the
functions of which are not yet clearly dened, but show some homology to ras GTPase-
activating protein (GAP) domains, and in the case of Plexin B1 has been shown to act as
a GAP for R-Ras (Oinuma et al., 2004).
Sema 3A contains both a NRP binding site, and potential sites of interaction with Plexins.
Antipenko et al. (2003) have proposed a model based on the crystal structure of the Sema
3A Sema domain and mutagenic analysis, in which Sema 3A binding results in a 2:2:2
83complex between Sema 3A, plexin A1 and NRP1, and involving relief of autoinhibition of
plexin A1 . This results in activation of the plexin intracellular domain and the transduc-
tion of signals essential for chemorepulsion. Deletion of the cytoplasmic domain of NRP1
did not impair Sema 3A signalling (Nakamura et al., 1998), indicating that neuropilins
may function solely as the binding entity of the complex while plexins mediate signalling.
The cytoplasmic domain of plexins is responsible for downstream signalling induced by
semaphorin and resulting in the collapse of neurons (Rohm et al., 2000; Takahashi et al.,
1999; Tamagnone et al., 1999). Monomeric GTPases of the Rho family are thought to play
a key role in regulating actin-based motility in neuronal cells (Hall and Nobes, 2000), and
have been implicated in Semaphorin-mediated growth cone collapse (Negishi et al., 2005;
Rohm et al., 2000)]. Recruitment of Rnd to the cytoplasmic Plexin A1 domain triggers
cytoskeletal collapse, but this eect is antagonised by RhoD which is also able to bind to
Plexin A1 but blocks repulsion of sympathetic neurons (Figure 1.14) (Zanata et al., 2002).
Sema 3A-induced cytoskeletal collapse in Cos-7 cells was dependent on co-transfection of
Plexin A1 and NRP1, required activation of Rac, but not Rho, and involved a direct in-
teraction between Rac and the plexin A1 cytoplasmic domain (Meyer and Feldman, 2002;
Ng and Luo, 2004; Turner et al., 2004). If and how NRP1 regulates Plexin-dependent
signalling through small GTPases is unclear.
1.7.7.2 CAM (Cell-Adhesion Molecule) L1
The immunoglobulin superfamily cell adhesion molecule, L1, is also a potential partner for
NRP1 in mediating chemorepulsive Sema 3A signals (Figure 1.14). L1-decient mice are
smaller, less sensitive to touch and pain, and exhibit lack of hind limb coordination com-
pared to littermate controls, and display a striking reduction in the size of the corticospinal
tract and in the association of Schwann cells with axons, (Dahme et al., 1997). That part
of the phenotype in these mice results from defective axonal guidance orchestrated by
Sema 3A, is suggested by the inability of Sema 3A to repel L1-decient cortical axons
(Castellani et al., 2000), and the formation of stable complexes of L1 and NRP1 mediated
by interactions between their extracellular domains (Castellani et al., 2002). NRP2, which
is not required for Sema 3A signalling, was unable to associate with L1-CAM (Castellani
et al., 2002). Several L1 mutations located in the NRP1 binding region are associated
with a spectrum of human neurological disorders, including X-linked hydrocephalus and
MASA syndrome (Mental retardation, Aphasia, Shuing gait, Adduced thumbs). Inter-
estingly, one such mutation, L120V, also disrupts L1 association with NRP1, suggesting
84Figure 1.14: Mechanisms of NRP action
Left: In sensory neurons, NRP1 can complex with plexin A1 or A2, or with L1-CAM.
L1 CAM contains six Immunoglobulin(Ig)-like domains (red ellipses) and ve bronectin
type III domains (green squares) in its extracellular region. The L1 intracellular domain
associates with ankyrin (rounded brown rectangle), which may link L1 with spectrin (chain
of yellow ellipses) and actin (red chain of small red circles), and is implicated in mediating
eects of Sema 3A on the cytoskeleton. Plexin A1 activity is regulated by the rho-like
GTPases Rnd and its antagonist RhoD (respectively, beige and light blue circles), though
how NRP1 regulates this pathway is unclear; the inhibitory eect of RhoD on plexin A1
activity is represented by a red barred line.
Right: VEGF-A165 binds to NRP1 and promotes complex formation. The NRP1 carboxy-
terminal PDZ domain binding motif associates with the PDZ protein synectin and this is
thought to be important for the role of NRP1 in VEGF-A signalling and function mediated
via VEGFR2. In some contexts, VEGF-A165 and Sema 3A may also competitively bind
to NRP1 resulting either in inhibition of Sema 3A binding and downstream signalling, or
potentially the converse (indicated by a red bars). NRP1/VEGFR2 complex formation is
implicated in optimal activation (indicated by +), via a mechanism that is still unclear (?),
of VEGFR2 signalling via phospholipase C-gamma (PLC-), leading to activation of PKC
and ERK1/2, and PI3K, mediating activation of the serine-threonine kinase, Akt/PKB.
Figure adapted from Pellet-Many et al. (2008).
85a causal role of defective L1/NRP1 signalling in human neurological disease (Castellani
et al., 2002). Soluble L1 extracellular domain is able to convert repulsive Sema 3A signals
into chemoattraction by binding in trans to NRP-1 and this conversion is mediated by ni-
tric oxide-dependent activation of guanylate cyclase and consequent cyclic GMP synthesis
(Castellani et al., 2002), reminiscent of the role of asymmetric guanylate cyclase distribu-
tion in dertermining chemoattractant properties of Sema 3A in cortical apical dendrites
(Polleux et al., 2000). The eects of L1 deciency do not phenocopy the neural defects
of Sema 3A-decient or NRP1 Sema 3A =  mice, indicating that L1 regulates Sema 3A
signalling via NRP1 in a more restricted set of neurons. It is also unclear yet whether the
L1/NRP1 complex is either distinct from, or linked with, the plexin/NRP1 holoreceptor.
1.7.7.3 VEGFRs
In endothelial cells, neuropilins are co-receptor for VEGFs by forming complexes with
the VEGF protein tyrosine kinase receptor, VEGFR2/KDR. Soker et al. (1998) identied
NRP1 as a high anity receptor for VEGFA-165 in endothelial and tumour cells and found
that NRP1 co-expression with VEGFR2 enhanced VEGF-induced chemotaxis in compar-
ison to cells expressing VEGFR2 alone (Soker et al., 1998). Co-expression of NRP1 with
VEGFR2 also enhances VEGFR2 binding to VEGF, phosphorylation, signalling and mi-
gration (Mac Gabhann and Popel, 2005; Soker et al., 2002; Whitaker et al., 2001). Whether
or not NRP1 increases the anity of VEGFR2/KDR for VEGF-A remains uncertain.
However, the enhanced function of VEGFR2 in the presence of NRP1 has been attributed
to enhanced VEGFR2 signalling when it complexes with NRP1, rather than to an in-
crease in the intrinsic anity of VEGF for its receptors (Whitaker et al., 2001). There are
also diering reports as to whether or not VEGF binding is required for NRP1/VEGFR2
complexation. Two groups showed that association between NRP1 and VEGFR2 was
dependent on VEGF treatment (Pan et al., 2007a; Soker et al., 2002), whereas Whitaker
et al. (2001) and Shraga-Heled et al. (2007) found that co-immunopreciptation of VEGFR2
and NRP1 in Cos-1 cells co-expressing the two receptors and in HUVECs occurred inde-
pendently of VEGF-A165.
While the precise mechanism mediating the modulation of VEGFR2 signalling by NRP1
is unclear, complex formation does appear to play a crucial role. Complexation between
NRP1 and VEGFR2 enhances VEGF binding, and inhibition of complex formation is as-
sociated with reduced VEGFR2 phosphorylation, intracellular signalling, mitogenesis, cell
migration, and angiogenesis (Oh et al., 2002; Pan et al., 2007a; Soker et al., 2002; Wang
86et al., 2003; Whitaker et al., 2001). Since VEGF stimulates biological activities in PAE
cells expressing only VEGFR2, signalling via VEGFR2 can be triggered by VEGF-A165
independently of NRP1. Furthermore selective inhibition of VEGF-A165 binding to NRP1
and NRP1/VEGFR2 complex formation does not prevent either VEGFR2 signal trans-
duction or the stimulation of endothelial biological responses by VEGF-A165 (Jia et al.,
2006; Pan et al., 2007a). Thus, inhibition of VEGF165 binding to NRP1 using a specic
peptide antagonist (EG3287) that mimicks the VEGF NRP1 binding domain, attenuated
rather than inhibited VEGF-induced VEGFR2 tyrosine phosphorylation, and activation
of ERK and phospholipase C-, and reduced prostacyclin production, but had less eect
on Akt activation and did not reduce the cell survival or proliferative responses to VEGF
(Gluzman-Poltorak et al., 2000). Antibodies that specically block VEGF binding to
NRP1 prevented NRP1 complexation with VEGFR2, but had limited eects on VEGFR2
phosphorylation and signalling (Pan et al., 2007a). It seems therefore that NRP1 is not
essential for the full spectrum of signalling pathways and biological responses stimulated
by VEGF, but is instead required for optimal VEGF-induced VEGFR2 signalling through
some pathways and for maximum function in the case of certain biological processes, such
as migration.
Several mechanisms could theoretically account for the ability of NRP1 to enhance VEGFR2
signalling. NRP1 could increase the anity of VEGFR2 for VEGF-A, though previous
studies have concluded that NRP1/VEGFR2 complexation does not change the anity
of VEGF for VEGFR2 (Whitaker et al., 2001). However, selective antagonism of VEGF
binding to NRP1 also greatly reduced VEGF-A cross-linking to VEGFR2 in human en-
dothelial cells co-expressing the two receptors, though the antagonist had no eect on
VEGF-A binding to PAE cells expressing only VEGFR2 (Jia et al., 2006), suggesting that
NRP1/VEGFR2 complex formation may stabilise binding of VEGF-A165 to VEGFR2,
therefore increasing the longevity of VEGFR2 signalling. A second mechanism is that
NRP1/VEGFR2 complex formation may stabilise VEGFR2 at the cell surface, by render-
ing it less labile, and/or less prone to receptor-mediated endocytosis and therefore able
to increase the duration and amplitude of receptor activation and downstream signalling.
In support of this notion, siRNA-mediated NRP1 knockdown was recently reported to
both reduce VEGFR2 expression and attenuate VEGF-induced gene expression in human
endothelial cells (Holmes and Zachary, 2005). Thirdly, as discussed in more detail below,
NRP1 may itself either transduce intracellular signals, or participate in protein-protein in-
teractions, which enhance the signalling function of the NRP1/VEGFR2 complex relative
87to VEGFR2 alone.
NRP1 has been found to bind in vitro to the VEGFR1/Flt-1 extracellular Ig-like domains
3 and 4 (Fuh et al., 2000), and it is possible that such a complex may compete for VEGF
binding to VEGFR2/NRP1 heterodimers. Recent ndings indicate that NRP2 interacts
with VEGF-C in a heparin dependent manner and VEGF-D in a heparin-independent
manner (Karpanen et al., 2006). Moreover, VEGFR3 and NRP2 displayed colocalisation
and co-internalised following stimulation by VEGF-C and D (Karpanen et al., 2006). The
formation of complexes between NRP2 and VEGFR2 or VEGFR3 resulted in a lowering
of the activation threshold of VEGFR2 and an enhancement of cell survival and migration
induced by VEGF-A and the VEGFR3 ligand, VEGF-C (Favier et al., 2006). VEGFR3
and VEGF-C are both strongly implicated in lymphatic vascular development (Adams and
Alitalo, 2007), and complex formation between VEGFR3 and NRP2 may help to explain
the involvement of NRP2 in lymphangiogenesis as suggested by the phenotype of NRP2
knock out mice (Yuan et al., 2002) and Table 1.1. Co-immunoprecipitation of cross-linked
125I-VEGF also revealed the existence of a NRP2/VEGFR1 complex (Gluzman-Poltorak
et al., 2001), but the biological relevance of such a complex is not clear.
1.7.7.4 Other ligands and co-receptors
Recent evidence indicates that NRP1 may be a receptor for other growth factors in the
regulation of non-neuronal and non-endothelial cells (Glinka and Prud'homme, 2008; West
et al., 2005). over-expression of NRP1 in pancreatic cancer cells promotes tumour cell
invasion and HGF-induced c-Met signalling (Hu et al., 2007; Matsushita et al., 2007).
NRP1 can associate with c-Met (Matsushita et al., 2007), and NRP1 and NRP2 bind
HGF, and mediate HGF stimulation of endothelial cell migration and proliferation (Sulpice
et al., 2008). NRP1 also mediates VSMC motility induced by PDGF secreted by breast
cancer cells (Banerjee et al., 2006). The role of NRP1 in HGF and PDGF signalling is
presently unclear. The homodimeric animal lectin, Galectin-1, has also been identied
as a ligand for NRP1 in vascular endothelial cells and mediate VEGFR2 signalling and
endothelial cell migration (Hsieh et al., 2008).
1.7.7.5 NRP-interacting proteins
While there is strong evidence that NRP1 functions primarily as a co-receptor without
an independent signalling role, some ndings suggest that NRPs have functions that are
88not dependent on the known NRP ligands and interacting receptors, and further raise
the possibility that NRP1 is able to support functional cellular signalling. For example,
VEGF elicits biological responses in some cell types that are NRP-positive but express
little or no KDR, such as vascular smooth muscle cells (Ishida et al., 2001) and diverse
cancer cells (Table 1.2). As discussed above, antibodies and antagonists that selectively
block VEGF binding to NRP1 have restricted eects on endothelial VEGF signalling and
in in vivo models of angiogenesis, which do not replicate the eects of function-blocking
antibodies directed against VEGF (Jia et al., 2006; Pan et al., 2007a), suggestive that
NRP1 has VEGF independent roles in endothelial cells. Though the cytoplasmic domains
of NRP1 and NRP2 are small, they do contain a carboxy-terminal consensus PDZ binding
motif that associated with the PDZ protein, NIP1 (Neuropilin Interacting Protein-1), also
called synectin or GIPC1 (RGS-GAIP-interacting protein-1) in a yeast two-hybrid screen
(Cai and Reed, 1999). A functional role for NRP1 association with synectin in angio-
genesis is supported by the nding that expression of NRP1 lacking the C-terminal SEA
motif disrupted vessel formation in zebrash, and that knockdown of synectin in zebra
sh produced a similar vascular phenotype to that caused by NRP1 knockdown (Wang
et al., 2006). Furthermore, synectin was found to associate with NRP1 in human endothe-
lial cells, and synectin knockdown inhibited NRP1-mediated endothelial migration (Wang
et al., 2006). In contrast, the C-terminal PDZ-binding domain does not appear to be im-
portant for Sema 3A-mediated neuronal pathnding functions of NRPs (Nakamura et al.,
1998). Synectin/GIPC was originally found to associate with one of the regulators of G
protein signalling (RGS) proteins, called RGS19 (also known as GAIP) (De et al., 1998).
The GIPC/RGS19 complex is anchored to the cell membrane, localises to clathrin-coated
vesicles and has been implicated in endocytosis and intracellular membrane tracking
(Abramow-Newerly et al., 2006). Synectin/GIPC binds to G protein coupled receptors
and modulates their signalling (Abramow-Newerly et al., 2006), and can also interact
with up to twenty other proteins, including the proteoglycan, syndecan-4 (Gao et al.,
2000), the integrin 5 and 6 subunits (El et al., 2002), the transmembrane semaphorin,
M-SemaF (Wang et al., 1999), and rho GEF (rho guanine exchange factor or syx1) (Liu
and Horowitz, 2006). These ndings suggest that synectin has the potential to participate
in multimeric protein complexes or scaolds able to link surface receptors and integrins
with intracellular signalling networks. In vivo studies show the importance of synectin
in the development of a functional vascular system in both the zebrash and the mouse
(Chittenden et al., 2006). Synectin decient mice are viable, but the mice are smaller
89(30% less than littermate controls), and the number of small arteries were signicantly
reduced, resulting in impaired vascular functions (Chittenden et al., 2006). Arterial cells
from synectin =  mice exhibited reduced angiogenic and endothelial responses in vitro,
and aberrant cellular distribution of rac1 (Chittenden et al., 2006). The mainly microvas-
cular arterial defects in synectin knockout mice do not phenocopy the embryonic lethality
or aberrant macrovascular development of either global or endothelial-specic NRP1 de-
ciency, indicating that not all developmental functions of NRP1 are dependent on synectin
association. However, it is possible that other related molecules, such as GIPC2 or GIPC3,
may compensate for loss of synectin (Katoh, 2002). Nevertheless, the fact that synectin
binds to the C-terminus of NRP1 is suggestive of independent cytoplasmic signalling and
suggest the existence of other as yet unidentied interacting proteins.
1.7.8 Neuropilin Functions in Disease and Adult Tissues
1.7.8.1 Cancer
NRP1 and NRP2 are expressed by a wide variety of human tumour cell lines and diverse hu-
man neoplasms (Bielenberg et al., 2006; Ellis, 2006; Soker et al., 1998), and are implicated
in mediating eects of VEGF and Semaphorins on the proliferation, survival and migration
of cancer cells (Bachelder et al., 2001; Chabbert-de et al., 2006; Miao et al., 2000). Table
1.2 summarises the expression of NRPs and other VEGF receptors in a panel of represen-
tative carcinoma cells. Over-expression of NRP1 in Dunning rat prostate AT2.1 carcinoma
cells increased tumour growth in vivo (Miao et al., 2000), while NRP1 knockdown using
siRNA inhibited breast carcinoma cell migration (Bachelder et al., 2003), and a peptide
targeted to the VEGF binding site of NRP1 induced breast tumour cell apoptosis (Barr
et al., 2005). NRP1 is expressed in patient specimens from lung, breast, prostate, pan-
creatic and colon carcinomas, but not in corresponding normal epithelial tissues (Fukahi
et al., 2004; Kawakami et al., 2002; Lantuejoul et al., 2003; Latil et al., 2000; Parikh
et al., 2004, 2003; Stephenson et al., 2002). NRP1 has also been found in several other
tumours including melanoma (Straume and Akslen, 2003), astrocytoma (Broholm and
Laursen, 2004) and neuroblastoma (Fakhari et al., 2002). NRP2 expression was reported
in lung cancer (Kawakami et al., 2002; Lantuejoul et al., 2003), neuroblastoma (Fakhari
et al., 2002), pancreatic cancer (Cohen et al., 2002), osteosarcoma (Handa et al., 2000)
and bladder cancer (Sanchez-Carbayo et al., 2003). It has been suggested that NRP1 is
more prevalently expressed in carcinomas (mainly of epithelial origin), whereas NRP2 may
90be more frequently expressed in non-carcinoma neoplasms such as melanomas, leukaemias
and neuroblastomas (Vales et al., 2007; Bielenberg et al., 2006; Ellis, 2006). However, as
Table 1.2 indicates there is no sharp distinction between the types of neoplasms expressing
NRPs 1 and 2 (Marcus et al., 2005), and often they are co-expressed. Furthermore, dif-
ferent cell lines derived from the same tumour types, such as glioma (Rieger et al., 2003),
may exhibit divergent patterns of NRP1 and NRP2 expression.
Table 1.2: Neuropilins and VEGFRs expression in tumour cells AML, acute
myeloid leukaemia cell lines; CML, chronic myeloid leukaemia cell lines; ND, not deter-
mined; ?, very low or uncertain expression; +/-, low expression or no expression in other;
+, moderate expression; ++, strong expression. Figure from Pellet-Many et al. (2008).
91Clinical studies suggest that NRP1 plays a role in tumour growth and disease progression
(Bielenberg et al., 2006; Ellis, 2006; Guttmann-Raviv et al., 2006). Over-expression of
NRPl has been demonstrated to be associated positively with the metastatic potential,
advanced stage and clinical grade of prostate carcinoma (Latil et al., 2000). NRP1 up-
regulation in gastrointestinal carcinomas appears to correlate with invasive behaviour and
metastatic potential (Hansel et al., 2004). Co-expression of NRP1 and NRP2 also increased
in the progression from dysplasia to microinvasive lung carcinoma, and correlated signif-
icantly with tumour progression and poor prognosis in patients with non-small cell lung
carcinoma (Kawakami et al., 2002). NRP1 also appears to be preferentially expressed
in metastatic cells, and is found, for example in the metastatic breast cancer cell lines
MDA-MB-231 and MDA-MB-435 but not in the nonmetastatic cell line MDA-MB-453 or
some nonmetastatic tumours (Bachelder et al., 2001; Soker et al., 1998).
Although most studies have indicated a pro-tumourigenic role of NRPs, some reports
suggest that NRP1 plays a more complex role in some tumour types. Thus, NRP1 over-
expression in Panc-1 cells was found to reduce tumour volume and incidence (Gray et al.,
2005), whereas the same group showed that FG pancreatic carcinoma cells expressing
NRP1 have increased resistance to anoikis and cytotoxic drugs (Wey et al., 2005). Fur-
thermore, some ndings suggest that not all eects of VEGF in tumour cells may be
dependent on NRP1. Lee et al. (2007) found that survival eects of VEGF in the breast
carcinoma MDA-MB-231 and MCF-7 cell lines were mediated by internally expressed
VEGFR1/Flt-1, and were unaected by NRP1 knockdown.
There is also some evidence pointing to potentially dierential or antagonistic roles of
NRP1 and NRP2 in tumour cell regulation. Sema 3F, the best-characterised ligand for
NRP2 induces a poorly vascularised non-metastatic phenotype in xenografts of melonoma
in mice (Bielenberg et al., 2004). Sema 3F and a second NRP2 ligand, Sema 3B, are both
localised to the 3p21.3 chromosomal region, which is commonly deleted in human lung
cancers (Sekido et al., 1996; Tomizawa et al., 2001). These ndings suggest that Sema
ligands for NRP2 are potential tumour suppressors.
Recent studies provide direct evidence that NRP1 contributes to tumour cell growth and
tumour neovascularisation in vivo. A peptide that inhibits VEGF binding to NRP1 has
been reported to inhibit angiogenesis and growth of tumour xenografts (Starzec et al.,
2006). An antibody targeted to the b1 domain that specically blocks VEGF-A bind-
ing to NRP1 causes a range of eects in endothelial cell cultures including inhibition of
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angiogenesis in a neonatal retinal neovascularisation model, and inhibits tumour growth
and tumour vascularisation in mouse xenograft models. A blocking NRP1 antibody alone
had a relatively small eect on tumour growth, but produced a strong additive eect when
used in combination with the blocking VEGF antibody, bevacizumab or avastin (Pan et al.,
2007a), now approved for clinical use in several late stage carcinomas. Interestingly, Pan
et al. (2007a) reported that the anti-tumour activity of blocking NRP1 antibodies was
not dependent on NRP1 expression in the tumour cell line used in the xenograft model.
Furthermore, this study also found no evidence of direct eects of NRP1 antibodies on
tumour cell proliferation, suggesting that their anti-tumourigenic eects were mainly due
to inhibition or destabilisation of the tumour vasculature. However, any conclusion that
the role of NRP1 in tumourigenesis is restricted to vascularisation should be considered
in the light of studies, discussed above, implicating NRP1 in cell migration and adhesion.
Furthermore, NRP1 plays a role in potentiating the eect of HGF (hepatocyte growth fac-
tor)/Scatter factor signalling through the c-Met receptor in both glioma and pancreatic
cancer cell lines, regulating tumour progression and invasion (Hu et al., 2007; Matsushita
et al., 2007). These ndings taken together with the expression of NRPs in diverse neo-
plasms, suggests a possible role for this molecule in tumour invasion and metastasis in
addition to its involvement in tumour vascularisation.
1.7.8.2 Immune system
NRP1 was found to be expressed in naive T-cells and immature dendritic cells (antigen-
presenting cells), cell types that interact during the primary immune response in the sec-
ondary lymphoid organs (Tordjman et al., 2002), and are essential for triggering the pro-
liferation and dierentiation of mature T-cells that will later interact again with antigen-
presenting cells to mediate antigen elimination (Wulng and Rupp, 2002). NRP1 expressed
on naive T-cells also mediated their clustering with NRP1-expressing Cos-7 cells, and the
stimulation of resting T-cell proliferation by dendritic cells was reduced by  50% by
blocking NRP1 antibodies (Tordjman et al., 2002). T-cell activation was also reduced by
Sema 3A (Catalano et al., 2006; Moretti et al., 2006). NRP1 distribution in T-cells was
polarised, and NRP1 co-localised with the T-cell marker, CD3, at the interface between
dendritic cells and immature T-cells (Tordjman et al., 2002). Although the biological rel-
evance of these ndings for the immune response in vivo is unclear, they are consistent
with the formation of homophilic NRP1 interactions between dendritic cells and imma-
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essential for T-cell maturation (Tordjman et al., 2002).
1.7.8.3 Wound healing
There is evidence that NRP1 is up-regulated in response to tissue injury and may be
involved in regeneration and repair. In Xenopus, when the optic nerve was crushed and
allowed to regenerate, the level of NRP1 increased and remained elevated for weeks be-
fore nally declining after healing (Fujisawa et al., 1995). NRP1 was also found to be
strongly expressed in the neovasculature during wound angiogenesis in a murine model of
dermal wound healing, whereas blocking anti-NRP1 antibody reduced wound vasculariza-
tion (Matthies et al., 2002). Optic nerve injury in a rat model resulted in cell invasion at
the site of injury by microglia, oligodendrocytes and astrocytes associated with induction
of Sema 3A and NRP1 (Nitzan et al., 2006). NRP1 may protect neuronal cells against
damage resulting from stress or injury. Thus IFN (interferon ) activation of microglia, a
cell type that becomes activated following neuronal injury, caused up-regulation of NRP1
and plexin A1 and was associated with induction of microglial apoptosis by Sema 3A,
suggesting that a NRP1-mediated pathway may protect neurons against damage caused
by activated microglia (Majed et al., 2006). Expression of NRPs, VEGFs and class 3
semaphorins are also up-regulated by cerebral ischaemic injury in dierent animal models
(Ara et al., 2004; Fujita et al., 2001; Gavazzi et al., 2000; Jin et al., 2000; Lindholm et al.,
2004; Pasterkamp et al., 1999; Winter et al., 2002; Zhang et al., 2001). For example,
in a mouse model of cerebral ischaemia, NRP1 mRNA expression increased rapidly and
remained elevated for at least a month after the ischaemic event (Zhang et al., 2001).
Interestingly, NRP1 was not only localised to the ischaemic neurons, but also to the en-
dothelial cells of the brain vessels. These ndings are suggestive of a dual role for NRP1 in
the response to cerebral injury, in the promotion of both neuronal growth and in cerebral
angiogenesis.
1.7.8.4 Other functions
NRP1 expression has been reported in other cell types, including bone-marrow-derived
progenitor cells (Fons et al., 2004), platelets (Kashiwagi et al., 2005) and the granulosa
and theca cells in the follicles of the bovine ovary (Shimizu et al., 2006), although the role
of NRP1 in these systems has not yet been dened.
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When I rst began to study for my PhD, an important role for the VEGF co-receptor,
NRP1, in cancer cells and in endothelial cell biology was widely accepted and several
colleagues in this lab were working on aspects of these questions. However, little was
known regarding the mechanism of action through which NRP1 regulated endothelial cell
function. It was also unknown whether NRP1 had a role in other cell types associated with
the vasculature. The initial overall aim of my thesis was to characterise the role of NRPs in
vascular cells and to elucidate intracellular mechanisms that conferred an important role
for NRP in vascular development as indicated by the phenotypes of NRP knockout and
transgenic mice. To do this I started to investigate the expression of NRPs in endothelial
cells (EC). At the same time, it was also of interest to examine whether NRP1 was also
expressed in vascular smooth muscle cells (VSMC), a major constituent of many blood
vessels. Interestingly, I observed strong NRP1 expression in human primary VSMC from
coronary arteries, and additionally also noted a dierent pattern of NRP1 expression in
VSMC compared with EC, notably, the expression of a novel high molecular weight NRP1
species not present in EC, but also expressed in diverse tumour cells. Since at that time,
very little if anything was known concerning expression of NRP1 in VSMC, or about the
identity of a high molecular weight NRP1 species, I decided to focus in my thesis on the
role of NRP1 in VSMC and the characterisation of this novel NRP1 form. The specic
aims of my thesis were to:
 Identify the high molecular weight form of NRP1 expressed in VSMC.
 Examine the possible role of NRP1 in functions of VSMC such as cell migration.
 Determine the role of NRP1 in the biological actions of known growth factors for
VSMC, particularly PDGF and VEGF.
 Investigate the role of NRP1 in intracellular signalling in VSMC, particularly sig-
nalling linked to cell migration, and compare its role in VSMC signalling with that
in EC.
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Materials and Methods
2.1 Materials
NRP1, NRP2 and synectin small interfering ribonucleic acids (siRNAs) were purchased
from Ambion and a nucleofection kit was used for transfection of smooth muscle cells
(Amaxa). Oligofectamine and lipofectamine 2000 (Invitrogen) were used to transfect HU-
VECs and cancer cells with siRNAs and plasmids, respectively. Human recombinant
soluble NRP1 was purchased from R&D systems. Recombinant soluble NRP1 b1 domain
was a kind gift from Dr Charles Allerston (Centre for Structural Biology, UCL). Tuni-
camycin, Chondroitinase ABC and Heparinase I and III (heparitinase) were purchased
from Sigma. Antibodies were obtained from Santa Cruz Biotechnologies, Cell signaling,
Seigaku and BD biosciences (see Table 2.1). ELISA kits for the detection of both total and
phospho PDGFR and  were obtained from R&D. Recombinant VEGF-A165 were from
R&D systems, and recombinant PDGF-AA and PDGF-BB were from Peprotech. 125I-
VEGF-A165 was purchased from Amersham and 125PDGF-BB from Perkin-Elmer. Pro-
tease inhibitor cocktail was CompleteTMfrom Roche and Phosphatase inhibitor cocktail
were from Sigma. The protease inhibitor comprises aprotinin, bestatin, calpain inhibitor,
chymostatin, leupeptin, pepstatin, PMSF, trypsin inhibitor. Phosphatase Cocktail 1 con-
tains microcystin LR, cantharidin, and (-)-p-bromotetramisole, and phosphatase cocktail
2 contains sodium vanadate, sodium molybdate, sodium tartrate, and imidazole. Prod-
ucts used for the generation of adenoviruses were obtained from Invitrogen and were part
of the Gateway R cloning system technology. Unless stated otherwise, all other chemicals
were obtained from Sigma, Merck or QUIAGEN and were of the highest grade available.
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Antigen Catalogue Company Host Dilution
number
NRP1 N-terminus A-12 Santa Cruz Mouse 1:300
NRP1 C-terminus C-19 Santa Cruz Goat 1 :750
NRP1 N-terminus AF566 R&D Goat 1:500
NRP1 N-terminus AF3870 R&D Sheep 1:1000
NRP2 N-terminus C-9 Santa Cruz Mouse 1:500
Flk-1 A-3 Santa Cruz Mouse 1:300
Flt-1 C-17 Santa Cruz Rabbit 1:300
PDGFR A-12 Santa Cruz Rabbit 1:500
PDGFR P-20 Santa Cruz Rabbit 1:500
Phospho-PDGFR Tyr720 Santa Cruz Goat 1:300
Phospho-PDGFR Tyr1021 Santa Cruz Rabbit 1:300
Synectin N-19 Santa Cruz Goat 1:500
GAPDH V-18 Santa Cruz Goat 1:750
Heparan Sulphate (clone 10E4) 370255 Seigaku Mouse 1:500
Chondroitin Sulphate C8035 Sigma Mouse 1:500
Phospho-Tyrosine 4G10 9411 Cell signaling Mouse 1:1000
Akt 4685 Cell signaling Rabbit 1:1000
Phospho-Akt (Ser473) 9271 Cell signaling Rabbit 1:1000
p44/42 MAPK (Erk1/2) 9102 Cell signaling Rabbit 1:1000
Phospho-Erk1/2 (Thr202/ Tyr204) 9101 Cell signaling Rabbit 1:1000
p130Cas 610271 BD Biosciences Mouse 1:1000
phospho-p130Cas (Tyr 410) 4011 Cell signaling Rabbit 1:1000
Phospho-Src 2101 Cell signaling Rabbit 1:1000
Phospho-CAMKII (Thr286) 3361 Cell signaling Rabbit 1:1000
Colin 3312 Cell signaling Rabbit 1:1000
Phospho-colin (Ser3) 3311 Cell signaling Rabbit 1:1000
972.1.1 NRP1 antagonists
The neuropilin 1 antagonist EG3287 was synthesised as described previously (Jia et al.,
2006) and was the generous gift of Ark Therapeuthics Ltd. It is a small peptide of
28 amino acids with the sequence H2N-SCKNTDSRCKARQLELNERTCRCDKPRR-OH,
and was shown to bind to the VEGF binding site of NRP1, subsequently decreasing VEGF
signalling in cells co-expressing NRP1 and KDR (Jia et al., 2006). Synthetised later was
EG00086 which has the same peptide sequence as EG3287, but is modied at its amino-
terminus by addition of an octanoyl group, and has somewhat improved potency compared
with EG3287 (Figure 2.1 and 2.2).
Figure 2.1: EG00086 amino acid sequence
Figure 2.2: EG00086 competitive binding curve
Binding assays were performed in PAE NRP1 cells in the presence of EG00086 at dierent
concentrations (from 10M to 1 nM). Results are expressed in percentage of VEGF-
A165 specic binding in function of the log of EG00086 Molar concentration. The IC50
(inhibitory concentration 50%) which corresponds to the concentration of EG00086 that
produces half of the total 125VEGF-A165-specic binding. Data kindly provided by Haiyan
Jia.
982.2 Cell culture
2.2.1 Primary cells
Human coronary smooth muscle cells (HCASMCs; TCS CellWorks) or human aortic
smooth muscle cells (HAoSMCs; TCS CellWorks) were grown on cell cultureware in a
37C, 95% air/5% CO2 incubator. Smooth muscle cell basal medium (SmBM; TCS Cell-
Works) supplemented with 0.5 ml antibiotic cocktail with gentamycin (25 g/ml) and am-
photericin B (50 g/ml) and growth supplement was used to maintain the cells. Human
umbilical vein endothelial cells (HUVECs; TCS CellWorks) or human coronary artery
endothelial cells (HCAECs; TCS CellWorks) were grown in gelatin-coated cell culture-
ware in a 37C, 95% air/5% CO2 incubator. Endothelial basal medium (EBM; Cambrex
BioScience Ltd) supplemented with gentamycin-ampicillin, epidermal growth factor and
bovine brain extract (Singlequots; Cambrex) and 10% foetal bovine serum (FBS) was used
to maintain the cells. The cells were passaged by trypsinisation and used at no later than
passage 6 for endothelial cells and passage 5 for SMC.
2.2.2 Cell lines
Porcine Aortic endothelial cells (PAE), A549 cells (human alveolar basal epithelial cells
carcinoma) and ACHN cells (human renal adenocarcinoma cells) were cultured in F12,
DMEM and RPMI media respectively (GIBCO), all containing 10% FBS and penicillin-
streptomycin (SIGMA, 10,000 units/ml penicillin and 10 mg/ml streptomycin). Lysates
from Skov-3 (human ovarian adenocarcinoma cells), Skbr-3 (human breast adenocarcinoma
cells), MCF-7 and MDA-MB-231 (both human breast adenocarcinoma cells) were a kind
gift from Dr Gianluca Sala.
Human embryonic kidney (HEK) 293A cells (Invitrogen) were grown in cell cultureware
in a 37C, 95% air/5% CO2 incubator. Cells were maintained in DMEM (Invitrogen) sup-
plemented with 10% FBS, 1% penicillin-streptomycin (Sigma), and passaged by trypsini-
sation.
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Abbreviation Full name or type Culture medium
HCASMC Human coronary artery smooth muscle cell SMC basal medium
HAoSMC Human aortic artery smooth muscle cell SMC basal medium
HUVEC Human umbilical vein endothlial cell EC basal medium
HCAEC Human coronary artery endothlial cell EC basal medium
PAEC Porcine aortic endothelial cell RPMI
PAEC/NRP1 Porcine aortic endothelial cell RPMI
stably expressing NRP1 with geneticin
A549 Human alveolar epithelial carcinoma cells DMEM
ACHN Human renal adenocarcinoma cells F-12
Skov-3 Human ovarian adenocarcinoma cells lysates
Skbr Human breast adenocarcinoma cells lysates
MCF-7 Human breast adenocarcinoma cells lysates
MDA-MB-231 Human breast adenocarcinoma cells lysates
HEK 293A Human embryonic kidney DMEM
2.3 Immunoprecipitation
2.3.1 Principle
Immunoprecipitation consists of the capture of a protein from solution. An antibody
directed against a protein of interest binds to its target in a cell lysate. This primary
antibody is then bound by a secondary reagent, inert beads conjugated to Staphlococ-
cus protein A or G, which bind to the constant region of antibodies. These beads are
then separated (along with their complexed antibody/protein) from the cell lysate by
centrifugation. Other endogenous binding partners that interact with the target protein
are co-puried and might appear in the immunoprecipitate, depending on the stability of
these interactions.
2.3.2 Experimental details
For co-immunoprecipitation experiments, cells were washed twice in ice-cold phosphate
buered saline (PBS) and lysed by scraping in lysis buer containing 20 mM Na2HPO2
pH 7.4, 150 mM NaCl, 1% Triton X-100, 5 mM EDTA with protease and phosphatase
inhibitor cocktails. Lysis was allowed to continue on ice for 30 minutes, after which the
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discarded. The lysate was then pre-cleared by incubating with washed protein A/G plus
agarose beads (Santa Cruz) for 30 minutes followed by antibody binding overnight at 4C.
Protein A/G plus agarose beads were added to capture the immunocomplex for 4 hours
at 4C with constant rotation. The IP complex was then dissociated by incubation with
2x SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) sample buer
(4% SDS, 20% glycerol, 10% 2-mercaptoethanol, 0.004% bromophenol blue, 0.125 M Tris
HCl, pH 6.8) and heating at 100C for 5 mins. Lysates were stored at -20C until used.
In experiments where NRP1 immunoprecipitates were treated with lyases (chondroitinase
and heparitinase), cells were washed twice in ice-cold PBS and lysed by scraping in lysis
buer with protease and phosphatase inhibitor cocktails. NRP1 was immunoprecipitated
from the cell lysates by incubating with an antibody directed against the NRP1 carboxy
terminus (C-19) overnight at 4C. Immunocomplexes were captured with protein A/G
Plus-Agarose Beads (Santa Cruz Biotechnologies) for 4 hours at 4C. Immunoprecipitates
were then washed, and subjected to various enzyme treatments, as described in paragraph
2.4.2.2, before analysis by western blot.
2.4 Enzyme and drug treatments
2.4.1 Tunicamycin treatment
Tunicamycin is a mixture of antibiotics which inhibit the enzyme N-acetylglucosamine
phosphotransferase which catalyses a key rate-limiting step in protein N-linked glycosyla-
tion. Tunicamycin blocks the synthesis of all N-linked glycoproteins but also causes cell
cycle arrest in G1 phase.
On the day prior to the treatment, fresh medium was added to conuent cells seeded in 6
well-plates. Tunicamycin was added to a nal concentration of 5 g/ml and incubated at
37C, for 16 hours. Cells were then lysed with RIPA buer (30 mM TrisHCl, pH 7.4, 150
mM NaCl, 1% NP-40, 0.5% Deoxycholate, 2mM ETDA) containing protease inhibitors
and phosphatase inhibitor cocktails. Lysates were stored at -20C until used for western
blotting.
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Chondroitinase (produced in Proteus vulgaris) and heparinase (produced in Flavobac-
terium heparinum) are lyases that catalyse the degradation of glycosaminoglycans to un-
saturated oligosaccharides and unsaturated disaccharides. Their primary substrates are
chondroitin sulphate and heparan sulphate proteoglycan, respectively.
2.4.2.1 In intact cells
Chondroitinase was reconstituted in a buer containing 0.01% BSA and heparinase I and
III (heparitinase) solutions were prepared in a buer containing 20 mM Tris-HCl, pH 7.5,
containing 0.1mg/ml BSA and 4 mM CaCl2. The enzymes were added to the culture
medium of the cells (complemented with 3% BSA) at a nal concentration of 1 unit per
ml. Cells were then incubated for a further 2 hours at 37C. Cells were then used in
further experiments.
2.4.2.2 In immunoprecipitates
NRP1 immunoprecipitates were treated for 2 hours at 37C with chondroitinase and hep-
aritinase at 1 Unit per ml in 1% NP-40, 0.15 M NaCl, 0.05 mM CaCl2, 20 mM Tris, pH 7.2.
Immunoprecipitates were then washed 3 times with lysis buer (20 mM Na22HPO2 pH
7.4, 150 mM NaCl, 1% Triton X-100, 5 mM EDTA, proteases and phosphatases inhibitors)
and nally resuspended in SDS-PAGE sample buer for protein analysis.
2.5 siRNAs transfection
2.5.1 Principle of siRNA mediated knockdown
RNA interference (RNAi) is a method for silencing gene expression. Two types of RNA
molecules, microRNAs (miRNA) and small interfering RNAs (siRNA) are central to RNA
interference. Briey, dsRNAs resulting from transcription are degraded to 20nt short
fragments by an endonuclease called Dicer, and then incorporated into a large multiprotein
complex, called RISC (RNA induced silencing complex). Cellular RNA complementary
to the incorporated RNA fragment is recognised by RISC and then degraded. SiRNAs
(and other nucleic acids) are negatively charged and therefore, are not readily taken up
by most cells. SiRNAs can be introduced into cells by binding with a cationic liposome-
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the siRNA into the cell. However, some cells such as primary vascular smooth muscle
cell are known to be dicult to transfect, in these cases, siRNA can be introduced via
electroporation. This technique involves applying an electric eld to induce the formation
of microscopic pores within the cell membrane through which nucleic acids can pass.
2.5.2 Experimental details
Pre-designed siRNAs (small interfering RNA) to NRP1, NRP2, GIPC1 (synectin) and
p130Cas were obtained from Ambion (Applied Biosystems); details for the siRNA sequence
are in the table below (Table 2.3). Negative control siRNAs with sequence that do not
target any gene product were used for determining transfection eciency and to control
the eects of siRNA delivery. These non targeting siRNAs have no sequence similarity
to known genes and are validated for use in human, mouse, and rat cells. We used the
Silencer R Negative Control siRNA 1 (catalogue number: AM4635).
Table 2.3: Nucleotide sequence of siRNAs used in this study (Ambion)
Target Gene Catalogue # Sequence (5'!3') Locus ID
NRP1 AM16704 GGAUUUUCCAUACGUUAUGtt 8829
NRP2 16704 GGUCGUUUGAAUUCCAAAGtt 8828
GIPC1 4392420 AGGACAAAAGGAACCCGGAtt 10755
p130Cas s18373 GGUCGACAGUGGUGUGUAU 9564
2.5.2.1 HUVECs and cancer cell lines.
Transfection of HUVECs and cancer cells were performed in 6-well plates and the volumes
of reagent used in the following protocol are adapted to this cultureware format. siRNAs
and transfection reagents (oligofectamine or lipofectamine 2000, Invitrogen) were diluted
in warm optimem as follow:
 Tube A: 176 l Optimem medium (GIBCO) + 4 l siRNA (nal siRNA concentra-
tion 200 nM) or 1 g plasmid DNA
 Tube B: 10 l Optimem medium (GIBCO) + 10 l oligofectamine or lipofectamine
2000
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plasmid DNA) was mixed with tube B (oligofectamine or lipofectamine 2000) to give a
total volume of 200 l. This solution was incubated for 25 minutes at room temperature
with occasional mixing to allow the transfection complexes to form. Meanwhile, the cells
were washed with optimem and 800 l of warm optimem was added in each well. The 200
l of complexed siRNA/DNA was added to the cells (nal volume, 1ml) and incubated
for 4h at 37C. After this period, 500 l of 30% FBS in optimem without antibiotics
was added to each well without removing the siRNA-containing media, to give a nal
concentration of 10% FBS. The medium was changed back to cell-type specic complete
medium and incubated for a further 48-72h and the cells were used for further experiments
and knockdown/DNA expression was assessed by Western blot.
2.5.2.2 HEK 293A Cells
The following technique and reagents were used to transfect HEK (Human embryonic
kidney) 293A cells in order to produce the crude stock of adenovirus. The following
description is for the treatment of a 100 mm dish containing cells at approximately 60%
conuence.
8 l of Fugene transfection reagent were added to 350 l of serum free DMEM and in-
cubated for 5 minutes at room temperature. Then, 4 g of DNA was added to this
Fugene/DMEM solution and incubated for a further 15 minutes. In the meanwhile, the
cell culture medium was replaced and 10 ml of new complete medium was added to the
cells. Finally, the DMEM/DNA/Fugene mixture was added to the cells and incubated
overnight. The cell medium was replaced the next day with some fresh complete medium,
containing 10% FBS and antibiotics. The eciency of the transfection was evaluated by
performing a control transfection with pmaxGFP (Lonza, 0.5g/l) and observing the
cells under a uorescent microscope.
2.5.2.3 VSMC
Electroporation was used for VSMCs transfection with siRNAs (nucleofector kit, Amaxa),
as these cells have proven particularly dicult to transfect using other approaches. Briey,
106 cells were resuspended in 100 l of transfecting reagent in the presence of 200 nM
siRNA (e.g. NRP1, NRP2, synectin, p130Cas and negative control) and transfered to the
nucleofector's carousel, in which an electrical eld (program A-33) was applied, causing
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membrane, thus allowing entrance of siRNA in the cytoplasm. After treatment, 500 l of
prewarmed complete medium was added to the cuvette and cells were then transfered to
two 6-well plates (one plate was used for further experiments and the other was used to
assess protein knock down by Western blotting). The medium was changed the day after
nucleofection and cells were used 24 to 72 hours after transfection.The eciency of the
transfection was evaluated by performing a control transfection with pmaxGFP (Lonza,
0.5g/l) and observing the cells under a uorescent microscope.
2.6 125I-VEGF-A165 and 125I-PDGF-BB binding assays
2.6.1 Principle of radiolabeled ligand binding assay
A radioligand is a radioactively labeled molecule that can specically associate with a
receptor. The rate and extent of radioligand binding provides information on the number of
binding sites on the surface of the cell, and their anity. Competitive binding experiments
measure the binding of a single concentration of this labeled ligand in the presence of
unlabeled ligand which compete for the same binding sites. In this study, I aimed to
quantify the amount of binding of 125I-VEGF-A165 and 125I-PDGF-BB to cells in the
presence of 100-fold excess concentration of the respective unlabeled growth factor.
2.6.2 Experimental details
HCASMC and EC were seeded in 24-well plates so they were conuent for the day of the
binding assay. Cells were then washed twice with cold PBS. Binding medium (DMEM, 25
mM HEPES pH 7.3 containing 0.1% BSA and other agents as indicated) was added (with
antagonists in some experiments), followed by addition of 0.1 nM of 125I-VEGF-A165 (1200-
1800 Ci/mmol, GE Healthcare Plc) or 0.1 nM of 125I-PDGF-BB (1825 Ci/mmol, Perkin-
Elmer), in the absence or presence of a 100-fold excess concentration of the respective
unlabelled growth factor. After 2 hours of incubation at 4C, the medium was aspirated,
and cells washed four times with cold PBS. The cells were then lysed with 0.25 M NaOH,
0.5% sodium dodecyl sulphate (SDS) solution, and the bound radioactivity of the lysates
was measured. Non specic binding was determined as the total binding minus binding
(non-specic) in the presence of 100-fold excess unlabeled VEGF-A165 (R & D Systems)
or PDGF-BB (Peprotech).
1052.7 Western blotting
2.7.1 Principle of Western blotting
Heating of cell lysates with sample buer containing SDS, an anionic surfactant, and
dithiothreitol (DTT) (or Tris(2-carboxyethyl)phosphine, TCEP) as reducing agent, re-
duces protein disulphide bonds to thiol groups and disrupt non-covalent bonds in the
proteins, denaturing them, and causing the molecules to lose their native conformation.
The proteins migrate through a gel which pore size is determined by the concentration
of acrylamide in the gel, under the inuence of an electric eld. Larger proteins migrate
slower than smaller proteins, resulting in a separation of proteins largely based on molec-
ular size. The proteins are then transferred onto a protein-binding membrane (typically
nitrocellulose or Polyvinylidene uoride, PVDF) under the inuence of an electric eld.
For antibody detection, protein binding sites on the membrane are blocked by incubating
with a protein solution such as milk or BSA, and a protein of interest is then specically
bound with an antibody. This primary antibody is then detected with a secondary an-
tibody conjugated to an enzyme, often a peroxidase. A liquid substrate is then added,
which in the presence of the peroxidase enzyme emits light in a chemiluminescent reaction,
and this light is detected using photographic lm. Western blotting is often described as
a semi-quantitative technique, with the amount of protein originally present in the lysate
proportional to the amount of peroxidase enzyme bound to protein on the membrane, and
so the amount of light generated and area and intensity of the band present on the lm.
The amount of protein in each sample was assessed before loading, to quantify the amount
of protein present in the lysates and thus allowing equal loading. Blotting with an anti-
body to glyceraldehyde 3-phosphate dehydrogenase (GAPDH), the enzyme that catalyzes
the sixth step of glycolysis, was used to visually conrm comparable protein loading.
2.7.2 Protein assay
The Bio-Rad DC protein assay was used to determine the protein concentration of lysates
following detergent solubilisation. Similarly to the Lowry assay, two steps lead to color
development: the reaction between protein and copper in an alkaline medium, and the
subsequent reduction of Folin reagent by the copper-treated protein. The characteristic
blue color with a maximum absorbance at 750 nm and minimum absorbance at 405 nm is
due to the amino acids tyrosine and tryptophan, and to a lesser extent, cystine, cysteine,
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to 20l of the alkaline copper tartrate solution, and mixed in a 96-well plate with 200l
of a dilute Folin reagent. The absorbance of each well at 690 nm was determined. Stan-
dards containing 0 to 2 mg/ml BSA were used to construct a (linear) standard curve of
protein concentration. The protein concentration of unknown samples was determined by
extrapolation from the standard curve.
2.7.3 Experimental details
Cell lysates were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) on
10% or 4-12% Bis-Tris polyacrylamide pre-cast gels (Invitrogen), and electrotransfered to
PVDF membrane. Membrane were blocked with 5% milk in PBST (Phosphate buered
saline with 0.1% Tween-20) or TBST (tris(hydroxymethyl)aminomethane buered saline
with 0.1% Tween-20) then incubated with primary antibodies overnight (dilutions of an-
tibodies as provided by the manufacturer: see table 2.1). Membranes were then washed
5 times in PBST or TBST, incubated for 1 hour with horseradish peroxidase (HRP)-
labeled secondary antibody (anti-goat, anti-mouse, anti-sheep and anti-rabbit IgG, all
from Santa Cruz), and proteins were detected using the ECL or ECL-plus (depending on
signal strength) western blotting detection system and hyperlm ECL (both Amersham
biosciences).
2.8 Enzyme-linked immunosorbent assay: ELISA
2.8.1 Principle
ELISAs were performed to quantitatively evaluate the presence of both total and phospho
PDGFR and . The DuoSet IC ELISA contains the basic components required for the
development of sandwich ELISAs to measure human PDGFR and  in cell lysates, an
immobilised capture antibody specic for human PDGFR and  binds both tyrosine-
phosphorylated and unphosphorylated PDGFR and . After washing away unbound
material, a biotinylated detection antibody specic for total PDGFR and  is used to
detect both tyrosine-phosphorylated and unphosphorylated receptor, utilising a standard
Streptavidin-HRP format, while an HRP-conjugated detection antibody specic for phos-
phorylated tyrosine is used to detect only tyrosine-phosphorylated receptor, utilising a
standard HRP format.
1072.8.2 Experimental details
Briey, the capture antibody was diluted to a working concentration of 4 g/ml in PBS,
without carrier protein and 100l were immediately added to a 96 well microplate for
overnight incubation at room temperature. The day after, each well was washed 4 times
with washing buer (0.05% Tween 20 in PBS, pH 7.2-7.4) and blocked for 2 hours with
300l of PBS containing 1% BSA. Wells were washed again 3 times before adding 100l
of lysate prepared in the following diluent: 1% NP-40, 20 mM Tris (pH 8.0), 137 mM
NaCl, 10% glycerol, 2 mM EDTA, and 1 mM activated sodium orthovanadate. The same
diluent without protein was used as the blank. The plate was left to incubate for 2 hours
at room temperature and washed again. 100l of detection antibody diluted according
to the manufacturer's recommendations in 20 mM Tris, 137 mM NaCl, 0.05% Tween 20,
0.1% BSA, pH 7.2-7.0 was added directly to the well, and left to incubate for a further
2 hours. When measuring total PDGFR and PDGFR levels, the following extra step
was required: after another 3 washes, Streptavidin-HRP was diluted according to the
manufacturer's recommendations in the same buer as the detection antibody (see above)
and 100l added to each well for 20 minutes at room temperature. Finally, 100l of
substrate solution was added to each well for 20 minutes, complemented after this time
by 50l of stop solution. The absorbance of each well was determined immediately, using
a Tecan Genios plate reader at 450nm with a reference wavelength at 595nm.
2.9 Flow cytometry
2.9.1 Principle
Flow cytometry determines the properties of individual cells, including size and the ab-
sence or presence of particular uorescently labeled antibodies associated with the cell
membranes, and can be used to sort cells into populations dened by these parameters. A
beam of light of a single wavelength is directed onto a hydrodynamically-focused stream of
uid containing cells conjugated with uorophore probes such as antibodies, which allows
the determination of the proportion of cells analysed that express the antigen.
1082.9.2 Experimental details
HUVEC and HCASMC were harvested using a non-enzymatic dissociation buer that
chelates Ca2+ions and therefore allows the cells to detach. Because antibodies can bind
non-specically to the FcR (crystallisable fragment receptors) of cells, we blocked these
receptors by pre-incubating the cells with an FcR blocking reagent (Miltenyl Biotech).
Cells were spun down and resuspended in blocking buer (1% BSA/HEPES with FcR
blocking reagent) to which antibodies to NRP1, VEGFR1 and VEGFR2 (KDR) were
added for 20 minutes at 4C . NRP1 and VEGFR1 antibodies were purchased from Mil-
tenyl Biotech, VEGFR2 was obtained from R&D Systems, all antibodies were conjugated
to phycoerythrin (PE), used at a 1:10 dilution and the isotype-matched (mouse IgG1)
antibodies were used as a control. Cells were then washed with PBS containing 0.2%
BSA, spun down and resuspended in PBS containing 1% BSA, 20mM HEPES and 7-
aminoactinomycin D (7AAD, 1:100 dilution, Sigma Aldrich). Because 7-AAD is a u-
orescent chemical compound with a strong anity for DNA and does not readily pass
through intact cell membranes, cells with compromised membranes (dead cells) will stain
with 7-AAD, while live cells with intact cell membranes will remain dark. Cells were gated
according to forward and side scatter and 104 gated events (uorescent signal emitted from
a single live cell) were acquired using a Becton Dickinson FACScan ow cytometer and
with CellQuestProTMsoftware.
2.10 Transwell migration assay
2.10.1 Principle
The Boyden chamber assay, was originally developped by Boyden for the analysis of leuko-
cyte chemotaxis (Boyden, 1962). The assay is based on a chamber of two medium-lled
compartments separated by a microporous membrane. Cells are seeded in the upper com-
partment and are allowed to migrate through the pores of a membrane into the lower
compartment comprising chemotactic molecules. After an appropriate incubation time
depending on the cell type, the membrane between the two compartments is xed and
stained, and the cells that have migrated to the lower side of the membrane are counted.
Therefore, the Boyden chamber-based cell migration assay has also been called a lter
membrane migration assay, trans-well migration assay, or chemotaxis assay.
1092.10.2 Experimental details
This type of transwell assay was used to assess cellular migration through a porous
polyethylene terephtalate membrane (Figure 2.3). Transwell membranes were coated with
collagen overnight at 4C (0.01% collagen solution, Sigma), inserted into a 24-well plate,
while serum free medium with or without growth factor (e.g. VEGF-A at 25 ng/ml,
PDGF-AA or PDGF-BB at 30 ng/ml) was added at the bottom of the well, underneath
the transwell. Cells were grown to 90% conuence, trypsinised and resuspended in serum
free medium before seeding into the transwell at a density of 1x105 cells per insert for EC,
or 5x104 cells per ml for HCASMC (8m membrane pore size, 6.4 mm diameter, BD Fal-
con). Treatments with the NRP1 antagonist, EG3287, soluble NRP1 or b1 domain were
performed by incubating the reagents for 30 minutes with the resuspended cells prior to
seeding, and those treatments were also added to the bottom of the well with the growth
factors. Cells were then allowed to migrate for 4 hours, after which, the upper surface of
the transwell membrane was gently swiped with a cotton bud to remove non-migrated cells
and stained with Reastain Quick-Di Kit (Reagena). The cells that traversed the mem-
brane were counted under bright eld microscopy (x200 magnication) using an eyepiece
indexed graticule. Eight elds were counted per insert, each treatment was performed in
duplicate and each experiment was performed at least three times (n = 3). The mean
count was used as the count for that insert.
2.11 Immunouorescence
2.11.1 Principle
Staining of permeablised cells with uorophore-conjugated antibodies allows the detection
a target protein within a cell. Using confocal microscopy, proteins can be localised to a
single plane and co-localisation with other proteins stained with a dierent dye can be
assessed given that the high Z-axis resolution is correctly set.
2.11.2 Experimental details
Cells were grown on gelatin-coated glass cover slips (15 mm diameter) in 24-well plates.
After treatment, cells were xed for 15 minutes in 4% paraformaldehyde and permeabilised
to allow penetration of the antibodies for 10 minutes with 0.1% Triton-X. They were then
110Figure 2.3: Schematic representation of the modied Boyden chamber system
for migration assay
In the bottom of the well, serum free medium is supplemented with the chemoattractant
(PDGF-BB or VEGF165) while the resuspended cells are seeded in the upper chamber in
serum free medium and left to migrate through the porous membrane for 4 hours. Figure
modied from the BD falcon catalogue.
111incubated overnight at 4C with the primary antibody solutions (chondroitin sulphate,
heparan sulphate, PDGFR, PDGFR and NRP1 antibodies diluted at 1:200 in 0.1%
TWEEN 20, 1% BSA in PBS). The secondary antibodies, Alexa uor 488-conjugated
anti-goat and Alexa uor 555-conjugated anti-mouse (Invitrogen Molecular Probes) were
prepared in 0.1% TWEEN 20, 1% BSA in PBS (dilution 1:1000) and applied to the cells for
1 hour in the dark. Cells were then rinsed several times with PBS and nally, the coverslip
was mounted on to a slide using Citiuor AF-1TM glycerol based medium (Citiuor Ltd.).
Samples were kept in the dark at 4C until they were analysed by confocal microscopy.
Images were acquired using a Leica TCS SP2 confocal microscope (excitation at 488 nm
and 543 nm).
2.12 Molecular biology
Adenoviruses were generated using the Gateway system from Invitrogen to study the eect
of wild-type (WT) NRP1 and NRP1 mutant lacking the intracellular domain (C) as well
as a NRP1 mutant lacking the major glycosaminoglycan (GAG) modication (S612A). The
amino acid and mRNA nucleotide sequences for NRP1 are shown in the Appendix, Figures
A.1 and A.2.
2.12.1 Adenoviral vectors
Structure and infection
Adenoviruses are medium-sized (  100 nm), non-enveloped, icosahedral viruses composed
of a nucleocapsid and a double-stranded linear DNA genome. There are over 51 dierent
serotypes in humans, which are dierentiated on the basis of variable regions of their
capsid proteins (Russell, 2000). They are able to infect various species of organisms,
including humans, and are responsible for several diseases, such as, infections of the upper
respiratory tract, infantile gastroenteritis, tonsilitis and conjunctivitis.
Replication
The adenovirus genome is composed of linear, non-segmented double stranded (ds) DNA
and around 3038 kilo base pairs (kbp) long, which allows the virus to theoretically carry
30 to 40 genes. Adenoviruses are able to replicate in the nucleus of mammalian cells
using the host replication machinery. Entry of adenoviruses into the host cell requires two
sets of interactions between the virus and the host. Entry into the host cell is initiated
112by the binding of the bre protein of the viral capsid to the cell receptor. There are
two well-described receptors: CD46 for the group B human adenovirus serotypes and the
coxsackievirus/adenovirus receptor (CAR) for all other serotypes. CAR is expressed by
ECs and proliferating SMCs in vitro and its expression can be induced in SMCs in vivo
after balloon angioplasty in the rat carotid (Nasuno et al., 2004). This is followed by a
second interaction between a specialised motif in the penton base protein interacting with
an integrin molecule. This interaction stimulates cell signaling and thus induces actin
polymerisation resulting in entry of the adenovirus into the host cell within an endosome
(Wu and Nemerow, 2004).
Once inside the cell, the virus exits the endosome and with the help of cellular microtubules
is transported to the nuclear pore complex whereby the adenovirus particle disassembles.
Viral DNA is subsequently released and enters the nucleus via the nuclear pore (Meier
and Greber, 2004). After this, the DNA associates with histone molecules and viral gene
expression starts. As early as 1-2 hours after infection, viral DNA can be detected in the
nucleus. The adenovirus genome has two phases of gene expression, an early and a late
phase, separated by viral DNA replication. The early genes are responsible for expressing
mainly non-structural, regulatory proteins that alter the expression of host proteins neces-
sary for DNA synthesis and for the inhibition of premature death of the infected cell by the
host-immune defenses. Once the early genes have generated the adequate virus proteins,
the replication of the adenovirus genome starts. The late phase of the adenovirus life cycle
consists of producing the structural proteins to assemble the genetic material produced by
DNA replication. Finally, once all the viral components have been generated, the virus is
packed into its protein coat. The host cell is then lysed, releasing the virus particle for
the next round of infection.
Relevance of adenoviral vectors in this study
Because primary cells and especially vascular smooth muscle cells are particularly dicult
to transfect, adenoviruses were chosen as a delivery vehicle for the NRP1 constructs. They
have been shown to be a powerful tool to produce strong expression of constructs inserted
in their genome in a wide variety of cells including HUVECs (Riccioni et al., 1998) and
SMCs (Shintani et al., 2006). The adenoviral vector used in this study and provided in
the Gateway System, pAd/CMV/V5-DEST, is unable to synthetise viral proteins and
therefore cannot produce a viable virus capable of infecting other cells. This is due to
the removal of the E1 and E3 regions responsible for activation of genes necessary for
113expression of certain transcription factors that control the expression of viral proteins.
The gene coding for a protein of choice, inserted in the adenoviral genome will be ex-
pressed under the control of the host cell transcription factors. The expression level of
the construct decreases with time and this decline is further accentuated by cell division
because adenoviruses do not integrate into the host genome, but are expressed episomally.
Accordingly, a multiple of infection (MOI) of 20 was used in this study and cell functions
were investigated at 3 to 4 days after infection.
2.12.2 Adenovirus production using the Gateway R cloning system
The Gateway R Technology is a universal cloning method based on the site-specic recom-
bination properties of bacteriophage lambda (Landy, 1989). The Gateway R Technology
enables movement of DNA sequences into multiple vector systems for functional analysis
and protein expression (Hartley et al., 2000).
The rst step of the cloning process requires the introduction of a construct sequence
into a universal Entry vector (pENTRTM/D-TOPO R ) (Figure 2.4). This reaction is
catalysed by the enzyme topoisomerase which allows the ligation of the linearised entry
vector comprising a four nucleotide (nt) overhang (attP-containing donor) with a blunt-
ended fragment (attB-anked PCR product) with a 5' CACC sequence (complementary
to the overhang sequence). The entry vector comprises a kanamycin resitance gene to
select for positive recombinant Entry clones. Once in the Entry vector, the sequence of
interest can be transfered to several destination vectors. This is the second step of the
cloning process, which is performed by recombination between the attL1/L2 sites in the
entry vector and the attR1/R2 sites in the recombination vector.
pAd/CMV/V5-DEST Vector is a Gateway R adapted vector specically designed to allow
transient expression of recombinant fusion proteins in dividing and non-dividing mam-
malian cells. Key Features of the destination vector include a CMV (cytomegalovirus)
promoter for high level of expression of the gene of interest and a C-terminal V5 epitope
for detection of recombinant protein using the Anti-V5 antibodies (Figure 2.5). Also,
positive recombinants possess an ampicilin resistance to allow for their selection. When
transfected to 293A cells, the Pac I linearised pAd/CMV/V5-DEST vector produces E1,
E3 lacking adenoviruses containing the sequence of interest (crude adenoviral stock). This
cell line, a subclone of the 293 cell line, supplies the E1 (E1a and E1b) proteins required
for production of replication-competent adenovirus and exhibits a attened morphology
114to enhance visualization of plaques. If the construct is engineered so it is lacking a stop
codon at the end of its nt sequence, the destination vector adds a C-terminus tag. The
V5 epitope tag is derived from a small epitope present on the P and V proteins of the
paramyxovirus of simian virus 5 (SV5) and contains the 14 amino acids GKPIPNPLL-
GLDST, which adds 4.3 kDa to the protein of interest. No V5 tag is added if the construct
includes an in-frame stop codon.
Figure 2.4: Map of pENTRTM/D-TOPO R  from the Gateway R Technology manual.
115Figure 2.5: Map of pAd/CMV/V5-DESTTM from the pAd/CMV/V5-DESTTM and
pAd/PL-DESTTM Gateway R user manual.
116Table 2.4: Features of pENTRTM/D-TOPO R  from the Gateway R Technology man-
ual.
117Table 2.5: Features of pAd/CMV/V5-DESTTM from the pAd/CMV/V5-DESTTM
and pAd/PL-DESTTM Gateway R user manual.
1182.12.3 Mutagenesis
2.12.3.1 Mutagenesis strategy
First of all, I had to identify which Serine-Glycine (SG) consensus site was the site of GAG
attachment. There was a total of nine SG sites in the NRP1 amino acid sequence. Table
2.6 shows the amino acid sequence of human NRP1 and NRP2 aligned with one another
and table 2.7 shows the SG sites that are relatively well conserved across vertebrate species
and only present in the NRP1 sequence. A total of three SG consensus sites were found to
be both exclusive to NRP1 and highly conserved between species. In order to determine
the role of these sites in NRP1 O-linked glycosylation, the serine residues were mutated
alone or in combination to alanine using the Quickchange II technology (Stratagene).
In order to generate the NRP1 construct lacking the C-terminus domain, I determined the
position of the transmembrane domain and the amino acid sequence of the intracellular
domain using the SMART database (Figure 2.6). I found that the transmembrane domain
extended from aa 857 to aa 879 and the cytoplasmic domain from aa 880 to aa 923. The
following 44 amino acid sequence corresponds to the intracellular domain:
YCACWHNGMSERNLSALENYNFELVDGVKLKKDKLNTQSTYSEA
To delete the intracellular domain, I inserted a stop codon after the amino acid in position
879. The amino acid in position 880 is a tyrosine coded by the three nucleotides TAC, we
therefore mutated TAC into TAG (codon stop) using site-directed mutagenesis.
2.12.3.2 Mutagenesis principle
Site-directed mutagenesis is used to make point mutations and performed using PfuTurbo
DNA polymerase and a temperature cycler. PfuTurbo R DNA polymerase replicates both
plasmid strands with high delity and without displacing the mutant oligonucleotide
primers. The basic procedure utilises a supercoiled double-stranded DNA vector with
an insert of interest and two synthetic oligonucleotide primers containing the desired mu-
tation. The oligonucleotide primers, each complementary to opposite strands of the vector,
are extended during temperature cycling by PfuTurbo DNA polymerase. Incorporation of
the oligonucleotide primers generates a mutated plasmid containing staggered nicks. Fol-
lowing temperature cycling, the product is treated with Dpn I. The Dpn I endonuclease
(target sequence: 5' GATC 3') is specic for methylated and hemimethylated DNA and
119is used to digest the parental DNA template and to select for mutation-containing syn-
thesized DNA. DNA isolated from almost all E. coli strains is methylated and therefore
susceptible to Dpn I digestion. The nicked DNA vector containing the desired mutation(s)
is then transformed into TOP10 E. coli. The small amount of starting DNA template re-
quired to perform this method, the high delity of the PfuTurbo DNA polymerase, and the
low number of thermal cycles all contribute to the high mutation eciency and decreased
potential for generating random mutations during the reaction.
2.12.4 Experimental details
2.12.4.1 Agarose gel electrophoresis and recovery of DNA
Amplied PCR product was mixed with 6X loading buer (Fermentas) and run on a
1% agarose gel containing ethidium bromide (200 ng/ml) at 100 V, using TAE running
buer (40 mM tris-acetate, pH 8.3; 1 mM EDTA). After adequate separation, the gel
was observed under UV illumination and the band of interest was excised and added to a
preweighed tube. DNA was recovered from the gel piece using the Qiaquick Gel Extraction
Kit (Qiagen) and nally eluted into 50l of double-distilled water. DNA concentration
was determined by absorbance at 260 nm on a Biophotometer (Eppendorf).
2.12.4.2 TOPO cloning into pENTR/D-TOPO entry vector
WT full-lenght Human NRP1 expressed in pcDNA 3.1(+) was available in the laboratory.
NRP1 open reading frames (ORF) were sub-cloned into the pENTR/D-TOPO vector by
PCR amplication with primers designed according to the manufacturer recommenda-
tions (5'CACCATGGAGAGGGGGCTGCC 3' and Rev: 5'TCATGCCTCCGAATAAG-
TACTCTGTG 3') using TOPO cloning (Invitrogen). Briey, gel-puried PCR product
was added to pENTR/D-TOPO vector with the provided salt solution. The reaction
was mixed and incubated at room temperature for 5 mins, and then used to transform
competent TOP10 E. coli.
2.12.4.3 Transformation and growth of competent E. coli
One-shot chemically competent TOP10 Escherichia coli bacteria (Invitrogen) were used
for transformations. A vial of TOP10 bacteria was slowly thawed on ice. The plasmid was
added and gently mixed with the bacteria for 30 min on ice, after which the bacteria were
heat-shocked in a water bath at 42C for 30s and then placed on ice again for a few minutes.
120200 l SOC medium (Invitrogen) was added to the cells which were incubated for 1 h at
37C with shaking. The culture was plated on to prewarmed 10 cm dishes containing
Lysogeny broth (LB) agar and either 100g/ml kanamycin (for pENTR) or 100 g/ml
ampicillin (for pAd) as appropriate for the plasmid used for transformation. Plates were
incubated overnight at 37C. The day after, individual colonies were picked and transferred
into 14 ml round bottomed tubes containing 3 ml LB broth and the appropriate antibiotic.
Cells were grown overnight at 37C with shaking, and used immediatly for minipreps or
stored at 4C until further use.
2.12.4.4 Plasmid DNA minipreps
The QIAprep miniprep procedure (QIAGEN) uses the modied alkaline lysis method of
Birnboim and Doly (1979). Bacteria are lysed under alkaline conditions, and the lysate is
subsequently neutralised and adjusted to high-salt binding conditions in one step. After
lysate clearing, the sample is ready for purication on the QIAprep silica membrane.
Briey, a single colony was picked from a selective plate and used to inoculate 3 ml of LB
medium containing the appropriate selective antibiotic which was incubated overnight at
37C with vigorous shaking. The pelleted bacterial cells were resuspended in 250l buer
P1 and transfered to a centrifuge tube, followed by addition of 250l of buer P2 and 350l
of buer N3. After centrifugation, the supernatant was applied to the miniprep column
and the ow-through discarded. The column was then washed with the application of
PB buer followed by the addition of 0.75ml of PE buer and nally elution of the DNA
in 50l of water. DNA concentration was determined by absorbance at 260 nm on a
biophotometer.
2.12.4.5 Site-directed mutagenesis
Site-directed mutagenesis was performed using the Quickchange II kit (Stratagene) ac-
cording to the manufacturers instructions. PCR reactions, containing 30ng pENTR-WT
NRP1 template plasmid and 10 pmol of each primer, were performed in a nal volume of
50 l. Cycling parameters (22 cycles) were 1.5 min initial melt at 95C; melting for 1 min
at 95C; annealing for 1.5 min at 55C; extension for 5 min at 68C and nal extension
for 10 min at 68C. Dpn I was added to the cooled sample and digestion was allowed to
proceed at 37C for 12 h. 2l of the cooled sample was used to transform supercompetent
TOP10 E. coli, which were plated onto kanamycin-containing agar plates to select for the
presence of the pENTR plasmid. The primers used for the nine Serine to Alanine substi-
121tutions and the insertion of a stop codon after the transmembrane domain are shown in
table 2.8.
2.12.4.6 DNA sequencing
Sequencing was performed by Cogenics (Takeley, Essex). The primers used for sequencing
are detailed in table 2.9. The complete integrity of the NRP1 nucleotide sequence was
assessed after cloning into the pENTR and pAd vectors, while only the mutated region
of NRP1 was sequenced after the site directed mutagenesis. The NRP1 sequence was
veried by manually checking the chromatogram supplied by the sequencing service using
the Sequencher software package (Gene Codes).
2.12.4.7 Cloning into pAd/CMV/V5-DEST destination vector
NRP1 with the desired mutations were cloned from the pENTR/D-TOPO entry vector
into the pAd/CMV/V5-DEST destination vector (Invitrogen) according to the manufac-
turers instructions. Briey, the pENTR plasmid containing the NRP1 constructs were
mixed with the pAd/CMV/V5-DEST vectors and clonase II enzyme mix (Invitrogen) was
added to initiate recombination. Recombination was allowed to proceed at room tem-
perature overnight and was stopped by addition of proteinase K and incubation at 37C
for 10 min. The mixture was then transformed into TOP10 E. coli and grown overnight
on ampicillin-containing plates. The following day, colonies were picked and grown in
ampicillin-containing broth and large quantities of DNA were produced by maxi-preps
using the HiSpeed Plasmid Maxi kit (Qiagen). DNA was recovered and its integrity and
correct orientation was assessed by sequencing.
2.12.4.8 Preparation of low-titre adenoviral stock
pAd maxipreps were digested by Pac I (New England Biolabs) to linearise the pAd plasmid
and expose the viral inverted terminal repeat (ITR) sequences. At the end of the enzymatic
reaction, phenol-chloroform extraction was performed to remove the enzyme and other
possible contaminants. The pAd vector was transfected into HEK 293A cells using Fugene
(see 2.5.2.2). Around 10 days later, the cells rounded up and started to detach from the
dish. The cell suspension was transferred to a 50 ml Facon tube and the virus was released
from the cells by using three repeated freeze-thaw cycles (30 min at -70C and 10 min at
37C). The supernatant containing the virus was obtained by centrifugation (3000g for 15
122min), and then stored at -70C or used immediately to produce a high-titre viral stock.
2.12.4.9 Preparation of high-titre adenoviral stock: Caesium chloride virus purication
100 l low-titre virus stock were used to infect fteen 15cm dishes of HEK 293A cells.
After a few days, when cells rounded up and detached from the plate, cells were squirted
o the dish and centrifuged for 5 minutes at 500g. The cell pellet was resuspended in
8 ml sterile PBS and the suspension was freeze-thawed 4 times before the supernatant
was transferred to a fresh tube containing 4.4g caesium chloride. The CsCl/virus mixture
was transferred to an Optiseal centrifuge tube (Beckman) and centrifuged in a Ti 70.1
rotor overnight at 60000 rpm at 10C. The virus particles were concentrated in a discrete
band, which was withdrawn using a needle. The virus was then mixed with an equal
concentration of sterile 2X freezing buer (5 mM Tris-HCl pH 8; 50 mM NaCl; 0.05% w/v
BSA; 25% glycerol) and stored at -70C.
2.12.4.10 Virus titration
Viral titre was determined using the QuickTiter Adenovirus Titer Immunoassay kit (Cell
Biolabs). Briey, 293 cells were plated in 24-well plates at 2.5.105 cells/ml. One hour
after plating cells, virus at 10-fold serial dilutions (103 - 106) were added to each well.
The cells were allowed to grow for 2 days for virus production to occur before being
xed in methanol, blocked with BSA, incubated in anti-hexon antibody and then alkaline
phosphatase-conjugated secondary antibody. Virus-containing cells were visualised by
incubation in diaminobenzidine (DAB) for 10 minutes, and stored in PBS at 4C. For most
microscopes, a standard 10X objective lens with 10X eyepiece lens has a eld diameter
(D) of 1.8 mm, then:
Area per eld = 3.14 x (D/2)2 = 3.14 x 0.92 = 2.54 mm2
For 24-well plate, area of a well is 2 cm2, therefore,
Fields/well = 2 cm2/ 2.54 2 mm2 = 3.8 cm2 / 2.54 x 10 2 cm2 = 79
The average number of positive cells was counted in ve dierent elds (100X magnica-
tion) and the viral titre determined from the following equation:
Viral Titre (ifu/ml) =
(positive cells/ eld) x (79 elds/well) x (dilution factor)
(0.1 ml)
1232.13 Statistical analysis
Results were obtained from at least three separate experiments. Representative Western
blots are shown to present protein expression. Other results are represented in bar graphs,
where bars represent the average of three experiments and the brackets represent standard
error mean. Statistical analysis was performed using Prism (GraphPad) on normalised
data by either one- or two-way ANOVA as appropriate, with Bonferronis test for multiple
comparisons used to locate dierences. Statistical signicance was accepted at P<0.05.
Figure 2.6: NRP1 domain homologies obtained from the SMART database and
their corresponding amino acid position.
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127Table 2.9: Nucleotide sequence of primers used for sequencing
Number Sequence (5'!3')
1 ACCTTACATCTCCTGGTTATCCT
2 TCCTGTTGTGTCTTCAGG
3 GGATGTTCTGTCGCTACG
4 TCCTACCGAGAGTGGATACAGGTA
5 CCACTGATAACTCGATTTGTC
6 GAAGCACCGAGAGAACAAGG
7 AACTATGATACACCTGAGC
8 ACGGTCATAGACAGCACC
9 AAGGTGACCACTGGAAGG
10 AGGTGACAAGAACATCTCCAGG
128Chapter 3
Characterisation of Neuropilins in
vascular cells
When I rst started this project, a role for NRPs in endothelial and cancer cell biology
was already established and commonly accepted. During the characterisation of NRP
expression in these cells, I noticed that NRP1 was expressed as a single band in EC
while it was expressed as two separate bands in cancer cells. I also decided to investigate
NRP expression in VSMC as these cells interact with EC. NRP1 was found to be highly
expressed in SMC, something unknown at that time. As with cancer cells, NRP1 is
expressed as two separate species in SMC. I then went on to investigate the nature of
these novel NRP1 species and characterise NRP expression in VSMC in more detail.
3.1 Identication of Neuropilins in vascular and cancer
cells
Immunoblotting of lysates prepared from Human coronary artery smooth muscle cells
(HCASMC), Human aortic smooth muscle cells (HAoSMC), Human umbilical vein en-
dothelial cells (HUVEC) and Human coronary artery endothelial cells (HCAEC) showed
that NRP1, NRP2 and synectin, the only NRP1 interacting protein (NIP) known to date,
were all expressed in these cells (Figure 3.1). In contrast, the major signalling VEGF
receptor (VEGFR2/KDR), could not be readily detected in smooth muscle cells by West-
ern blot. Although a faint VEGFR2 signal was seen in HCASMC, no signal at all was
observed in HAoSMC, whereas VEGFR2 was strongly expressed in both endothelial cell
types. PDGF receptor expression was not observed in endothelial cells, but was read-
ily detected in both smooth muscle cell types. PDGFR and PDGFR were expressed
in both cell types, though more PDGFR was expressed in HAoSMC. Interestingly, in
addition to the normal full length NRP1 band of 130 kDa, a high molecular weight NRP1-
immunoreactive band was prominently expressed in HCASMC and HAoSMC but was not
129seen in endothelal cells.
A similar high molecular weight NRP1 species is also expressed in several cancer cell
lines including A549 (pulmonary carcinoma cell line), ACHN (renal carcinoma cell line),
Skov-3 (ovarian carcinoma cell line), Skbr3 (mammary carcinoma cell line) and MB-231
(mammary carcinoma cell line), while in comparison, this high molecular weight signal
was not detected in HUVEC or in MCF-7 (mammary carcinoma cell line) (Figure 3.2).
Moreover, U87 a glioblastoma cell line and DU145,a prostate carcinoma cell line both
express both NRP1 species (data observed by colleagues, not shown).
I used ow cytometry to further assess the expression of NRP1, VEGFR1 and VEGFR2 in
vascular cells. VEGFR1, VEGFR2 and NRP1 were all expressed signicantly in HUVEC
while only NRP1 was expressed at signicant levels by HCASMC (Figure 3.3). The
proportion of cells expressing these receptors are given in table 3.1.
Table 3.1: Percentage of HUVEC and HCASMC expressing VEGFR1 and 2 and NRP1
VEGFR1 VEGFR2 NRP1
HUVEC 25% 79% 99%
HCASMC 7% 9% 88%
130Figure 3.1: NRPs, VEGFR2, synectin and PDGFRs expression in vascular cells
This Western blot shows NRP1, NRP2, VEGFR2, PDGFR and PDGFR expression
vascular cells. Cell lysates were prepared from HUVEC, HCAEC, HCASMC and HAoSMC
run on SDS-PAGE and blotted for NRP1, NRP2, VEGFR2, synectin, PDGFR, PDGFR
and GAPDH as a loading control. Note the presence of a high molecular species in SMC.
131Figure 3.2: NRP1 expression in dierent cell lines
This Western blot shows NRP1 protein expression in the vascular cells HUVEC and
HCASMC, as well as in several cancerous cell lines. Lysates were prepared from HU-
VEC, HCASMC, and the following cancerous cells: A549: lung cancer, ACHN: kidney
cancer, Skov-3: ovarian cancer, Skbr3: breast cancer, MCF-7: breast cancer and MB-231:
breast cancer. Note the presence of a high molecular species in some cell lines.
Figure 3.3: Flow cytometry
Flow cytometry data showing the expression of NRP1, VEGFR2 and VEGFR1 at the
surface of HCASMC and HUVEC.
1323.2 The high molecular weight NRP1-immunoreactive
band corresponds to a specic NRP1 species
To assess the specicity of the higher molecular weight band observed in Figure 3.2, siRNA
knockdown of NRP1 and NRP2 in A549 cells and VSMC, which strongly expressed both
forms of NRP1 was performed.
NRP1 siRNA-mediated knockdown abolished expression of the high molecular weight band
in A549 and VSMC, while control and NRP2-specic siRNAs had no eect (Figure 3.4
and 3.5). An antibody against NRP2 did not recognise a similar high molecular weight
band in HCASMC (Figure 3.1) and in A549 (Figure 3.4). These results suggested the
existence of two NRP1 species: one at the known and predicted molecular weight of 130
kDa, and another species greater than 250 kDa in several cancer cell lines and in VSMC.
This >250 kDa form is not expressed in endothelial cells, and does not exist in NRP2.
3.3 Neuropilin 1 and 2 are and N-glycosylated
I addressed the possibility that the high molecular weight NRP1 band in HCASMC could
be due to N-linked glycosylation by using the antibiotic tunicamycin, which prevents the
linkage of carbohydrates to the amide group of asparagine residues in the protein core of
N-glycosylated proteins. SMC and EC were treated with tunicamycin, and lysates were
then immunoblotted with NRP1 antibody. After 16 hours of treatment, a clear shift was
observed in the apparent 130 kDa molecular weight NRP1 band in EC and of both the high
molecular weight and typical full length 130 kDa NRP1 bands in SMC, but tunicamycin
did not abolish expression of the high molecular weight species (Figure 3.6). The same
lysates were run and blotted for NRP2 protein expression (Figure 3.6). Similar to NRP1, a
shift was observed in the NRP2 band, showing that it is also post-translationally modied
by N-glycosylation. It was also noted that tunicamycin reduced the level of expression
NRP1 and NRP2, an eect which is most likely due to the known inhibitory eect of
tunicamycin on protein synthesis.
133Figure 3.4: Eects of NRP1 and NRP2 knockdown in A549 cells
A549 cells were transfected with NRP1 and NRP2 siRNA using oligofectamine 2000. 72
hours after transfection, cells were harvested with RIPA buer and protein lysates were
prepared and 5 g of total protein were run on SDS-PAGE, blotted, and probed with the
indicated antibodies.
a) Western blot for NRP1 shows the presence of two populations of NRP1. The arrow
points out the NRP1 population at 250 kDa that disappears when cells were treated with
siRNA. b) Western blot for NRP2, shows no evidence of a high molecular weight form.
Figure 3.5: Eects of NRP1 and NRP2 knockdown in HCASMC
HCASMC cells were transfected with NRP1 and NRP2 siRNA using the nucleofactor kit
(AMAXA). 72 hours after transfection, cells were harvested with RIPA buer and protein
lysates were prepared and 5 g of total protein were run on SDS-PAGE and probed with
the indicated antibodies. On the left panel, the Western blot for NRP1 shows the presence
of two populations of NRP1. The arrow points out the NRP1 population at 250 kDa that
disappears when cells were treated with siRNA. On the right, the Western blot for NRP2,
shows no evidence of a high molecular weight form.
134Figure 3.6: NRP1 and NRP2 is modied by N-linked glycosylations in vascular
cells
Human aortic and coronary smooth muscle cells and Human umbilical vein and coronary
artery endothlial cells were pretreated in the presence or absence of 5 g/ml tunicamycin
for 16 hours, lysates were then prepared, ran on SDS-PAGE and immunoblotted with
antibody to NRP1 and NRP2.
1353.4 Neuropilin 1 is O-glycosylated
3.4.1 Enzyme treatment on intact cells
I next investigated whether appearance of the high molecular weight NRP1 band was due
to the addition of O-linked glycosaminoglycans (GAG) containing either chondroitin sul-
phate (CS) or heparan sulphate (HS). Addition of GAG is known to produce very high
molecular weight proteoglycan (PG) species and is an important post-translational mech-
anism in VSMC (see Chapter 1.6). I used chondroitinase and heparitinase (also known
as heparinase III), two lyases that catalyse the cleavage of carbon-oxygen bonds of CS-
and HS-GAGs respectively, thereby degrading the long polysaccharide chains into short
oligosaccharides. Treatment of SMC cultures with chondroitinase caused a marked reduc-
tion in the level of the high molecular weight NRP1 band, with a concomitant increase in
expression of the 130 kDa band, while heparitinase had a smaller but also signicant eect,
and a combination of chondroitinase and heparitinase completely abolished the presence
of the high molecular weight band (Figure 3.7). It was noted that chondroitinase did not
completely remove the >250 kDa species in VSMC, whereas the high molecular weight
band was entirely abolished in A549 cells using chondroitinase alone and heparitinase had
no eect at all (Figure 3.9). Moreover, treatment of A549 cells and VSMC with chondroiti-
nase and heparitinase did not result in an increase in the 130 KDa population of NRP2,
suggesting that NRP2, unlike NRP1, is not O-glycosylated, consistent with Figures 3.1
and 3.4 (Figure 3.10).
3.4.2 Enzyme treatment of NRP1 immunoprecipitates
To further verify the nature of NRP1 post-translational modication, NRP1 immuno-
precipitates were also treated with lyases. Treatment of NRP1 immunoprecipitates from
HCASMC with chondroitinase resulted in the disappearance of the high molecular weight
NRP1, while heparitinase had a smaller eect (Figure 3.8). These results indicate that the
high molecular weight NRP1 band in HCASMC results primarily from post-translational
addition of CS-containing GAG, while only a small fraction is modied by the addition
of HS-containing GAG. Both high molecular weight and 130 kDa NRP1 are additionally
modied by some N-linked glycosylations. In contrast to NRP1, NRP2 does not appear
to undergo GAG modication, but is also modied by N-glycosylations (Figure 3.6). The
ecacy of the enzymes in removing CS-GAG and HS-GAG from VSMC surface was con-
136rmed by immunouorescent staining with specic CS and HS antibodies (Figures 3.13
and 3.14).
I quantied the proportion of glycanated and non-glycanated NRP1 by densitometry us-
ing Image J. I also analysed the proportion of each glycanated population (chondroitin
sulphate versus heparan sulfate). A possible limitation of this method is that it is assumed
that the antibody recognises all NRP1 forms with similar anity.
The non-modied population NRP1 accounted for approximately 54% of the total popula-
tion, hence the glycanated population (CS- and HS- modied) for 46%. Then I examined
the proportion of chondroitin sulphate modied population and heparan sulphate pop-
ulation in function of the appearance of the high molecular weight band intensity and
also in function of the appearance of the 130 kDa NRP1 band in response of chondroiti-
nase and heparitinase treatment. I rst analysed the disappearance of the high molecular
weight band with the treatment of chondroitinase decreasing the signal more signicantly
than with heparitinase (Figure 3.11 a). Moreover, chondroitinase treatment of HCASMC
increased the 130 kDa band more signicantly than the heparitinase treatment (Figure
3.11 b). Combining these data, I concluded that the chondroitin sulphate modied NRP1
population accounted for approximatively 70% of the glycanated population and therefore
the heparan sulphate population, for  30% (Figure 3.12).
Figure 3.7: Chondroitinase and heparitinase treatment of HCASMC
The cells were incubated for 2 hours either with or without chondroitinase and hepari-
nase III (heparitinase) or with a combination of both (each at 1 Unit/ml),lysates were
then prepared and 5 g of total protein were run on SDS-PAGE and blotted with NRP1
antibody. Results are representative of three independent experiments.
137Figure 3.8: Chondroitinase and heparitinase treatments of NRP1 immunopre-
cipitates obtained from HCASMC lysates
NRP1 was immunoprecipitated from HCASMC and incubated for 2 hours with or without
chondroitinase, heparitinase, or with a combination of chondroitinase and heparitinase (all
at 1U/ml), lysates were then prepared and 5 g of total protein were run on SDS-PAGE
and blotted with NRP1 antibody (to the C-terminus). Results are representative of three
independent experiments.
Figure 3.9: Chondroitinase and heparitinase treatment of A549
The cells were incubated for 2 hours with either with or without chondroitinase and
heparinase III (heparitinase) or with a combination of both (each at 1 Unit/ml), lysates
were then prepared and 5 g of total protein were run on SDS-PAGE and blotted with
NRP1 antibodies raised against both N and C termini.
138Figure 3.10: Chondroitinase and heparitinase treatment of A549
The cells were incubated for 2 hours with either with or without chondroitinase and
heparinase III (heparitinase) or with a combination of both (each at 1 Unit/ml), lysates
were then prepared and 5 g of total protein were run on SDS-PAGE and blotted with an
antibody raised against the N-terminus of NRP2.
Figure 3.11: Relative intensity of NRP1 signals in function of lyases treatment
Western blots of NRP1 in HCASMC that were treated with chondroitinase and hepar-
itinase were analysed by densitometry using Image J. a) The disappearance of the high
molecular weight band with the treatment of chondroitinase decreasing the signal more sig-
nicantly than with heparitinase. b) The chondroitinase treatment of HCASMC increased
the 130 kDa band more signicantly than the heparitinase treatment. These results are
means of values obtained from three independent experiments +/- SEM.
139Figure 3.12: Relative percentage of NRP1 populations
From Western blot analysis by densitometry using Image J in Fig. 3.11, the relative pro-
portions of glycanated versus non-glycanated NRP1 population were determined as 54%
vs. 46% respectively. CS-modied NRP1 accounted for 70% of the glycanated popula-
tion of NRP1, 30% for the heparan sulphate modied. These results are means of values
obtained from three independent experiments, brackets represent the SEM.
3.4.3 NRP1 colocalises with CS and HS
I next investigated the localisation of chondroitin sulphate (CS) and heparan sulphate
(HS) glycosaminoglycans and NRP1 in vascular cells using confocal immunouorescent
microscopy. These studies showed that NRP1 partially colocalised with CS and HS in
HCASMC both in the cytoplasm and at the membrane (Figures 3.13 and 3.14). Some
NRP1 colocalised with both GAG species (in yellow on the merged confocal images), and
another NRP1 pool did not colocalise with CS or HS. The same staining was performed
in HUVEC, and, in contrast to HCASMC, little colocalisation of NRP1 with CS could be
observed, consistent with the nding that NRP1 is not expressed as a GAG modied form
in endothelial cells (Figure 3.15).
140Figure 3.13: NRP1 and CS colocalisation in HCASMC
Immunouorescent staining of xed and permeabilised HCASMC was performed using the
C-terminus NRP1 antibody with FITC-anti goat as the secondary antibody, CS antibody
with Alexa Fluor 555 anti mouse secondary antibody as secondary reagent.
CS is seen on the red channel (a) and NRP1 on the green channel (b). Staining of
both NRP1 and CS can be observed in the cytoplasm and at the membrane where they
both partially colocalise (c,d). On the merged confocal image, white arrows indicate
colocalisation between CS and NRP1, and the region framed in green is magnied to
clearly identify colocalisation (d). The confocal image on the bottom left (e) shows the
merged images obtained after chondroitinase (Case) treatment of HCASMC. The images
are representative of three independent experiments yielding similar results.
141Figure 3.14: NRP1 and HS colocalisation in HCASMC
Immunouorescent staining of xed and permeabilised HCASMC was performed using the
C-terminus NRP1 antibody with FITC-anti goat as the secondary antibody, HS antibody
with Alexa Fluor 555 anti mouse secondary antibody as secondary reagent.
HS is seen on the red channel (a) and NRP1 on the green channel (b). Staining of
both NRP1 and HS can be observed in the cytoplasm and at the membrane where they
both partially colocalise (c,d). On the merged confocal image, white arrows indicate
colocalisation between HS and NRP1, and the region framed in green is magnied to
clearly identify colocalisation (d). The confocal image on the bottom left (e) shows the
merged images obtained after Heparinase (Hase) treatment of HCASMC. The images are
representative of three independent experiments yielding similar results.
142Figure 3.15: Cellular distribution of NRP1 and CS in HUVEC
Immunouorescent staining of xed and permeabilised HUVEC was performed using the
C-terminus NRP1 antibody with FITC-anti goat as the secondary antibody, CS antibody
with Alexa Fluor 555 anti mouse secondary antibody as secondary reagent.
CS is seen on the red channel (a) and NRP1 on the green channel (b). NRP1 can been
observed at the membrane and CS mostly in the cytoplasm. On the merged confocal
images (c and d), in contrast to HCASMC, little colocalisation between NRP1 and CS
can be observed.
1433.5 Identication of the site of attachment of NRP1 GAG
modication
Both chondroitin and heparan sulphate chains can contain over 100 individual sugar
residues, each of which can be covalently sulphated in variable positions and quantities.
CS- and HS- GAGs are linked to hydroxyl groups on serine residues of protein cores.
Usually, glycosylated serines are often followed by a glycine and have neighbouring acidic
residues, but this motif does not always predict glycosylation. I therefore examined the
amino acid (aa) sequence of both NRP1 and NRP2 across species and found several NRP1
Serine-Glycine (SG) conserved sites that were highly conserved between species and absent
from the NRP2 aa sequence. I used the NRP1 and NRP2 amino acid aligned sequences
and the NRP1 aa sequences across species to identify those sites (Tables 2.6 and 2.7). The
three serines in positions 240, 432 and 612 were good potential candidates as they were
only present in the NRP1 sequence and conserved between vertebrate species. Table 3.2
highlights how the dierent SG candidates sites were selected.
pcDNA 3.1(+) NRP1 WT and NRP1 with Serine to Alanine substitution at the three SG
sites (S240A/S432 double mutant and S612A) were generated via site-directed mutagenesis
as described in section 2.12.3.1. I transfected Porcine Aortic Endothelial Cells (PAEC)
with the NRP1 mutant constructs using lipofectamine 2000 because these cells are known
to express no or very little endogenous NRP1 (Figure 3.16). As expected, there was
no endogenous NRP1 expressed in PAEC and transfection of the NRP1 WT construct
resulted in the expression of both the 130 kDa and high molecular weight forms. The
expression of the S240A/S432A mutant also resulted in the expression of both the 130
kDa and high molecular weight species. On the other hand, the single point mutation at
position 612 resulted in the expression of only 130 kDa NRP1 with no expression of the
high molecular weight NRP1 species.
The other NRP1 mutants, with an alanine at position 115, 283, 439 and 729 were also
transfected into PAEC (Figure 3.17). None prevented the expression of the high molecular
weight NRP1 species. It was noted, however, that the S240A/S432A double mutant caused
some reduction in expression of the >250 kDa NRP1 species compared with NRP1 WT.
144Figure 3.16: Expression of the three candidate NRP1 mutant constructs in
PAEC
NRP1 WT pcDNA 3.1 (+) construct as well as two NRP1 mutants with a Serine sub-
stituted to an Alanine at the position indicated were expressed in PAEC. Non trans-
fected PAEC were used as control. 48h after transfection, lysates were obtained from the
transfected cells and run on SDS-PAGE. NRP1 expression was checked using the NRP1
C-terminus antibody.
Figure 3.17: Expression of all potential NRP1 mutant constructs in PAEC
NRP1 WT pcDNA 3.1 (+) construct as well as the three NRP1 mutants with a Serine
substituted to an Alanine at the position indicated were expressed in PAEC. Non trans-
fected PAEC were used as control. 48h after transfection, lysates were obtained from the
transfected cells and run on SDS-PAGE. NRP1 expression was checked using the NRP1
C-terminus antibody.
145Table 3.2: Identication of potential SG sites for GAG addition
Mutation mutation conserved conserved good
number site between species between NRP1 and NRP2 candidate
1 S115A + + No
2 S155A - + No
3 S240A + - Yes
4 S283A + + No
5 S432A + - Yes
6 S439A + + No
7 S469A - + No
8 S612A + - Yes
9 S729A + - Yes
1463.6 Discussion
NRP1 is widely expressed in several cell types, particularly neuronal, endothelial and
tumour cells. However, at the onset of my PhD research, nothing was known regarding
NRP1 expression in VSMC. The experiments presented in this chapter demonstrate that
NRP1 and NRP2 are strongly expressed in HCASMC and HAoSMC. Furthermore, in
addition to the 130 kDa NRP1 band corresponding to the major species in endothelial
cells, a high molecular weight NRP1 species at around 250 kDa is also expressed in VSMC.
This NRP1 high molecular weight band was specic to NRP1 because knocking down the
receptor by siRNA silencing resulted in the disappearance of both bands on Western blot,
whereas NRP2 knockdown had no eect. Moreover, I observed that a wide range of cancer
cells express NRP1 (Appendix ??) and most of these cells also express both NRP1 species
(Figure 3.2 and appendix A.3). In contrast, NRP2 was not expressed as a high molecular
weight species in any cell type examined, as judged by Western blot.
Subsequent experiments presented in this chapter showed that NRP1 is modied by a
combination of N-linked and O-linked glycosylations. Treatment with tunicamycin which
specically blocks N-linked glycosylation caused relatively small shift (10-20 kDa) in
the position of both 130kDa and >250kDa NRP1 bands to smaller species, indicative of
N-glycosylation of both NRP1 forms. The apparent molecular weight of NRP2 was also
shifted by tunicamycin suggesting that it, too, is N-gycosylated. However, tunicamycin
did not block expression of the >250kDa band, indicating that N-glycosylation could
not fully account for expression of this NRP1 form. The NRP1 aa sequence contains
six potential sites for N-linked oligosaccharide attachment. Two Asparagines occur in a
consensus sequence, Asparagine - X - Serine (where X is any aa except Proline), which
corresponds to the preferential acceptor motif and are situated in the second CUB (a2)
domain. Four Asparagine - X - Threonine consensus sequences were found in the FV/VIII
domains (b1/b2) and between the MAM (c) and transmembrane domain. I did not have
time to pursue further investigation on the function of post-translationnal modication
by N-oligosaccharides although it is known that their addition to a target molecule is
important for the folding of some proteins and also can inuence ligand binding anities
(Tit et al., 1992). Further study of the role of NRP glycosylation is warranted.
I then investigated the potential involvement of O-glycosylations in the generation of the
high molecular NRP1 species. This type of glycosylation occurs at a later stage during
protein processing, probably in the Golgi apparatus and O-linked glycoproteins are usu-
147ally large proteins (>200 kDa) that have comparatively less branching than N-glycans.
Chondroitinase and heparitinase (also known as heparinase III), are lyases that catal-
yse the cleavage of carbon-oxygen bonds of chondroitin sulphate- and heparan sulphate
glycosaminoglycans respectively, thereby degrading the long polysaccharide chains into
short oligosaccharides. These ndings demonstrate that the high molecular weight form
of NRP1 expressed in VSMC and tumour cells is due largely to O-linked glycosylation
either predominently (as in VSMC) or solely (as in A549 cells) resulting from CS-GAG
addition, but with some addition of HS-GAG in VSMC. Treatment of HCASMC with
chondroitinase removed most of the >250 kDa species but did not completely abolished
it, while heparitinase alone caused a small reduction in this band, and chondroitinase
and heparitinase together completely abolished it. Quantication indicated that the non-
modied NRP1 form accounted for approximately 54% of the total NRP1 in HCASMC,
while CS-modied NRP1 accounted for approximatively 70% of the glycanated NRP1 and
HS-NRP1 for the remaining 30%, 35% and 15% of the total NRP1 population respec-
tively. However, analysis of NRP1 glycosylation in A549 cancer cells indicated that, the
post-translational modication was uniquely due to the addition of chondroitin sulphate
moiety to the NRP1 protein core.
As mentioned in the introduction, it is known that O-linked GAGs attach preferentially to
consensus sites consisting of serines often followed by a glycine with neighbouring acidic
residues. Mutation of candidate consensus sites and expression of these mutants showed
that a single Serine at position 612, between the second FV/VIII domain and the MAM
domain, was the major site of O-linked GAG attachment to NRP1 (Figure 2.6). However it
was noted that expression of a double NRP1 mutation at Serines 240 and 432 also resulted
in substantially less expression of the GAG-modied NRP1 species than NRP1 WT. This
observation suggests that other potential sites of glycosylation may contribute to O-linked
glycosylation, though as the S612A mutation completely abolished the modication, this
is clearly the primary site of GAG addition. It is unclear why O-linked glycosylation is
dierent qualitatively and quantitatively in dierent cell lines. In particular, the apparent
absence of GAG-modied NRP1 in HUVEC and HCAEC is puzzling. It is plausible that
the lack of GAG-modied NRP1 in endothelial cells may be due to a lack of expression
of enzymes essential for this modication, e.g. CS synthase. However, this would imply
the existence of enzymes with a specic or selective role in NRP1 glycosylation, since it
is implausible that endothelial cells are devoid of the enzymatic mechanisms necessary for
O-linked glycosylation in general. Alternatively, tracking of newly synthetised NRP1
148may dier in dierent cell types, routing NRP1 for O-linked glycosylation in some but
not in endothelial cells. There is evidence that elongation of O-linked glycans can occur
in a protein-specic manner (Moloney et al., 2000). The molecular basis for dierential
glycosylation of NRP1 in VSMC and EC warrants further study. Regardless of the precise
mechanisms involved, the abundant expression and absence of GAG-modied NRP1 in
cognate VSMC and EC, respectively, is suggestive of cell-type specic functions of this
species. It is also unclear why NRP2 seems to be only post-translationaly modied by
N-glycosylations, even though its sequence contains consensus sites for O-linked oligosac-
charides attachment. Presumably, the three-dimensional structure of NRP2 in which these
consensus sites occur do not permit recognition by the enzymes essential for GAG chain
initiation or elongation.
Clinical studies suggest that NRP1 expression is related to cancer aggressiveness and plays
a role in tumour growth, disease progression, and potentially in metastasis. Recent studies
in our group unveiled a role for the CS post-translationnal modication in cancer cells
which will be developed in more detailed in the next chapter. Several biopsies of human
gliomas were probed for the expression of NRP1. Although several samples showed strong
expression of NRP1 in both low- and high-grade gliomas, little expression of NRP1-CS
in all samples was detected. These data suggest that there is a correlation between the
highly invasive nature of these tumours, and a low NRP1-CS to NRP1 expression ratio
(Frankel et al., 2008).
While this work was in progress, NRP1 expression in human VSMC and NRP1 GAG
modication in VSMC were reported by Shintani et al. (2006). The results presented in
this chapter are in close agreement with those of Shintani et al. (2006). However, GAG-
modication of NRP1 in tumour cells has not been reported by other groups. In addition,
NRP1 expression in VSMC has also been reported by two other groups (Banerjee et al.,
2006; Liu et al., 2005).
The relevance of NRP1 expression or function in cultured human VSMC is unclear. How-
ever, in other work from this laboratory, immunouorescent staining of NRP1 in injured rat
carotid arteries revealed strong NRP1 staining in the neointima (appendix A.4). Further-
more qRT-PCR showed that NRP1 mRNA was upregulated following injury of rat carotid
arteries (appendix A.5). These results indicate a potential role for NRP1 in VSMC pro-
liferation and for migration in neointima formation. Whether NRP1 has a role in normal
VSMC functions in healthy blood vessels in animals or humans will require generation of
149VSMC-specic NRP1 knockouts and analysis of NRP1 expression in human tissues.
150Chapter 4
Function of NRP1 in vascular cells
At the beginning of this PhD I focused my attention on the role of NRPs in endothelial
cells as it was known that the receptor played an essential role in angiogenesis and therefore
in EC migration. The role of NRP1 in endothelial and tumour cell biology as well as its
importance in development, had been studied, but several aspects remained unclear.
A novel discovery, described in Chapter 3, was the signicant expression of NRP1 in
vascular smooth muscle cells. Results in the previous chapter also indicated that NRP1
was GAG modied in VSMC and some tumour cells but underwent little modication in
endothelial cells. I therefore wanted to examine the role of GAG modication in ligand
binding to NRP1 function in cells, and, in particular, to examine the role of NRP1 in
VSMC.
4.1 Role for NRP1 in EC biology
Previous work in this laboratory, led to the development of a NRP1 antagonist called
EG3287 (and later, its other more stable version, EG00086) that specically inhibits
VEGF-A165 binding to to porcine aortic endothelial cells expressing NRP1 (PAE/NPR1)
and breast carcinoma cells expressing only NRP1 receptors for VEGF-A165, but had no ef-
fect on binding to PAE/KDR or PAE/Flt-1. This useful tool as well as the use of siRNAs,
soluble recombinant forms of NRP1 and virus over-expression of the receptor allowed me
to study the role of NRP in vascular cells. First I decided to investigate the role of NRP1
in EC and whether NRP1 post-translational modication had an eect on VEGF-A165
binding to NRP1.
1514.1.1 Lyases does not alter 125I-VEGF-A165 binding in porcine aortic endothe-
lial cells
Though HUVEC and HCAEC displayed no apparent GAG-modied NRP1, I tested
whether chondroitinase and heparitinase could aect VEGF-A165 binding to NRP1. Firstly,
I used the porcine aortic endothelial cell line PAE NRP1 that expresses exclusively NRP1
and no other VEGF receptor as a tool to study specic binding of VEGF-A165 to NRP1.
In contrast to HUVEC and HCAEC, PAE NRP1 cells also expressed the GAG-modied
NRP1 species (Figure 3.16). The binding assay was optimised and an average of 16.6%
was obtained for non specic binding, 83.4% for specic 125I-VEGF-A165 binding. Before
the binding assay, cells were pre-treated or not (Control) for 2 hours with chondroitinase,
heparinase III (heparitinase) or both enzymes. Treating the cells with lyases had no signif-
icant eect on 125I-VEGF-A165 specic binding (Figure 4.1). These results indicate that,
in PAE NRP1 cells at least, the addition of the GAG moiety has no eect on VEGF-A165
ability to bind NRP1.
Figure 4.1: Lyases do not alter 125I-VEGF-A165 binding in PAE NRP1 cells
PAE NRP1 cells were pre-treated or not (Control) for 2 hours with chondroitinase, hep-
arinase III or both at 1 U/ml in complete RPMI medium with 0.1% BSA. After 2 hours
incubation, cells were lysed and bound radioactivity measured with a gamma-counter.
Bars represent the mean of three independent experiments +/- SEM.
1524.1.2 Lyases does not alter 125I-VEGF-A165 binding in Human coronary artery
endothelial cells
I also used HCAEC that express NRP1 in addition to the other VEGF receptors KDR
(VEGFR2) and Flt-1 (VEGFR1). The binding assay produced on average 26% non specic
binding and 74% of specic 125I-VEGF-A165 binding. Similarly to PAE NRP1 cells, treat-
ing HCAEC with chondroitinase or heparinase III had no eect on specic 125I-VEGF-A165
binding (Figure 4.2).
Figure 4.2: Lyases does not alter 125I-VEGF-A165 binding in HCAEC
HCAEC were pre-treated or not (Control) for 2 hours with chondroitinase, heparinase III
or both at 1 U/ml in complete EC medium with 0.1% BSA. After 2 hours incubation, cells
were lysed and bound radioactivity measured with a gamma-counter. Bars represent the
mean of three independent experiments +/- SEM.
1534.1.3 NRPs knockdown inhibit EC migration towards VEGF-A165
A role for NRP1 in EC migration has previously been demonstrated, but has not been
examined specically in HCAEC. The role of NRP1 in the migratory response of HCAEC
towards VEGF-A165 was examined by siRNA-mediated knockdown of NRP1 and NRP2 ex-
pression. Transfection of HCAEC with siRNAs targeted to NRP1 and NRP2 signicantly
reduced protein expression in HCAEC (Figure 4.3). When siRNA-transfected cells were
used to perform a migration assay in response to VEGF-A165, NRP1 knockdown caused
a signicant decrease in migration (Figure 4.4). NRP2 siRNA also signicantly inhibited
the migratory response to VEGF-A165. These results obtained in HCAEC are similar
to those obtained using HUVEC and Human microvascular endothelial cells (HMVEC)
(Murga et al., 2005; Favier et al., 2006).
Figure 4.3: NRP1 and NRP2 protein expression levels after siRNA transfection
HCAEC were transfected with NRP1, NRP2 and control scrambled siRNA using oligo-
fectamine and, at the times indicated after transfection, lysates were prepared and 5 g
of total protein were run on SDS-PAGE and blotted for NRP1 and NRP2. Signicant
knockdown was obtained for both receptors up to 72 hours after the transfection. The
cells were used for migration assays 48 hours after transfection.
154Figure 4.4: NRP1 and NRP2 knockdown inhibit EC migration towards VEGF-
A165
HCAEC were transfected with NRP1, NRP2 and control scrambled siRNA using oligo-
fectamine. Signicant knockdown was obtained after 48h and cells were then used for
migration assay. After 4 hours, the cells that migrated through the porous membrane
were xed, stained and counted at x200 magnication. Bars represent the means of three
independent experiments +/- SEM. *P<0.05 versus VEGF-A165 plus scrambled siRNA.
4.1.4 Overexpression of NRP1 C mutant, lacking the C-terminus, decreases
VEGF-A165 stimulated HUVEC migration
The NRP1 cytosolic domain has previously been implicated in the functions of NRP1 in
endothelial cells. I used an adenoviral construct expressing NRP1 extracellular domain
and transmembrane domain to further explore the role of the cytoplasmic domain of NRP1
in EC. Protein expression was conrmed by Western blotting using the NRP1 antibody
targeting the extracellular domain. Infection of HUVEC with Ad.NRP1 resulted in a
signicant increase in protein expression above the endogenous level (Figure 4.5), but did
not signicantly alter the migration of HUVEC towards a gradient of either VEGF-A165,
compared to control cells infected with Ad.GFP (Figure 4.5). In contrast, Ad.NRP1 C
infection, resulting in over-expression of NRP1 lacking the intracellular domain, caused a
signicant inhibition of cell migration induced by VEGF-A165.
155Figure 4.5: Overexpression of NRP1 C mutant, lacking the C-terminus, de-
creases VEGF-A165 stimulated HUVEC migration
HUVEC were infected with the following adenoviral constructs: Ad.GFP, Ad.NRP1 WT
and Ad.NRP1 C at a MOI of 20. Three day after the infection, cells were harvested and
seeded into a transwell to perform a migration assay. VEGF-A165 was the chemoattractant
at the bottom of the insert at a concentration of 25 ng/ml. After 4 hours, the cells
that migrated through the porous membrane were xed, stained and counted under the
optic microscope at a x200 magnication. Overexpression of the NRP1 constructs was
conrmed by western blotting (upper panel). Bars represent the mean of three independent
experiments +/- SEM. *P<0.05 versus VEGF-A165 plus Ad.GFP and VEGF-A165 plus
Ad.NRP1 WT.
1564.2 Role for NRP1 in VSMC biology
When I initially discovered high expression of NRP1 and its post-translational modication
in vascular smooth muscle cells, there was no report in the literature of a role for NRP1 in
VSMC biology. Therefore, I decided to further examine the role of NRP1 GAG addition
as well as a broader role for NRP1 in VSMC biology.
Several studies previously reported that VEGF-A165 is able to stimulate the migration of
rat aortic VSMC and other VSMC species (Khurana et al., 2004; Liu et al., 2005). This
led me to examine the binding anity of VEGF-A165 in VSMC as well as its ability to
trigger VSMC migration.
4.2.1 VEGF-A165 response in vascular smooth muscle cells
4.2.1.1 VEGF-A165 binds to NRP1 of Human coronary artery smooth muscle cells
Assays of 125I-VEGF-A165 binding to HCASMC typically produced 35.8% non specic 125I-
VEGF-A165 binding and 64.2% specic binding. In contrast to endothelial cells, treatment
of HCASMC with chondroitinase alone or chondroitinase led to a signicant increase in
125I-VEGF-A165 binding while heparinase III (heparitinase) alone did not aect signi-
cantly 125I-VEGF-A165 binding (Figure 4.6).
4.2.1.2 VEGF-A165 does not stimulate HCASMC migration
Preliminary experiments shown no signicant migration of HCASMC in response to VEGF-
A165 at a biologically active concentration (25 ng/ml). Investigation of the response of
these cells to dierent VEGF-A165 concentrations showed that none of the VEGF-A165
concentrations used (25, 50, 100 and 200 ng/ml) were able to stimulate HCASMC migra-
tion (Figure 4.7).
As mentioned earlier, pre-treatment with chondroitinase increased specic 125I-VEGF-
A165 binding to HCASMC. I therefore hypothesised that, by treating the cells with lyases,
one might be able to trigger HCASMC migration in response to VEGF-A165. However, the
chondroitinase pre-treatment of HCASMC did not alter their lack of migratory response
towards VEGF-A165 (Figure 4.8).
157Figure 4.6: Eects of chondroitinase and heparinase III treatment on 125I-
VEGF-A165 binding in HCASMC
HCASMC cells were pre-treated or not (Control) for 2 hours with chondroitinase, hep-
arinase III or both at 1 U/ml in complete SMC medium with 0.1% BSA. After 2 hours
incubation, cells were lysed and bound radioactivity measured with a gamma-counter.
Bars represent the mean of three independent experiments +/- SEM. *P<0.05 versus
control and heparinase treatment.
Figure 4.7: HCASMC migration in response to VEGF-A165
HCASMC were harvested and seeded into transwell to migrate towards VEGF-A165 at
the indicated concentration for 4 hours. Then, cells that migrated through the porous
membrane were xed, stained and counted at x200 magnication. Bars represent the
mean of three independent experiments +/- SEM.
158Figure 4.8: Eect of chondroitinase on HCASMC migration in response to
VEGF-A165
HCASMC cells were pre-treated or not (Control) for 2 hours with chondroitinase at 1
U/ml in complete SMC medium with 0.1% BSA. After 2 hours incubation, cells were
harvested and seeded into a transwell to perform a migration assay. VEGF-A165 was the
chemoattractant at the bottom of the insert at a concentration of 25 ng/ml. After 4 hours,
the cells that migrated through the porous membrane were xed, stained and counted at
x200 magnication. Bars represent the mean of three independent experiments +/- SEM.
4.2.2 Role of NRP1 in vascular smooth muscle cells functions
4.2.2.1 Radiolabeled PDGF binding to VSMC and PAEC
Other heparin-binding growth factors, including FGF-2 and HGF, have been reported to
bind to NRP1. In addition, while this study was ongoing, PDGF-BB was reported to co-
immunoprecipitate with NRP1 (Banerjee et al., 2006), suggesting that PDGF-BB, a potent
chemoattractant for VSMC, might bind directly to NRP1. I investigated this possibility
by determining the specic ligand binding of 125I-PDGF-BB to porcine aortic endothelial
cells expressing NRP1 (PAE NRP1). While 125I-PDGF-BB showed signicant specic
binding to HCASMC, 125I-PDGF-BB exhibited little specic binding to PAE NRP1 cells
above the level observed in wild-type PAE not expressing NRP1 (Table 4.1). It was also
noted that a high percentage (80-85%) of the total 125I-PDGF-BB binding to PAE and
PAE NRP1 cells was non-specic.
159Table 4.1: 125I-PDGF-BB binding in PAEC and HCASMC
This table summurises the amount of specic 125I-PDGF-BB binding to HCASMC, PAE
and PAE/NRP1 cells in count per minutes (cpm) and also as a percentage of specic bind-
ing (rst item in the parenthesis). HCASMC were incubated with 0.1 nM of 125I-PDGF-BB
for 2 hours at 4C. Cells were then lysed with 0.25 M NaOH, 0.5% SDS solution, and the
bound radioactivity of the lysates was measured. Non specic binding was determined
in the presence of 100-fold excess unlabeled PDGF-BB (Peprotech). The results are ex-
pressed as the mean of three independent experiments (the SEM is the second item given
in the parenthesis).
4.2.2.2 PDGF stimulates HCASMC migration and signalling
I next investigated whether NRP1 was involved in cell migration stimulated by PDGF.
PDGF is a potent mitogenic factor as well as a chemoattractant for VSMC through the
activation of its receptors PDGFR and PDGFR (Heldin et al., 1985). PDGF occurs as
two major homodimeric isoforms, PDGF-AA and PDGF-BB with diering receptor speci-
cities: PDGF-BB binds to both  and  receptors, whereas PDGF-AA recognises only 
receptors with high anity. Since HCASMC expressed both PDGFR and PDGFR at
signicant levels, I initially examined the response of VSMC to PDGF-BB. As expected,
PDGF-BB at 30 ng/ml induced HCASMC migration, while VEGF (25 ng/ml) could not
(Figure 4.9).
Moreover, stimulation of HCSMC with PDGF-AA and PDGF-BB at 30 ng/ml induced the
phosphorylation of the signalling molecules, Akt, ERK 1/2 and p130Cas, while VEGFA165
at 25, 50 or 100 ng/ml could not stimulate their activation. In contrast, PDGF-AA and
PDGF-BB at 30 or 60 ng/ml could not induce the activation of these intracellular eectors
in HUVEC, while VEGF (25 ng/ml) could. These results suggest the specicity of the
growth factors for each cell type, probably in accordance with the expression of their
corresponding receptors on the cell surface. Moreover, in HCASMC, the lack of activation
of intracellular eectors by VEGF-A165 is in agreement with the lack of migration in
response to a VEGFA165 gradient.
160Figure 4.9: HCASMC migration in response to VEGF-A165 and PDGF-BB
Cells were harvested and seeded into a transwell to perform a migration assay. VEGF-A165
and PDGF-BB were the chemoattractants at the bottom of the inserts at a concentration
of 25 ng/ml and 30 ng/ml respectively. After 4 hours, the cells that migrated through the
porous membrane were xed, stained and counted at x200 magnication. Bars represent
the mean of three independent experiments +/- SEM. *P<0.05 versus control and VEGF-
A165.
161Figure 4.10: HUVEC and HCASMC stimulation with VEGF-A165 and PDGFs
HCASMC and HUVEC were stimulated with VEGF-A165, PDGF-AA and PDGF-BB
for 10 minutes. The concentration of the growth factors used to stimulate the cells are
indicated in parenthesis. Cell lysates were then prepared and 5 g of total protein were
run on SDS-PAGE and blotted for the indicated antibodies.
1624.2.2.3 NRP1 antagonists decrease PDGF-BB stimulated HCASMC migration
The role of NRP1 in the migratory response to PDGF-BB was addressed by examining the
eect of a specic bicyclic peptide antagonist, EG3287, which blocks VEGF binding to the
b1 domain of NRP1, and inhibits VEGF-dependent signalling and functions in endothelial
cells (Cheng et al., 2004; Jia et al., 2006). Though it was not possible to obtain clear
evidence for specic binding of PDGF-BB to NRP1, it was hypothesised that a peptide
antagonist of VEGF binding to NRP1 could change the conformation and function of
NRP1 by binding directly to the b1 domain even in the absence of a competing natural
ligand. Pre-treatement of HCASMC with 100 M EG3287 signicantly inhibited migration
induced by PDGF-BB, by around 30% (Figure 4.11). Amino-terminally modied form of
EG3287, called EG00086, which inhibits VEGF-A165 binding to NRP1 with a potency
similar to that of EG3287 (Figure 2.2) was used in further work. When HCASMC were
pre-incubated in the presence of EG00086 at 10, 30 and 100 M, the antagonist reduced
the chemotactic response of the cells in a dose-dependent manner (Figure 4.13). At a 100
M concentration, both EG3287 and EG00086 decreased the migration of HCASMC by
around 40%. Also, it was interesting to see that only migration in response to PDGF-BB
was signicantly reduced by EG00086 as the pre-treatment with the antagonist did not
aect the migratory response of HCASMC towards PDGF-AA (Figure 4.12)
4.2.2.4 Soluble b1 domain and soluble NRP1 decrease PDGF-BB stimulated HCASMC
migration
NRP1 is expressed as a soluble form comprising the a1/a2 and b1/b2 domains, resulting
from alternative splicing. Since the soluble form would compete with membrane-associated
NRP for binding to its putative ligand(s) in VSMC, I hypothesised that soluble NRP1
might act as an inhibitor of NRP1-mediated eects in VSMC. sNRP1 might also prevent
interaction of NRP1 with other receptors, e.g. PDGFRs, by forming non-functional dimers
with membrane-associated NRP1. Furthermore, since the ligand binding domain resides in
part in the b1 domain, soluble recombinant b1 domain might similarly act as an inhibitor
of NRP1 dependent cell migration. As shown in Figure 4.14, pre-incubation of HCASMC
with soluble NRP1 and soluble b1 domain signicantly inhibited migration in response to
PDGF-BB with a similar degree of inhibition that was obtained by EG3287 pre-treatment.
163Figure 4.11: The NRP1 antagonist, EG3287, decreases HCASMC migration in
response to PDGF-BB
HCASMC were harvested and incubated for 30 minutes with 100M of EG3287, seeded
into a transwell to perform a migration assay. PDGF-BB was the chemoattractant at the
bottom of the insert at a concentration of 30 ng/ml. After 4 hours, the cells that migrated
through the porous membrane were xed, stained and counted at x200 magnication.
Bars represent the means of three independent +/-SEM. *P<0.05 versus control plus
PDGF-BB.
164Figure 4.12: The NRP1 antagonist, EG00086, decreases HCASMC migration in
response to PDGF-BB but not to PDGF-AA
HCASMC were harvested and incubated or not (Control) for 30 minutes with EG00086
at the 100M, then seeded into a transwell to perform a migration assay. PDGF-AA and
PDGF-BB was the chemoattractants at the bottom of the insert at a concentration of 30
ng/ml. After 4 hours, the cells that migrated through the porous membrane were xed,
stained and counted at x200 magnication. Bars represent the means of three independent
experiments +/-SEM. *P<0.05 versus control plus PDGF-BB.
165Figure 4.13: The NRP1 antagonist, EG00086, decreases HCASMC migration in
response to PDGF-BB
HCASMC were harvested and incubated or not (Control) for 30 minutes with EG00086
at the indicated molarity, then seeded into a transwell to perform a migration assay.
PDGF-BB was the chemoattractant at the bottom of the insert at a concentration of 30
ng/ml. After 4 hours, the cells that migrated through the porous membrane were xed,
stained and counted at x200 magnication. Bars represent the means of three independent
+/-SEM. *P<0.05 versus control plus PDGF-BB.
166Figure 4.14: sNRP1 and sb1 treatment decrease PDGF-BB stimulated
HCASMC migration
HCASMC were harvested and pre-incubated or not (Control) for 30 minutes with sNRP1
and sb1, then seeded in the upper chamber of a transwell to perform a migration assay.
PDGF-BB was the chemoattractant at the bottom of the insert at a concentration of 30
ng/ml. After 4 hours, the cells that migrated through the porous membrane were xed,
stained and counted at x200 magnication. Bars represent the means of three independent
experiments +/-SEM. *P<0.05 versus control plus PDGF-BB.
1674.2.2.5 Eects of NRP1, NRP2 and synectin knockdown on PDGF-BB stimulated HCASMC
migration
The role of NRP in the migratory response of HCASMC to PDGF-BB was further ex-
amined by siRNA-mediated knockdown of NRP1 and NRP2 expression. Transfection of
HCASMC with siRNAs targeted to NRP1, NRP2 and synectin signicantly reduced pro-
tein expression in HCASMC (Figure 4.15). When siRNA-transfected HCASMC were used
to perform a migration assay in response to PDGF-BB, NRP1 knockdown was found to
cause a signicant decrease in migration (Figure 4.16). NRP2 siRNA also signicantly in-
hibited the migratory response to PDGF-BB though somewhat less so than NRP1, while
synectin knockdown tended to reduce the migratory response of HCASMC but the eect
was not statistically signicant (Figure 4.16).
Figure 4.15: NRP1, NRP2 and synectin knockdown in HCASMC
HCASMC cells were transfected with NRP1, NRP2 and synectin (SYN) siRNAs using the
AMAXA nucleofection kit. 48h after transfection, lysates were prepared and blotted for
NRP1, NRP2 and synectin.
168Figure 4.16: Eects of NRP1, NRP2 and synectin knockdowns on HCASMC
migration in response PDGF-BB
HCASMC cells were previously transfected with NRP1, NRP2, synectin (syn) and scram-
bled (Scr) siRNAs using the AMAXA nucleofection kit. 48 hours after the transfection,
cells were harvested and seeded into a transwell to perform a migration assay. PDGF-BB
was the chemoattractant at the bottom of the insert at a concentration of 30 ng/ml. Af-
ter 4 hours, the cells that migrated through the porous membrane were xed, stained and
counted at x200 magnication. Bars represent the means of three independent experiments
+/-SEM. *P<0.05 versus control scrambled plus PDGF-BB.
1694.2.2.6 NRP1 knockdown decreases PDGF-AA and PDGF-BB stimulated HCASMC mi-
gration
PDGF-AA also stimulated migration of VSMC, but induced a smaller response compared
with PDGF-BB. PDGF-AA-induced migration was also signicantly reduced by NRP1
siRNA transfection, by around 40% (Figure 4.17). Therefore, NRP1 also plays a role in
PDGF-AA mediated HCASMC migration (Figure 4.17).
Figure 4.17: NRP1 knockdown decreases PDGF-AA and PDGF-BB stimulated
HCASMC migration
HCASMC cells were previously transfected with NRP1 siRNAs using the AMAXA nu-
cleofection kit. 48 hours after the transfection, cells were harvested and seeded into a
transwell to perform a migration assay. PDGF-AA and PDGF-BB were the chemoattrac-
tants at the bottom of the inserts, both at a concentration of 30 ng/ml. After 4 hours,
the cells that migrated through the porous membrane were xed, stained and counted at
x200 magnication. Bars represent the means of three independent experiments +/-SEM.
*P<0.05 versus corresponding control scrambled plus PDGF-AA and PDGF-BB.
1704.2.2.7 Overexpression of NRP1 mutant, lacking the C-terminus, decreases PDGF-AA
and PDGF-BB stimulated HCASMC migration
The NRP1 cytosolic domain has been implicated in the functions of NRP1 in endothe-
lial cells, but its precise role remains unclear. To further substantiate the role of NRP1
in the PDGF migratory response in HCASMC, I examined the eects of adenoviral over-
expression of wild-type (WT) NRP1 and a mutant NRP1 lacking the cytosolic domain. Ex-
pression of Ad.NRP1 adenoviral constructs after infection of HCASMC is shown on Figure
4.18. As expected, the over-expression of Ad.NRP1 C was only detected by an antibody
specic for the N-terminus, and not by a C-terminus antibody. Infection of HCASMC with
Ad.NRP1 resulted in a signicant increase in protein expression above the endogenous level
(Figure 4.18), but did not signicantly alter the migration of HCASMC towards a gradi-
ent of either PDGF-AA or PDGF-BB, compared to control cells infected with Ad.GFP
(Figure 4.19). In contrast, Ad.NRP1 C infection, resulting in over-expression of NRP1
lacking the intracellular domain, caused a signicant inhibition of cell migration induced
either by PDGF-AA or by PDGF-BB, similar to the eect of NRP1 knockdown (Figure
4.19). It was also noted that Ad.NRP1 C over-expression also reduced the basal level of
HCASMC migration seen in the absence of PDGF stimulation.
4.2.2.8 Chondroitinase decreases PDGF-BB stimulated HCASMC migration
Chondroitin sulphate chains (CS), which are abundant in the extracellular matrix have
been shown to physically interact with growth factors and particularly with PDGF-BB
helping the modulation of its biological function. For example, the addition of exogenous
free CS chains causes a signicant downregulation of the PDGF-BB mediated mitogenic
and chemotactic responses in human lung broblasts (Fthenou et al., 2008). In this study,
the migratory response of HCASMC in response to PDGF-BB was signicantly reduced
after treatment of intact cells with 1U/ml of chondroitinase (Figure 4.20).
171Figure 4.18: Western blot showing the overexpression of NRP1 WT and C
constructs in HCASMC
HCASMC cells were previously infected with Ad.GFP, Ad.NRP1 WT or Ad.NRP1 C
adenoviruses constructs. 48 hours after the transfection, cells were lysed to assess the
expression of the NRP1 constructs. The upper panel corresponds to the Western blot
obtained using the NRP1 antibody targeting NRP1 C-terminal cytosolic domain (NRP1
C-term), and the lower panel to the Western blot obtained with the antibody targeting the
extracellular domain (NRP1 N-term). The position of GAG-modied NRP1 (NRP1-CS),
unmodied WT NRP1 (WT NRP1) and NRP1 C are indicated.
172Figure 4.19: Overexpression of NRP1 C mutant, lacking the C-terminus, de-
creases PDGF-AA and PDGF-BB stimulated HCASMC migration
HCASMC cells were previously infected with Ad.GFP, Ad.NRP1 WT or Ad.NRP1 C
adenoviruses constructs. 48 hours after the transfection, cells were harvested and seeded
into a transwell to perform a migration assay. PDGF-AA and PDGF-BB were the
chemoattractants at the bottom of the inserts, both at a concentration of 30 ng/ml.
After 4 hours, the cells that migrated through the porous membrane were xed, stained
and counted at x200 magnication. Bars represent the means of three independent ex-
periments +/-SEM. *P<0.05 versus corresponding control, Ad.GFP, Ad.NRP1 WT plus
PDGF-AA and PDGF-BB.
173Figure 4.20: Chondroitinase treatment of HCASMC decreases migration in re-
sponse to PDGF-BB
HCASMC cells were pre-treated or not (Control) for 2 hours with chondroitinase at 1
U/ml in complete SMC medium with 0.1% BSA. After 2 hours incubation, cells were
harvested and seeded into a transwell to perform a migration assay. PDGF-BB was the
chemoattractant at the bottom of the insert at a concentration of 30 ng/ml. After 4 hours,
the cells that migrated through the porous membrane were xed, stained and counted at
x200 magnication. Bars represent the means of three independent experiments +/-SEM.
*P<0.05 versus control plus PDGF-BB.
1744.2.2.9 Overexpression of NRP1 S612A mutant lacking GAG modication does not im-
pair PDGF-AA and PDGF-BB stimulated HCASMC migration
To study the eect of the GAG modication of NRP1 in HCASMC, I over-expressed an
adenoviral NRP1 construct with a Serine substituted to an Alanine in position 612. Two
day after transfection, the level of over-expression of the NRP1 construct were assessed,
and as expected, only the non-glycosylated form of NRP1 at a molecular weight of 130
kDa was observed on the Western Blot whereas the NRP1 WT construct resulted in the
expression of both GAG modied and non-modied (Figure 4.21). In parallel, I used
the infected cells to assess migration. A small reduction in the migratory response of
HCASMC was observed, but it was not statistically signicant altered (Figure 4.22).
Figure 4.21: Western blot showing the overexpression of NRP1WT and S612A
constructs in HCASMC
HCASMC cells were previously infected with Ad.GFP, Ad.NRP1 WT or Ad.NRP1 S612A
adenoviruses. 48 hours after the transfection, cells were lysed to assess the expression of
the NRP1 constructs.
175Figure 4.22: Overexpression of NRP1 S612A mutant, lacking GAG modication,
does not impair PDGF-AA and PDGF-BB stimulated HCASMC migration
HCASMC cells were previously infected with Ad.GFP, Ad.NRP1 WT or Ad.NRP1 S612A
adenoviruses constructs. 48 hours after the transfection, cells were harvested and seeded
into a transwell to perform a migration assay. PDGF-AA and PDGF-BB were the
chemoattractants at the bottom of the inserts, both at a concentration of 30 ng/ml. Af-
ter 4 hours, the cells that migrated through the porous membrane were xed, stained and
counted at x200 magnication. Bars represent the means of three independent experiments
+/-SEM.
1764.3 Discussion
Role for NRP in migration of endothelial cells
In HUVECs and in HCAEC, NRP1 does not appear to be modied by the addition of
O-linked GAG and the lyases did not aect VEGF-A165 binding to the EC. Neverthe-
less, VEGF-A165 is known to bind to HS with high anity (Robinson et al., 2006), and
in endothelial cells where HS, but not CS, have been enzymatically removed, VEGF-
A165 signalling is impaired, with lower level of VEGFR2 and ERK1/2 phosphorylation
(Ashikari-Hada et al., 2005). VEGFR2 and NRP1 also bind to heparan sulfate, suggest-
ing that the HSPG may play a role in facilitating the formation of the active signalling
complex (Jakobsson et al., 2006). In this study, heparinase III (also called heparitinase)
that cleaves heparan sulfate exclusively, and does not cleave unfractionated heparin or low
molecular weight heparins, had no eect on VEGF-A165 binding. This might result from
the persistence of other heparan-like GAG or heparin that are not recognised and hence
not degraded by the enzyme, but still might play a role in VEGF-A binding.
In PAE NRP1 cells, NRP1 is expressed as both its O-linked GAG form and non-modied
form. Nevertheless, the use of chondroitinase and heparinase which results in the removal
of the GAG moiety did not alter VEGF-A165 binding. This suggest that the GAG moiety
does not play any role in VEGF-A165 binding to NRP1 in PAEC.
The role for neuropilins in endothelial cell biology is now well established, and both NRP1
and NRP2 have been shown to be important for EC proliferation, migration (Sulpice et al.,
2008; Favier et al., 2006) and adhesion (Murga et al., 2005). It therefore not surprising that
knockdown of NRP1 and NRP2 via siRNA transfection resulted in a signicant decrease
in migration of HCAEC. Nevertheless, to the best of my knowledge, previous studies have
not demonstrated a role for NRP1 in HCAEC. It was also important to demonstrate a role
for NRP1 in VEGFA165-regulated migration of HCAEC, given that an important goal of
this thesis was to examine the role of NRP1 in migration of cognate HCASMC.
Moreover, the results obtained with the over-expression of the NRP1 C adenoviral con-
struct, demonstrate an important role for the cytoplasmic domain in VEGF-A165-induced
EC migration. The NRP1 C mutant, by exerting a dominant negative eect, possi-
bly prevents interactions between the NRP1 cytoplasmic domain and intracellular bind-
ing molecules and could also result in the sequestration of inactive complexes of VEGF,
VEGFR and other cellular components important for chemotactic signalling.
177Role for NRP in migration of vascular smooth muscle cells
VEGF-A165 binds specically to the surface of HCASMC consistent with expression of
VEGFR2 and NRP1 in these cells. Nevertheless, the level of expression of VEGFR2 in
HCASMC appears markedly lower than the level of expression of NRP1 (Figure 3.1) and
this was further conrmed by ow cytometry which indicated that only 8.89% of the
cells expressed VEGFR2 at their surface. Therefore the relevance of the importance of
the VEGF receptor is not clear. Pre-treating the cells with chondroitinase resulted in a
signicant increase of VEGF-A165 binding which might be due in part to the removal of
the chondroitin sulphate moiety from NRP1. It could also be due to interactions of high
anity between CS and VEGF-A165 within the extracellular matrix (ECM), which once
abrogated, allow more specic binding between VEGF-A165 and its receptors, NRP1 in
particular. In VSMC, NRP1 appears to be the main VEGF receptor that is expressed as
a high molecular weight -CS or HS- modied form at signicant levels, suggesting that
any eect of chondroitinase on 125I-VEGF-A165 binding is due to to increased binding to
NRP1. However, VEGFR2 is also expressed at low levels (Figure 3.1) and some studies
reported VEGFR1 expression in VSMC (Mata-Greenwood et al., 2003). As the lyases act
globally on cell surface GAG-modied proteins, it is dicult to attribute their eects to
removal of GAG from NRP1 alone.
Several reports in the literature (Banerjee et al., 2008; Grosskreutz et al., 1999; Shintani
et al., 2006) have shown a signicant role for VEGF-A165 in SMC migration in cultured
cells. However, in these studies, the eect of VEGF-A165 on migration is considerably
less than the eects of serum or PDGF, and they should therefore to be interpreted
with caution. I could not detect any eect of VEGF-A165 on HCASMC migration at
concentrations from 25 to 200 ng/ml.
Since VEGF-A165 had no eect on HCASMC migration, I decided to investigate a potential
role for NRP1 in SMC migration in response to the potent VSMC mitogens, PDGF-
AA and PDGF-BB. I rst examined if PDGF-BB binds specically to HCASMC using
radiolabelled ligand. There was indeed specic binding of PDGF-BB to HCASMC. PDGF-
BB is the ligand for all three possible PDGF receptors dimers, ,  and , and PDGF-
BB has also been reported to bind NRP1 (Banerjee et al., 2006). Nevertheless, I did not
observe signicant specic binding of PDGF-BB to PAE cells that stably over-express
NRP1, suggesting that PDGF-BB does not bind to NRP1 directly. Moreover, in a cell free
competitive binding assay for VEGF to NRP1, PDGF-BB did not displace biotinylated
178VEGF-A binding to NRP1, suggesting that VEGF-A and PDGF-BB do not compete for
the same binding sites on NRP1 and further conrming the absence of interaction between
PDGF-BB and NRP1 (Appendix A.6). It is not possible to preclude the possibility that
PDGF binds to NRP1, but I was unable to obtain convincing evidence in support of this
conclusion, despite showing that labelled VEGF-A165 and PDGF-BB bound specically
to HCASMC.
PDGF are potent mitogenic factor chemotactic factors for VSMC through the activation
of their receptors PDGFR and PDGFR (Heldin et al., 1985). As expected, PDGF-BB
could induce a strong migratory response of HCASMC, of 5 fold compared to unstimu-
lated and VEGF-A stimulated cells (Figure 4.9). Pre-treating the cells with chondroitinase
resulted in a decrease of migration of HCASMC in response to PDGF-BB. In previous
studies by Denholm et al. (2001), chondroitinase treatment inhibited melanoma cell in-
vasion and proliferation as well as endothelial cell proliferation and angiogenesis. Other
studies shown that chondroitin and/or dermatan sulfate proteoglycans regulate the bind-
ing of platelet factor 4, bFGF, HGF and interferon- to their respective receptors in a
several cell types (Denholm et al., 2001; Hurt-Camejo et al., 1999; Petersen et al., 1998),
it is possible that CS could play a role in the binding of PDGF to its receptors. These
results therefore suggest a role for CS in SMC migration, but because chondroitinase has
a global eect on the cells, we can not draw any conclusion on the role for the chondroitin
modication of NRP1 in particular.
Several NRP1 antagonists were developed in our laboratories, EG3287 is a small bicyclic
peptide that binds to the VEGF-A165 binding domain of NRP1, and later was synthetised
EG00086 which has the same peptide sequence as EG3287, but is modied at its amino-
terminus by addition of an octanoyl group, and has somewhat improved potency compared
with EG3287. EG3287 has no eect on VEGF-A165 binding to VEGFR2 and VEGFR1,
but inhibited cross-linking of VEGF-A165 to KDR in HUVEC, inhibited stimulation of
VEGFR2 and PLC- tyrosine phosphorylation, activation of ERK1/2 and prostanoid
production (Jia et al., 2006). I used these antagonists to study the eects of NRP1 inacti-
vation on HCASMC migration. Pre-treatment of the cells with the antagonist decreased
the migratory response to PDGF-BB, while migration towards PDGF-AA was not altered
by the antagonist. Given the structural similarities between PDGF and VEGF, and also
evidence that VEGF can signal through PDGFR (Ball et al., 2007), it is plausible that
the antagonists could inhibit binding of PDGF and VEGF to NRP1 via a similar mecha-
179nism. However, my data suggest that it is unlikely that VEGF-A165 and PDGF-BB were
competing against each other for binding to NRP1 at the same site. It is therefore pos-
sible that the binding of the antagonists to NRP1 induces a change of conformation that
might render NRP1 less active, and thus impairs the response to PDGF-BB. Why the
antagonists specically aect the response to PDGF-BB and have little eect on PDGF-
AA-induced migration is unclear, but probably indicates that NRP1 acts to regulate mi-
gratory responses to PDGF-BB and -AA via dierent mechanisms. These mechanisms
are investigated in greater detail in the next chapter.
NRP1 is known to be expressed as a soluble form comprising the two CUB and two
FV/VIII domains, and because the soluble form could potentially compete with membrane-
associated NRP for binding to its ligand, I hypothesised that sNRP1 and sb1 domain, the
principal VEGF-A binding domain, might act as an inhibitor of NRP1-mediated eects in
VSMC. Pre-incubation of HCASMC with sNRP1 and sb1 signicantly inhibited migration
in response to PDGF-BB, suggesting that sNRP1 or sb1 complexes and sequesters either
a ligand or ligands yet to be identied that are important for NRP1 function, and/or
with PDGF receptors at the surface of the cell. Alternatively, sNRP1 might complex with
membrane-associated NRP1 to form dimers with reduced activity. The key nding of this
chapter is that NRP1 plays a signicant role in the stimulation of Human VSMC migration
in response to the potent chemoattractants, PDGF-AA and PDGF-BB. The conclusion
that NRP1 is important for PDGF-induced migration of HCASMC is supported by the
nding that siRNA-mediated NRP1 knockdown signicantly inhibited HCASMC migra-
tion induced either by PDGF-AA or by PDGF-BB.
During the course of this study, work published by Banerjee et al. (2006) also reported the
importance of NRP1 in PDGF-BB induced smooth muscle cell migration. They observed
that the depletion of NRP1 production by HAoSMC with short hairpin RNA (shRNA)
prevents the PDGF-BB dependent migration of VSMC (Banerjee et al., 2006). They also
observed a physical interaction between PDGF-BB and NRP1 via co-immunoprecipitation.
I was not able to show such an interaction, but as described in the following chapter, I
found that NRP1 could form a complex with PDGFR. This result further supports the
role of NRP in PDGF-induced migration.
A role for NRP1 in the migratory response to PDGF is also supported by the nding
that over-expression of the NRP1 adenovirus construct lacking the cytoplasmic domain
(Ad.NRP1 C) inhibited the chemotactic response of HCASMC to PDGF-AA and PDGF-
180BB. In endothelial cells, the NRP1 cytoplasmic domain is known to be able to mediate
protein-protein interactions and more precisely the C-terminal three amino acids of NRP1
(SEA-COOH) are required for NRP1-mediated angiogenesis (Wang et al., 2006). A NRP1
construct lacking the C-terminus domain caused an inhibition of the migratory response
towards PDGF-AA and PDGF-BB which suggests that NRP1 is required for optimal
signalling important for migration downstream of PDGF receptors. It was noted that
Ad.NRP1 C over-expression had a more marked inhibitory eect on PDGF-induced
HCASMC migration than NRP1 knock down via siRNA, and also reduced the basal un-
stimulated level of migration, whereas NRP1 siRNA did not. These results are consistent
with the conclusion that the NRP1 C mutant construct exerts a dominant negative eect,
possibly via prevention of interactions between the NRP1 cytoplasmic domain and intracel-
lular binding partners important for transducing chemotactic signals, and/or sequestration
in inactive complexes of PDGF, PDGFR and possibly other cellular components impor-
tant for chemotactic signalling. One known NRP1-binding molecule is synectin, and the
data shows that synectin knockdown reduced PDGF-BB-induced cell migration, though
this eect did not reach statistical signicance. I hypothesise that other proteins may in-
teract with the NRP1 cytoplasmic domain and contribute to PDGF-induced chemotactic
signalling.
Moreover, the O-linked post-translationnal modication of NRP1 does not seem to play a
role in the migratory response of VSMC, as the over-expression of the NRP1 S612A mutant
did not alter VSMC migration towards PDGF-AA or PDGF-BB. This result suggests
that the GAG modication is not important for PDGFR-mediated migration. In their
study, Shintani et al. (2006) showed that VSMC infected with the same S612A adenoviral
construct displayed an increased migration in response to VEGF-A165. However, because
I could not induce migration of HCASMC in response to VEGF-A165 and also because of
the relatively small induction observed by this group, I believe these results of Shintani
et al. (2006) should be considered with caution.
181Chapter 5
NRP1 signalling in vascular cells
Many dierent cytokines are involved in the regulation of chemotactic endothelial and vas-
cular smooth muscle cell migration during angiogenesis. A major promoter of actin-based
motility of EC is VEGF, while one of the most potent migratory cytokines for VSMC is
PDGF. The activation of small GTPases of the Rho family is involved in regulating EC
migration in response to VEGFR2 activation, but NRP1 did not seem to play a role in the
activation of the most common molecules involved in chemotaxis in U87 cells such as Akt,
Src, Hsp27 or FAK (Frankel et al., results not published). Colleagues in this laboratory
found that over-expression of NRP1 in U87MG glioma cells enhanced signalling through
p130Cas (Crk-associated substrate), a non-enzymatic docking protein which is strongly
implicated in cell migration and invasion (Frankel et al., 2008). The activation of p130Cas
was altered in cells depleted of NRP1 by siRNA-mediated knockdown in both EC and
VSMC, highlighting a possible role for this protein in regulating vascular cell migration
downstream of NRP1. Moreover, they identied the proline-rich tyrosine kinase 2 (Pyk2)
as another molecule of which activity is also regulated by NRP1 (Evans et al., MS sub-
mitted). This might not appear too surprising in the light of the formation of a stable
complex between pyk2 and p130Cas able to transduce signalling in response to stimu-
lation with various growth factors (Kodama et al., 2003) and data showing that VEGF
stimulate p130Cas tyrosine phosphorylation (Endo et al., 2003). Given these ndings, in
this chapter, I investigated the role of a new intracellular signalling pathway downstream
of NRP1 involving the docking protein p130Cas in both endothelial cells and VSMC.
1825.1 NRP1 signalling in endothelial cells
5.1.1 NRP1 antagonist and NRP1 blocking antibody decrease p130Cas phos-
phorylation in response to VEGF-A165 in endothelial cells
After observing the inhibitory eect of the NRP1 antagonist developed by colleagues in
this laboratory on the chemotactic response of vascular cells, I studied the eect of the
NRP1 antagonist, EG00086, on the phosphorylation of migratory molecules. A blocking
antibody was also used to block VEGF-A165 binding to NRP1 and potentially inhibit
phosphorylation of eector molecules. Pre-treatment of HUVEC with either the NRP1
blocking antibody (R&D systems, AF566) or the peptide antagonist (EG00086) for 30
minutes, inhibited tyrosine phosphorylation of p130Cas in response to VEGF-A165. Pyk2
activation was also reduced (Evans et al., MS submitted), but other signalling molecule
were not aected including Akt, Hsp27 and ERK. Quantication of p130Cas phosphory-
lation shows that when the cells were pre-treated with either reagent, VEGF-A165 failed
to trigger the activation seen in control cells (Figure 5.1).
5.1.2 NRP1 knockdown decreases p130Cas phosphorylation in response to
VEGF-A165 in endothelial cells
To further implicate NRP1 as an essential mediator in p130Cas phosphorylation, I trans-
fected endothelial cells with siRNA using Oligofectamine 2000. 72 hours later and after
overnight incubation in medium with 0.5% serum, cells were stimulated for 10 minutes
with VEGF-A165, lysed with RIPA buer and lysates were blotted for NRP1 expression,
to conrm knockdown of the receptor, p130Cas phosphorylation at Tyrosine 410, and the
total level of p130Cas. A clear knockdown was obtain in HUVEC as indicated by Western
blot (Figure 5.2). Knocking down NRP1 clearly inhibited p130Cas phosphorylation and,
quantication of phospho-p130Cas shows a complete lack of activation by VEGF-A165
in NRP1 siRNA transfected cells, indicating a role for NRP1 in p130Cas activation in
endothelial cells (Figure 5.2).
5.1.3 p130Cas plays a role in endothelial cell migration
To conrm a role for p130Cas in endothelial cell migration, I investigated the level of
migratory response of HUVEC in response to VEGF-A165 after p130Cas knockdown, as
shown in Figure 5.3 (inset). Three days after knockdown, the cells were used to perform
a migration assay and cells that had been transfected with p130Cas siRNA displayed
183Figure 5.1: NRP1 antagonist and NRP1 blocking antibody decrease p130Cas
phosphorylation in response to VEGF-A165 in EC
HUVECs were incubated overnight in medium containing 0.5% serum and pre-incubated
with 100 M EG00086 or NRP1 blocking antibody, and then stimulated for 10 minutes
with VEGF-A165 (25 ng/nl) or with serum-free medium and lysed in RIPA buer. Cell
lysates were then prepared, blotted, and probed with the indicated antibodies. Quantita-
tion of p130Cas phosphorylation was performed by densitometry using Image J. Data from
three independent experiments are presented as p130Cas phosphorylation in relative units
(RU) (means +/- SEM) normalised to total p130Cas. *P<0.05 versus VEGF control.
.
184Figure 5.2: NRP1 knockdown decreases p130Cas phosphorylation in response
to VEGF-A165 in EC
HUVEC cells were previously transfected with NRP1 or scrambled control siRNAs using
oligofectamine. After 48 hours, cells were incubated overnight in EC medium containing
0.5% serum. Cells were then stimulated for 10 minutes with 25 ng/ml VEGF-A165 or with
serum-free medium, and lysed in RIPA buer. Cell lysates were then prepared, blotted,
and probed with the indicated antibodies. Quantitation of p130Cas phosphorylation was
performed by densitometry using Image J. Data from three independent experiments are
presented as p130Cas phosphorylation in relative units (RU) (means +/- SEM) normalised
to total p130Cas. *P<0.05 versus VEGF with scrambled siRNA.
185a signicantly reduced migratory response to VEGF-A165 compared to cells transfected
with scrambled siRNA. This result stronlgy implies a role for p130Cas in the migration of
endothelial cells.
Figure 5.3: p130Cas plays a role in EC migration
HUVECs were transfected with p130Cas or scrambled control siRNA for 72h and then
harvested to perform a migration assay in response to VEGF-A165 (25 ng/ml). After
4 hours, the cells that migrated through the porous membrane were xed, stained and
counted at a x200 magnication. Bars represent the mean of three experiments +/- SEM.
*P<0.05 versus VEGF with scrambled siRNA.
Inset: Lysates of HUVEC prepared three days after transfection with scrambled or
p130Cas siRNA were blotted with total p130Cas antibody.
5.1.4 NRP1 C mutant overexpression decreases VEGF-A165 induced phos-
phorylation of p130Cas and migration in endothelial cells
As shown in the previous chapter, the NRP1 cytoplasmic domain plays a role in endothelial
cell migration, since infection of EC with an adenovirus over-expressing the NRP1 mutant
lacking its cytosolic domain results in a signicant reduction of migration in response to
VEGF-A165 (Figure 4.5). It is known that synectin interacts with the cytoplasmic domain
of NRP1, regulating in part EC migration, but I further investigated if this decrease in
186migration was also correlated with a decrease in phosphorylation of p130Cas. Cells were
infected with either GFP, NRP1 WT or NRP1 C mutant for 72h and incubated with
medium containing 0.5% serum for the last 12h before being stimulated with 25 ng/ml of
VEGF-A165. VEGF-A165 stimulation resulted in the signicant activation of p130Cas at
Tyrosine 410 and infection with the adenovirus construct overexpressing NRP1 WT did
not alter p130Cas activation. In contrast, over-expression of the NRP1 construct lacking
the cytoplasmic domain resulted in a signicant decrease of p130Cas activation in response
to VEGF-A165 (Figure 5.4). This result indicates that, not only NRP1 is important for
p130Cas activation, but that its cytosolic domain conveys some signalling input towards
this activation.
5.2 NRP1 signalling in vascular smooth muscle cells
5.2.1 NRP1 and PDGFR co-immunoprecipitate and colocalise at the cell
membrane
A mechanism through which NRP1 could regulate migratory responses of HCASMC to
PDGF is the formation of heterocomplexes between PDGF receptors and NRP1. As
seen in Figure 3.1, HCASMC express similar levels of PDGFRs  and , either of which
can mediate responses to PDGF-BB, whereas PDGFR only binds to PDGF-BB and does
not recognise PDGF-AA with high anity. To examine association between PDGFRs and
NRP1, I attempted to co-immunoprecipitate NRP1 with PDGFRs from HCASMC lysates.
Immunoblots of NRP1 in PDGFR immunoprecipitates detected signicant NRP1 com-
pared to IgG controls, indicating that PDGFR associated with NRP1 (Figure 5.5). How-
ever, NRP1 was not detected in PDGFR immunoprecipitates (5.6), indicating that in con-
trast to the  receptor, PDGFR might not interact with NRP1. Co-immunouorescent
staining of NRP1 and PDGFR in HCASMC also revealed signicant colocalisation of
these molecules at the cell membrane, consistent with the conclusion that they associate
(Figure 5.7). In contrast, co-staining of NRP1 and PDGFR revealed little signicant
colocalisation (Figure 5.8).
187Figure 5.4: NRP1 C mutant overexpression decreases VEGF-A165 induced
phosphorylation of p130Cas and migration in EC
HUVECs were infected with adenoviral constructs over-expressing either GFP, NRP1 WT
and NRP1 C and 48h later were incubated in medium containing 0.5% serum overnight.
Cells were then stimulated for 10 minutes with VEGF-A165 (25 ng/ml) or with serum free
medium and lysed in RIPA buer. Cell lysates were then prepared, blotted, and probed
with the indicated antibodies. Quantitation of p130Cas phosphorylation was performed
by densitometry using Image J. Data from three independent experiments are presented
as p130Cas phosphorylation relative units (RU) (means +/- SEM) normalised to total
p130Cas. *P<0.05 versus VEGF with Ad.NRP1 WT.
188Figure 5.5: NRP1 and PDGFR co-immunoprecipitate
HCASMC were incubated overnight in serum free medium, incubated with (+) PDGF-BB
(30 ng/ml) or with serum free medium (-) and then lysed. Protein lysates were pre-cleared
by incubating with washed protein A/G plus agarose beads for 30 minutes followed by
antibody binding overnight at 4C with PDGFR antibody. Rabbit IgG and agarose beads
alone were used as control for non-specic binding of the antibody. The day after, protein
A/G plus agarose beads were added to capture the immunocomplex for 4 hours at 4C in
a cold room on a rotator. The IP complex was then dissociated by incubation with sample
buer and heating at 100C, and run on a 4-12% Bis-Tris gel. Proteins were transfered to
membranes which were then incubated with NRP1 antibodies and HRP-labeled anti-goat
secondary antibody. The eciency of the IP was assessed by blotting the immunocomplex
for PDGFR and ran along some HCASMC lysate (right hand blot). The Western blot
shown are representative of two independent experiments yielding similar results.
189Figure 5.6: NRP1 and PDGFR do not co-immunoprecipite
HCASMC were incubated overnight in serum free medium, incubated with (+) PDGF-BB
(30 ng/ml) or with serum free medium (-) and then lysed. Protein lysates were pre-cleared
by incubating with washed protein A/G plus agarose beads for 30 minutes followed by
antibody binding overnight at 4C with PDGFR antibody. Rabbit IgG and agarose beads
alone were used as control for non-specic binding of the antibody. The day after, protein
A/G plus agarose beads were added to capture the immunocomplex for 4 hours at 4C in
a cold room on a rotator. The IP complex was then dissociated by incubation with sample
buer and heating at 100C, and run on a 4-12% Bis-Tris gel. Proteins were transfered to
membranes which were then incubated with NRP1 antibodies and HRP-labeled anti-goat
secondary antibody. The eciency of the IP was assessed by blotting the immunocomplex
for PDGFR and ran along some HCASMC lysate (right hand blot). The Western blot
shown are representative of two independent experiments yielding similar results.
190Figure 5.7: NRP1 and PDGFR colocalisation
HCASMC were xed with 4% PFA and permeabilised with 0.1% Triton X100. Cells were
stained with PDGFR and NRP1 (C-terminus) antibodies, and then FITC (green, NRP1)
anti-goat and Alexa uor 555 (red, PDGFR) anti-rabbit were used as secondary reagents.
The rst panel shows PDGFR on the red channel (a). On the right, the second panel
shows NRP1 staining on the green channel (b). The merged images (c,d) show partial
colocalisation between both receptors in the cytoplasm and also at the membrane, as seen
in the enlarged panel (d), indicated by the white arrows. Images are representative of
three independent experiments.
191Figure 5.8: NRP1 and PDGFR colocalisation
HCASMC were xed with 4% PFA and permeabilised with 0.1% Triton X100. Cells were
stained with PDGFR and NRP1 (C-terminus) antibodies, and then FITC (green, NRP1)
anti-goat and Alexa uor 555 (red, PDFGR) anti-rabbit were used as secondary reagents.
The rst panel shows PDGFR on the red channel (a). On the right, the second panel
shows NRP1 staining on the green channel (b). The merged images (c,d) show limited
colocalisation between both receptors in the cytoplasm and at the membrane, indicated
by the white arrows. Panel d is an enlargement of the boxed area in c. Images are
representative of three independent experiments.
1925.2.2 NRP1 knockdown decreases p130Cas phosphorylation in response to
PDGF in VSMC
PDGF-BB increased p130Cas Tyrosine phosphorylation in HCASMC consistent with this
pathway playing a role in the chemotactic response to PDGF-BB (Figure 5.9). Depletion
of NRP1 by siRNA-mediated knockdown reduced PDGF-BB-induced p130Cas Tyrosine
phosphorylation, but had no signicant eect on PDGF-BB-induced activation of ERKs
1/2 or Akt (Figure 5.9). PDGF-AA also stimulated p130Cas tyrosine phosphorylation,
though its eect was weaker than that of PDGF-BB, and this response to PDGF-AA was
also reduced by NRP1 siRNA (Figure 5.10).
5.2.3 NRP1 C mutant overexpression decreases PDGF-BB induced phos-
phorylation in VSMC
The role of the NRP1 cytosolic domain in PDGF-induced VSMC p130Cas signalling
was examined by over-expressing the NRP1 C mutant in HCASMC. As shown in Fig-
ure 5.11, Ad.NRP1 C inhibited PDGF-BB-induced p130Cas tyrosine phosphorylation.
Quantication of data from three independent experiments showed that Ad.NRP1 C
markedly and signicantly reduced the stimulation of p130Cas tyrosine phosphorylation
by PDGF-BB (Figure 5.11). In contrast, it was noted that adenoviral wild-type NRP1
over-expression was associated with some enhancement of p130Cas tyrosine phosphoryla-
tion, though the eect of Ad.NRP1 WT was not statistically signicant (Figure 5.11).
5.2.4 p130Cas plays a role in PDGF-induced VSMC migration
While p130Cas is implicated in the mechanisms underlying cell migration and associated
cellular processes such as cytoskeletal organisation (Delippi et al., 2006), the role of this
adapter protein in SMC migration has been little investigated. The role of p130Cas in
PDGF-induced cell migration was examined by determining the eect of p130Cas knock-
down on chemotaxis. As shown in Figure 5.12, p130Cas siRNA signicantly reduced the
migratory response of HCASMC to PDGF-BB by an amount similar to the eect of NRP1
knockdown, and also reduced the increase in migration induced by PDGF-AA, though the
latter eect was not statistically signicant.
193Figure 5.9: NRP1 knockdown decreases p130Cas phosphorylation in response
to PDGF-BB in VSMC
HCASMC were previously transfected with NRP1 or scrambled (scr) siRNAs. After 48
hours, cells were incubated overnight in serum free SMC medium. Cells were then stim-
ulated for 10 and 30 minutes with PDGF-BB (30 ng/ml) and lysed in RIPA buer. Cell
lysates were then prepared, blotted, and probed with the indicated antibodies. Results are
representative of three independent experiments yielding similar results. Quantitation of
p130Cas phosphorylation was performed by densitometry using Image J. Data from three
independent experiments are presented as p130Cas phosphorylation relative units (RU)
(means +/- SEM) normalised to total p130Cas. *P<0.05 versus PDGF with scramble
siRNA at the corresponding time point.
194Figure 5.10: NRP1 knockdown decreases p130Cas phosphorylation in response
to PDGF-AA in VSMC
HCASMC were previously transfected with NRP1 and scrambled control (scr) siRNAs.
After 48 hours, cells were incubated overnight in serum free SMC medium. Cells were
then stimulated for 10 minutes with PDGF-AA (30 ng/ml) and lysed in RIPA buer. Cell
lysates were then prepared, blotted, and probed with the indicated antibodies. Results
are representative of two independent experiments yielding similar results.
5.2.5 NRP1 modulates PDGFR activation
In order to further understand the mechanism through which NRP1 regulated PDGF-BB
chemotactic signalling, I investigated the contribution of NRP1 to PDGF-BB-stimulated
chemotactic cell signalling in HCASMC. I rst examined whether NRP1 is required for
activation of PDGFRs in VSMC, by determining the eect of NRP1 knockdown on
PDGF-induced receptor activation in a quantitative ELISA specic for phosphorylation of
PDGFR and PDGFR. The results indicate that NRP1 knockdown markedly inhibited
PDGF-AA stimulation of PDGFR activity and signicantly reduced PDGF-BB induc-
tion of PDGFR activity, though the eect of NRP1 siRNA on the response to PDGF-BB
was noticeably smaller than for PDGF-AA (Figure 5.13, upper). In contrast, NRP1 siRNA
had no signicant eect on PDGF-BB-induced PDGFR phosphorylation (Figure 5.13,
lower). It was conrmed that PDGF-AA did not stimulate PDGFR phosphorylation.
195Figure 5.11: NRP1 C mutant overexpression decreases PDGF-BB-induced
phosphorylation of p130Cas in VSMC
HCASMC were infected with adenoviral constructs overexpressing either GFP, NRP1 WT
or NRP1 C and 48h later were incubated in serum-free medium overnight. Cells were
then stimulated for 10 minutes with PDGF-BB (30 ng/ml) and lysed in RIPA buer. Cell
lysates were then prepared, blotted, and probed with the indicated antibodies. Quantita-
tion of p130Cas phosphorylation was performed by densitometry using Image J. Data from
three independent experiments are presented as p130Cas phosphorylation relative units
(RU) (means +/- SEM) obtained from three independent experiments and normalised to
total p130Cas. *P<0.05 versus Control, Ad.GFP and Ad.NRP1 WT.
196Figure 5.12: p130Cas plays a role in PDGF-induced VSMC migration
HCASMC cells were transfected with p130Cas siRNA for 72h and then harvested to per-
form migration assays in response to PDGF-AA and PDGF-BB (both 30 ng/ml). After
4 hours, the cells that migrated through the porous membrane were xed, stained and
counted at x200 magnication. Bars represent the means of three independent experi-
ments +/- SEM. *P<0.05 versus PDGF-BB plus scrambled siRNA.
Inset: HCASMC lysates prepared 72h after transfection with scrambled or p130Cas siRNA
were blotted with total p130Cas or GAPDH antibodies.
197Figure 5.13: Eects of NRP1 knockdown on PDGFRs activity
HCASMC cells were transfected with NRP1 siRNA for 60h and then incubated with
serum-free SMC medium for a further 12h. Cells were then stimulated for 10 minutes with
PDGF-AA and PDGF-BB (both 30 ng/ml) and lysed in the appropriate ELISA buer.
The protein lysate was then added to 96-well plate pre-coated with phospho- (or total)
PDGFR (upper) and phospho- (or total) PDGFR antibodies. Detection antibody was
nally added and the reaction stopped with appropriate solutions before the absorbance
was read using a Tecan Genios plate reader at A450nm with a reference wavelength at
595nm. Bars represent the means of three independent experiments +/- SEM. *P<0.05
versus PDGFs plus scrambled siRNA.
1985.3 Discussion
5.3.1 Role of NRP1 in VEGF signalling
At the beginning of this study, NRP1 was already known to play an essential role in EC
migration by forming complexes with VEGFR2 and further enhancing the VEGF-A165
induced signalling response (Soker et al., 2002). Nevertheless, only one molecule, synectin,
has been identied as a downstream eector of NRP1; and the receptor is still widely seen
as a purely binding entity of the receptor complex, while VEGFR2 is solely responsible
for mediating signalling. Here, several approaches were used to inhibit NRP1 function
and investigate its role in signalling: the use of a blocking antibody and of a peptide
antagonist that both block specically VEGF-A165 and siRNA-mediated knockdown. All
these approaches resulted in the decrease of the phosphorylation at Tyrosine 410 of the
non-enzymatic docking protein, p130Cas. Moreover, when over-expressing a NRP1 mutant
lacking the cytoplasmic domain in EC, phosphorylation of p130Cas was reduced, and the
EC migratory response towards VEGF-A165 was also decreased. The role of p130Cas was
further veried by knocking it down in HUVEC: p130Cas-depleted cells were less able
to migrate towards a VEGF-A165 gradient, indicating a role for p130Cas in chemotaxis.
These ndings demonstrate a critical role for NRP1 in mediating stimulation of p130Cas
Tyrosine phosphorylation in response to VEGF-A165, and further show that this novel
NRP1/p130Cas pathway is required for chemotactic migration induced by VEGF-A165
in endothelial cells. They also suggest that the NRP1 intracellular domain may itself
either transduce specic intracellular signals, or participate in protein-protein interactions,
resulting in the activation and/or recruitment of signalling eectors to the NRP1/VEGFR2
complex.
Previous ndings have shown that VEGF-A165 stimulates p130Cas Tyrosine phosphory-
lation in human brain microvascular EC (HBMEC) (Avraham et al., 2003) and in HAEC
(Endo et al., 2003), but the specic role for p130Cas in VEGF-dependent migration has
been little studied, and the mechanisms linking VEGF receptors to p130Cas signalling
are unclear. VEGF-A165 also activates Focal adhesion kinase (FAK) (Abedi and Zachary,
1997) and p130Cas SH3 domain associates with FAK (Polte and Hanks, 1995) and me-
diate FAK-promoted cell-migration (Cary et al., 1998). P130Cas also associates with the
FAK-related kinase Pyk2 (Ohba et al., 1998) and Pyk2 mediates endothelin-1 signalling
in endothelial cells via p130Cas (Kodama et al., 2003). VEGF is also known to activate
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together, previous work and the ndings presented in this chapter strongly indicate that
NRP1 mediates VEGF-A165 signalling leading to activation of either FAK and/or Pyk2
and subsequent Tyrosine phosphorylation of p130Cas. Studies by other workers in this
laboratory found no eect of NRP1 knockdown on FAK phosphorylation at its major au-
tophosphorylation site, Y397, but showed that NRP1 knockdown inhibits VEGF-induced
Pyk2 phopshorylation and that Pyk2 knockdown inhibits VEGF-induced p130Cas Ty-
rosine phosphorylation. These data suggest that NRP1 is a key mediator of p130Cas
signalling via Pyk2. However, given the complexity of FAK phosphorylation involving
multiple Tyrosine and Serine phosphorylation sites, the possibility is not precluded that
NRP1 mediates VEGF-A165-stimulated FAK phosphorylation at other sites.
Previous data from this group showed that selective inhibition of VEGF-A165 binding to
NRP1 using a peptide antagonist partially reduces VEGF-A165-induced VEGFR2 phos-
phorylation at Y1175 and partially inhibits VEGF-A165-induced ERK1/2 and Akt acti-
vation (Jia et al., 2006). Inhibition of VEGF-A165 binding to NRP1 using specic NRP1
blocking antibodies caused only a modest inhibition of VEGFR2 activity and other sig-
nalling events (Pan et al., 2007a). Together, previous data indicated that NRP1 made a
relatively small contribution to signalling via VEGFR2 despite its key role in angiogen-
esis in development. However, ndings presented here show that NRP1 plays a key role
in VEGF-A165 signalling via p130Cas, a molecule with an important role in cell migra-
tion, and indicate that NRP1-dependent p130Cas Tyrosine phosphorylation is an impor-
tant node in VEGF-A165-dependent chemotactic signalling. Whether NRP1-dependent
p130Cas signalling is important in vivo remains to be determined. However, it is of in-
terest that p130Cas knockout mice display aberrant cardiovascular development, similar
to the phenotype of NRP1-decient mice, and that p130Cas is predominantly expressed
in the heart and blood vessels at E11.5-E12.5, when the embryonic lethal cardiovascular
phenotype is manifested in p130Cas and NRP1 knockout mice (Honda et al., 1998).
The mechanism coupling NRP1 to VEGF-A165-induced Pyk2 activation and downstream
p130Cas phosphorylation is unclear, but seems to require the NRP1 cytosolic domain.
Initial results from co-workers in this lab show that synectin knockdown does not im-
pair VEGF-A165-stimulated p130Cas Tyrosine phosphorylation, raising the possibility that
other NRP1-associated proteins, yet to be identied, may link NRP1 physically to Pyk2.
2005.3.2 Role of NRP1 in PDGF signalling
The conclusion that NRP1 is important for PDGF-BB-induced migration of HCASMC is
supported by the eects of NRP1 siRNA and mutant over-expression: NRP1 knockdown
signicantly inhibited HCASMC migration induced either by PDGF-AA or by PDGF-BB.
Overexpression of the NRP1 lacking the cytoplasmic domain (NRP1 C) similarly inhib-
ited the chemotactic response to PDGF-AA and PDGF-BB. Since the NRP1 cytoplasmic
domain is known to mediate protein-protein interactions (Cai and Reed, 1999), the fact
that a NRP1 construct lacking this domain inhibited the migratory response to PDGF-
BB strongly suggests that NRP1 is required for optimal signalling important for migration
downstream of PDGFRs. Ad.NRP1 C expression had a more marked inhibitory eect
on PDGF-induced HCASMC migration than NRP1 siRNA, and also reduced the basal un-
stimulated level of migration, whereas NRP1 siRNA did not. These results are consistent
with the conclusion that the NRP1 C mutant exerts a dominant negative eect, possi-
bly via prevention of interactions between the NRP1 cytoplasmic domain and intracellular
binding partners important for transducing chemotactic signals, and/or sequestration in
inactive complexes of PDGF, PDGFR and possibly other cellular components important
for chemotactic signalling. One known NRP1-binding molecule is synectin, and this study
shows that synectin knockdown only tends to reduce PDGF-BB-induced cell migration
(Figure 4.16). I therefore hypothesise that other proteins may interact with the NRP1
cytoplasmic domain and contribute to PDGF-BB chemotactic signalling.
Though PDGF-BB has been reported to co-immunoprecipitate with NRP1 (Banerjee et al.,
2006), I did not nd compelling evidence that PDGF-BB could specically and with high
anity bind directly to NRP1 either in PAE/NRP1 cells or in a cell-free assay of ligand
binding to puried NRP1 b1 domain. These data indicate that PDGF-BB may not be able
to bind to the NRP1 extracellular domain with high anity, though one cannot preclude
the possibility that PDGF-BB binding is dependent on other co-factors or co-receptors.
The mechanism through which NRP1 regulates PDGF-BB-induced migration in HCASMC
may involve protein-protein associations between NRP1 and PDGFRs, similar to the for-
mation of complexes between NRP1 and VEGFR2/KDR, which is thought to be crucial
for the role of NRP1 in endothelial responses to VEGF. In support of this hypothesis, I
showed that NRP1 co-immunoprecipitates with PDGFR in HCASMC. However, there
was no similar complex formation between PDGFR and NRP1, indicating that NRP1
may associate preferentially with PDGFR. Since PDGFR is a ligand for PDGF-BB
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mechanism in which PDGF-BB and PDGF-AA act through PDGFR/NRP1 complexes
resulting in optimal chemotactic signalling. I further found that NRP1 siRNA-mediated
knockdown caused a marked inhibition of PDGFR activation in response to PDGF-AA,
and caused a signicant but more modest reduction in PDGF-BB-induced PDGFR ac-
tivation. In contrast, NRP1 knockdown had no detectable eect on PDGF-BB induction
of PDGFR activity. The molecular basis for the inhibitory eect of NRP1 knockdown
on PDGFR activity is unclear, but may suggest that the association we found between
NRP1 and PDGFR contributes to receptor activity. Such an eect would also provide
an underlying mechanism for the role of NRP1 in PDGF responses in VSMC mediated
through PDGFR. It is important to note that selective NRP1 inhibition in endothelial
cells, using either antibodies or antagonistic peptides that specically block VEGF bind-
ing to NRP1 (Jia et al., 2006; Pan et al., 2007a), causes only small or partial reductions
in VEGFR2 activity, indicating that NRP1 is not required for VEGFR2 activation in
endothelial cells.
Recently, we reported that over-expression of NRP1 in U87 glioma cells is able to regulate
tyrosine phosphorylation of p130Cas, an adapter protein, strongly implicated in signalling
pathways important for cell migration (Frankel et al., 2008). Here, I have shown that
PDGF-BB stimulates p130Cas tyrosine phosphorylation and that this response is partially
inhibited by both NRP1 knockdown and by expression of the NRP1 C mutant in vascular
smooth muscle cells. PDGF-AA also stimulated p130Cas tyrosine phosphorylation more
weakly and this eect was also reduced by NRP1 knockdown. As far as we are aware, these
ndings demonstrate for the rst time that the NRP1 cytosolic domain is required for a
specic signalling pathway leading to a functional cellular response. In contrast, NRP1
siRNA had little signicant eect on other PDGF-BB-stimulated signalling pathways, in-
cluding activation of ERK, Akt and FAK. P130Cas is an adapter protein, which is both a
substrate for FAK-directed phosphorylation and known to associate with FAK, and FAK is
thought to be one of the major distal pathways regulating the activity of p130Cas (Delippi
et al., 2006). Though we observed no detectable change in FAK phosphorylation status at
Tyr 397 with NRP1 knockdown, FAK is phosphorylated at multiple sites, and we cannot
preclude that NRP1 may also mediate PDGF-dependent FAK phosphorylation impor-
tant in turn for p130Cas phosphorylation. However, regardless of the precise mechanisms
leading to its phosphorylation in HCASMC, p130Cas is a good candidate for mediating
PDGF-BB dependent signalling pathways leading to actin cytoskeletal reorganisation and
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tial for the PDGF-BB migratory response, since p130Cas knockdown inhibited migration
in response to PDGF-BB. There are no previous reports showing PDGF-BB regulation
of p130Cas tyrosine phosphorylation in VSMC or other cell types; indeed, PDGF-BB
was shown to increase tyrosine phosphorylation of the Crk-associated substrate (CAS)
family member, HEF-1, but not p130Cas, in glioblastoma cells (Natarajan et al., 2006).
It remains unclear exactly how NRP1 is able to regulate p130Cas phosphorylation, and
investigation of the molecular mechanisms involved warrants further experimental work.
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Discussion
Neuropilins are co-receptors for Semaphorins that were initially discovered in the nervous
system and later identied as co-receptors for members of the VEGF family in the vascu-
lar system. In the nervous system, they play a role in axonal guidance during embryonic
development by mediating growth cone collapse of neurons when binding to their ligands.
In the vascular system, the analysis of NRP1 transgenic and decient mice established
an essential role for NRPs in vessel development (Gu et al., 2003; Kawasaki et al., 1999;
Kitsukawa et al., 1997; Lee et al., 2002). Moreover, expression of NRPs and functional
studies by cancer cells revealed their role in tumour growth and migration, and recent evi-
dence also implicates NRP1 in mediating the primary immune response. All these ndings
strongly suggest that NRPs are multi-functionnal co-receptors with essential roles in both
the nervous and cardiovascular systems as well as additional roles in other physiological
and disease-related settings (Pellet-Many et al., 2008).
At the beginning of this PhD study, I decided to investigate the expression of NRPs in
vascular cells and noticed a dierent expression pattern in HCAEC and HCASMC. Other
EC and VSMC, such as HAoSMC and HUVEC also showed similar dierences in NRP1
expression typied by expression of a single 130 KDa species in EC and the additional
expression of a form of >250 kDa in VSMC. This high molecular weight species was found
to correspond to a CS- and HS-GAG modied form expressed in VSMC and, in the case
of CS-GAG modied species, also in cancer cells.
My further studies led to the discovery of a role for NRPs in PDGF-stimulated migration
of SMC and provided evidence for the colocalisation of NRP1 with PDGFR, and the
occurence of a PDGFR/PDGF/NRP1 complex in SMC.
Finally, I went on to investigate the possible mechanism(s) underlying the role of NRP1 in
VSMC migration. This studies indicated that the phosphorylation of the non-enzymatic
docking protein, p130Cas, was reduced in cells depleted of NRP1. Moreover, by using
204a NRP1 mutant lacking the cytoplasmic domain, I also showed the importance of the
NRP1 cytoplasmic domain in the mediation of PDGF-induced signalling in SMC. Similar
ndings were obtained in EC and other colleagues in this laboratory further validated
this mechanism in cancer cells. Moreover, in SMC, the phosphorylation of PDGFR was
decreased in NRP1 depleted cells indicating the importance of NRP1 in the mediation of
PDGFR signalling in these cells.
6.1 Post-translationnal modications
In this thesis, I have shown that a substantial proportion of NRP1 in Human VSMC
undergoes post-translational modication by the addition of chondroitin sulphate (CS) and
heparan sulphate (HS) glycosaminoglycans (GAG). This modication does not occur for
the structurally-related molecule NRP2 or in the two Human endothelial cell types tested
(HUVEC and HCAEC). Moreover several cancer cell lines exhibited a similar pattern of
glycosylation but involving only CS-GAG (Frankel et al., 2008). While this research was
in progress, Shintani et al. (2006) reported modication of NRP1 by both HS- and CS-
GAGs in VSMC and EC. In contrast to their ndings, I could only detect the addition of
CS- and HS-GAG to the core protein in VSMC and did not identify such glysosylation in
endothelial cells. The GAG moiety is added to the Serine residue in position 612 which
is followed by a Glycine, SG motifs being the preferred sites of GAG attachment, in the
linker region between the b2 and MAM domains. This Serine residue is conserved amongst
mammals, but it is not present in the amino acid sequence of NRP2. Similar SG sites
exist in the amino acid sequence of NRP1 and are potential sites of attachment of GAG.
Nevertheless, a single point mutation to Serine 612 resulted in the complete disappearance
of the high molecular weight NRP1 species on Western blots. However, it was observed
that expression of a double NRP1 mutant at Serines 240 and 432 resulted in a decreased
expression of the GAG-modied NRP1 species compared to NRP1 WT. This observation
suggests that other sites of glycosylation may contribute to O-linked glycosylation, though
as the S612A mutation completely abolished the modication, this is clearly the primary
site of GAG addition.
It is unclear why O-linked glycosylations are dierent in dierent cell lines: either CS-
or HS-modied in HCASMC and HAoSMC, CS-modied in several cancer cell lines or
non-modied in HUVEC and HCAEC. It is possible that the expression of the enzymes
responsible for GAG addition and elongation are dierentially expressed in the dierent
205cell types. It seems unlikely, however, that EC lack the enzymatic machinery required
for GAG addition to core proteins. An alternative explanation for the lack of GAG-
modied NRP1 in EC is that NRP1 follows an itinerary through the Golgi apparatus which
through some undened mechanism, prevents its post-translational modication. It is also
plausible that EC possess mechanisms for rapid removal of GAGs, such that GAG-modied
NRP1 is expressed at an undetectable level. There might also be a possible interaction of
NRP1 with other co-receptors that make the NRP1 glycosylation site inaccessible for the
transferase to elongate the GAG chain; since EC express dierent co-receptors for NRP1
than VSMC, it might explain their dierence in glycosylation. This is one hypothesis
that I will look further into by expressing NRP1 with its co-receptors in PAE cells. Data
from Shintani et al. (2006) suggest that NRP1 expression and its GAG modication post-
transcriptionally regulate VEGFR2 protein expression, nevertheless, I would like to further
test if the presence of VEGFR2 inuences the expression of the NRP1 GAG modication.
It is also unclear why NRP2 does not undergo GAG-modication. However, one possibility
is that the tertiary structure of NRP2 might hide potential consensus sites and therefore
prevent recognition by the enzymes essential for GAG chain initiation or elongation.
The fact that the same serine residue can be modied by dierent GAG is also unusual.
Indeed, other GAG-modied proteins (for example, syndecan 1) contain distinct sites of
unambiguous attachment of specic GAG (Kokenyesi and Berneld, 1994). Clearly, the
selection of the nature of the GAG might not be dictated by the amino-acid sequence
of the core protein only but by some other factors such as the activity of the protein
synthases, and the nature of other co-receptors present at the cell surface, and/or the cell
extracellular matrix.
In addition, both NRP1 and NRP2 appear to be modied by asparagine (N)-linked glygo-
sylations as indicated by the eect of tunicamycin-mediated inhibition of N-glycosylation
on the apparent molecular weight of NRPs (Figure 3.6). This type of post-translational
modication is relatively common and occurs in many proteins. N-linked glycosylations
can profoundly aect protein folding, oligomerisation and stability (Mitra et al., 2006).
Neither the site(s) nor function of NRP1 N-glycosylations are known. In future work, site-
directed mutagenesis of predicted sites for N-glycosylation, corresponding to the tripeptide
sequences Asn-X-Ser, Asn-X-Thr or Asn-X-Cys, where X can be any amino acid except
Proline, may be performed to identify the site and function of this modication.
Specic VEGF-A165 binding was not altered by pre-treatment with lyases in endothelial
206cells but, interestingly, was increased in smooth muscle cells treated with chondroitinase.
Since GAG modication of NRP1 occurred in SMC but not in EC, and that other re-
ceptors for VEGF were not signicantly expressed in VSMC, these ndings suggest that
the addition of the CS chain to NRP1 in SMC inhibits VEGF-A165 binding, maybe by
blocking accessibility of the growth factor to its specic binding site.
Though VEGF-A165 was able to bind specically to SMC, no migratory response towards
a VEGF-A165 gradient was observed, and this was not altered by chondroitinase pre-
treatment. The lack of responsivness to VEGF in HCASMC may be due to the low
expression of VEGFR2/KDR, the major VEGF-A165 signalling receptor. In order to
study the role of NRP1 in migration of HCASMC, I investigated its contribution to the
eects of PDGF-BB, known to be a strong chemoattractant for SMC. Chondroitinase
resulted in a decreased migratory response of HCASMC towards PDGF-BB, suggesting
that CS-GAG NRP1 is important for PDGF-BB chemoattraction.
However, treatment of cells with chondroitinase and heparitinase (heparinase III) to re-
move GAGs does not adress the role of protein-specic GAG modication, since many
proteins are modied in this way, and removal of GAGs from dierent proteins may have
diverse and sometimes confounding eects on cell function. In general, binding of growth
factors to a proteoglycan (PG) could play a role in four dierent functions: (1) deter-
mining the concentration of the growth factor near the cell membrane and its interaction
with other cell surface receptors; (2) participation of the PG in a co-receptor complex
with dierent abilities to recognise ligands or transduce signalling relative to the more
simple growth factor/receptor complex; (3) inhibition of growth factor diusion to cre-
ate a more localised signal; and (4) formation of a pool of growth factor that can be
released by proteolysis of the GAG moiety or the growth factor (Iozzo, 2005). However,
dening GAG function in the VEGF-A165/VEGFR2/NRP1 complex is highly problematic
since each component is itself able to bind heparin and HS, and because NRP1 can be
GAG-modied (Shintani et al., 2006).
To probe the function of NRP1 GAG modication, I generated a mutant S612A NRP1
adenovirus construct for high eciency transduction of VSMC and EC in vitro and in vivo.
In U87MG human glioma cells, transient expression of this non-modiable NRP1 mutant
(S612A) resulted in enhanced invasion in three dimensions, whereas wild-type NRP1 had
no eect (Frankel et al., 2008). In contrast, in HCASMC, the over-expression of the S612A
NRP1 construct did not result in any signicant change in the cell migratory response.
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for PDGFR-mediated intracellular signalling and migration. Shintani et al. (2006) found
that cells infected with the NRP1 S612A adenovirus displayed an increased migration in
response to VEGF-A165. However, in the light of the absence of migration of HCASMC
in response to VEGF-A165 in my hands, I believe these results of Shintani et al. (2006)
should be considered with caution.
It is known that NRP1 can form an active complex with VEGFR2 on adjacent cells
(Cbe-Suarez et al., 2008). Moreover, an interesting study by Jakobsson et al. (2006)
showed that VEGF signalling in endothelial cells is supported by HS expressed in trans by
adjacent perivascular smooth muscle cells. Transactivation of VEGFR2 led to prolonged
and enhanced signal transduction due to HS-dependent trapping of the active VEGFR2
signalling complex (Figure 6.1). I suspect that an analogous model of transactivation of
VEGFR2 (in EC) by O-linked GAG NRP1, might be relevant to interactions between
VSMC and EC and appropriate to explain the relatively small eect of the NRP1 S612A
mutant in SMC. Thus, while the modication could have an eect in trans to activate
VEGFR2 on adjacent EC, it may not aect signalling in VSMC. This is a possibility that
warrant further investigation.
6.2 NRP1 functions in vascular cells
6.2.1 Role of NRP in endothelial cells
The results obtained in EC conrmed previous studies conducted by this and other groups,
showing that both NRP1 and NRP2 play an essential role in EC proliferation, migration
(Sulpice et al., 2008; Favier et al., 2006) and adhesion (Murga et al., 2005). However,
the function of NRPs in HCAEC had not been previously reported, and I conrmed
by knockdown experiments using siRNA transfection, that NRPs were also important
for migration of HCAEC towards VEGF-A165. The anti-angiogenic eect caused by the
inhibition of NRPs was also shown by other groups using blocking antibody (Pan et al.,
2007a; Sulpice et al., 2008), peptide antagonists (Jia et al., 2001) or with the use of the
other NRP ligands Sema3A and Sema3F that compete with VEGF-A165 for binding to
NRP1 (Miao et al., 1999) and NRP2 (Favier et al., 2006), respectively.
Evidence from Cai and Reed (1999) and Wang et al. (2006) attributed to the NRP1 cyto-
plasmic domain a role in angiogenesis through interaction with synectin. Indeed, in this
208Figure 6.1: Proposed model for a role for NRP1 SMC GAG modication in the
transactivation of VEGFR2
This schema represents the model proposed by Jakobsson et al. (2006) to explain the
transactivation of VEGFR2 by HSPG in trans, adapted to the hypothesis that NRP1
GAG modication might similarly play a role in the VEGFR2/NRP1 complex formation
between adjacent cells. Figure adapted from Jakobsson et al. (2006).
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domain, exerted a dominant negative eect, resulting in decreased endothelial cell migra-
tion. The expression of the C NRP1 receptor probably prevents interactions between
the NRP1 cytoplasmic domain and intracellular binding proteins, and also could result in
the sequestration of inactive complexes of VEGF, VEGFR and other cellular components
important for chemotactic signalling, which are then unable to link with other signalling
molecules via the NRP1 cytosolic domain. More work is required to dene the role of this
domain in EC migration and its intracellular partners.
6.2.2 Role of NRP in vascular smooth muscle cells
At the beginning of this work, NRP1 had not been characterised in VSMC. When I
discovered the high expression of NRP1 in these cells, several questions were raised: What
is the specic ligand for NRPs for this cell type? If NRP1 acts as a co-receptor, what is
the nature of its partners in VSMC? What is the function of NRP in VSMC?
Although some reports in the literature had shown eects of VEGF-A165 on VSMC via
the expression of VEGFRs (Liu et al., 2005; Shintani et al., 2006; Grosskreutz et al., 1999;
Ishida et al., 2001), I could not detect signicant eects of VEGF-A165 on migration or
signalling in HCASMC and decided instead to investigate the role of NRP in PDGF-
induced VSMC migration. PDGF-BB was shown to bind specically to the surface of
HCASMC but did not display convincing specic binding in PAEC or PAE cells stably
expressing NRP1 WT. Therefore, PDGF-BB might not be able to bind directly to NRP1
but they both might be part of a receptor/ligand complex. Moreover, results from cell-free
assay for VEGF binding to NRP1 suggests that VEGF and PDGF-BB did not compete
for the same binding site on NRP1.
PDGF is a dimeric molecule consisting of structurally similar A- and B-polypeptide chains,
exerting their cellular eects by binding to and activating the two related protein tyrosine
kinase receptors, PDGFR and PDGFR (Heldin and Westermark, 1999). The specicity
of interaction between the two ligands and their receptors, as well as the fact that the
receptors also exists as heterodimers, complicates the interpretation of studies of PDGF.
Nevertheless, NRP1 and NRP2 knockdown resulted in a signicant decrease of PDGF-AA
and PDGF-BB-stimulated SMC migration, suggesting an essential role for NRP in the
migratory response of HCASMC. A reduction in migration was also observed following
synectin knockdown but was not statisically signicant. Synectin is, to date, the only
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migration seen with synectin knockdown suggests some role for this intracellular molecule
in HCASMC migration but cannot account for the complete eect observed with the NRP1
knockdown. Thus, there may be either other, as yet unknown, molecules which interact
with the NRP1 cytoplasmic domain or, alternatively, NRP1 interacts with other receptors
whose intracellular signalling is altered in the absence of NRP1.
Pre-incubation of SMC with the specic bicyclic peptide antagonist EG3287, also reduced
the migratory response of the cells towards a PDGF-BB gradient. Moreover, another
specic antagonist which is an EG3287 derivative, EG00086, had a similar and dose-
dependent eect. Interestingly, those eects were only observed when cells were stimulated
with PDGF-BB, and the antagonists did not aect PDGF-AA-stimulated migration. If,
as my binding data suggest, PDGF does not bind to NRP1 itself, it is possible that the
binding of the antagonist alters the conformation of NRP1 which, in turn might impair its
ability to form an active complex with PDGF receptors or other signalling components,
hence causing a reduced intracellular response. Since eects of antagonists were observed
specically in response to PDGF-BB, presumably the antagonists selectively impact upon
signalling via PDGFR and for signalling of PDGF-BB mediated via  and/or  receptors.
To summarise, these experiments show that inhibition of NRP1 function using two inde-
pendent approaches - siRNA and peptide antagonists - had similar inhibitory eects on
PDGF-BB-induced HCASMC migration. My results strongly suggest that NRP1 plays
an important role in the chemotactic response to PDGF-BB.
NRP1 is expressed naturally in soluble isoforms comprising the a1/2 and b1/2 domains of
the extracellular region (sNRP1). These soluble forms can act by binding and sequestering
ligands such as VEGF and thereby inhibit VEGF-dependent biological processes such as
tumour growth and angiogenesis (Gagnon et al., 2000). Though we were unable to detect
a stimulatory eect of VEGF in HCASMC, I postulated that NRP1 could mediate PDGF-
BB induced cell migration by interacting with an extracellular ligand, either PDGF-BB
itself or another as yet unidentied ligand. This possibility predicts that sNRP1 might
inhibit responses mediated via membrane-associated cell surface NRP1 by competing with
endogenous or exogenous ligands. Incubation of HCASMC with sNRP1 signicantly inhib-
ited migration in response to PDGF-BB with a similar degree of inhibition as was obtained
using EG3287 or NRP1 siRNA. As the NRP1 ligand binding domain for VEGF resides
primarily in the b1 NRP1 domain, I therefore also examined the eect of recombinant b1
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HCASMC to PDGF-BB with a similar degree of inhibition as sNRP1. Thus, the presence
of sNRP1 or sb1 might result in the formation of complexes with PDGF receptors at the
surface of the cell which lack intracellular signalling downstream of NRP1, which, in turn,
result in the decrease in SMC migration in response to PDGF-BB.
In endothelial cells, the NRP1 cytoplasmic domain is able to mediate protein-protein in-
teractions and more precisely the C-terminal three amino acids of NRP1 (SEA-COOH) are
required for NRP1-mediated angiogenesis in zebrash (Wang et al., 2006). Moreover, the
overexpression of NRP1 adenovirus construct lacking the cytoplasmic domain (Ad.NRP1
C) inhibited the chemotactic response of EC in response to VEGF-A165. Similarly, in
HCASMC, the NRP1 C construct overexpression resulted in a reduction of cell migra-
tion in response to PDGF-AA and PDGF-BB, which suggests that NRP1 is required for
optimal signalling important for migration downstream of PDGF receptors. NRP1 C ex-
erts a dominant negative eect, possibly by preventing the interactions between the NRP1
cytoplasmic domain and intracellular binding molecules important for transducing chemo-
tactic signals, and/or sequestration in inactive complexes of PDGFR and possibly other
cellular components important for chemotactic signalling. I hypothesise that synectin and
possibly other proteins may interact with the NRP1 cytoplasmic domain and contribute
to PDGF-induced chemotactic signalling.
All the approaches used to inhibit NRP1, block binding of ligands to NRP1, and stop
intracellular signalling downstream of NRP1 cytoplasmic domain, reduced PDGF-BB-
induced migration and, except in the case of peptide antagonists, also reduced PDGF-AA
induced migration. These results strongly suggest a novel role for NRP1 in the mediation
of PDGF-induced migration of VSMC.
6.3 NRP1 signalling in vascular cells
Though NRP1 has been extensively studied for the last 10 years in dierent settings such
as in the nervous, cardiovascular, and immune systems and also in cancer, very little is
understood about the role of NRP1 in cell signalling and only one molecule, synectin, has
been identied as a potential downstream eector of NRP1. Generally, NRP1 has been
regarded as a passive binding entity in the complex formed with VEGFR2 and plexins,
which are acting as the signalling moieties. This may well be true in the case of the
212complex NRP forms with plexins, as deletion of the cytoplasmic domain of NRP1 does
not impair Sema3a signalling (Nakamura et al., 1998).
Although inhibition of NRP1 did not impair the activation of several signalling molecules
in VSMC and EC, it did result in the decrease of Tyrosine phosphorylation of the non-
enzymatic adapter protein, p130Cas. p130Cas (Crk-associated substrate), is a major Src
substrate localised at sites of cell adhesion to the extracellular matrix (ECM). It is a
non-enzymatic docking protein consisting of multiple protein-protein interaction domains
including an N-terminal SH3 domain, a substrate domain, a Src-binding domain near the
C terminus and a highly conserved C-terminal region. The substrate domain contains the
major sites of p130Cas tyrosine phosphorylation which create docking sites for recruitment
of SH2-containing signalling eectors (Sakai et al., 1994a,b). Notably, recruitment of Crk
adapter proteins to the substrate domain sites has been implicated in the promotion of
Rac activation and cell motility (Sharma and Mayer, 2008). Moreover, the overexpres-
sion of the NRP1 C in EC, similarly reduced p130Cas activation, concomitant with a
decrease migratory response towards VEGF-A165. A role of p130Cas in cell motility was
conrmed by siRNA mediated knockdown in HUVEC as p130Cas depleted cells migrate
less eciently towards VEGF-A165.
All these observations point towards a critical role for p130Cas in VEGF-A165 stimulated
signalling and migration downstream of NRP1. Moreover, the NRP1 cytoplasmic do-
main seems to be required for transducing intracellular chemotactic signalling induced by
VEGF-A165 in endothelial cells (Figure 6.2). By using the yeast two hybrid system, col-
leagues in this laboratory found a novel Neuropilin 1-associated protein capable of binding
to the cytoplasmic domain of NRP1. The role of this NRP1-associated protein, upstream
of p130Cas is currently being investigated. Interestingly, synectin knockdown does not
appear to impair VEGF-induced p130Cas phosphorylation (Evans et al., MS submitted).
Similar to the ndings in endothelial cells, NRP1 plays a role in PDGF-AA and PDGF-BB-
induced migration of HCASMC. NRP1 siRNA-mediated knockdown and NRP1 C over-
expression both inhibited HCASMC migration induced either by PDGF-AA or by PDGF-
BB, suggesting that NRP1 and its cytoplasmic domain are important for chemotactic
signalling downstream of PDGFRs. Interestingly, the over-expression of the NRP1 C
mutant inhibited PDGF-induced HCASMC migration to a greater extent than the siRNA
knockdown, as well as reducing the basal level of migration. These observations suggest
that the NRP1 cytoplasmic domain is important for the interaction with intracellular
213Figure 6.2: NRP1 signals through its cytoplasmic domain to activate a NRP1-
associated protein and downstream p130Cas to stimulate migration
This schema represents the possible pathway by which VEGF-A165 or PDGF-BB and
HGF (this thesis and data observed by colleagues for the later) activate downstream
chemotactic signalling molecules leading to the activation of a NRP1-associated protein,
p130Cas Tyrosine phosphorylation and cell motility.
molecules important for migration. Moreover the NRP1 mutant might act by sequestrating
PDGFRs in inactive complexes, disrupting signalling with several intracellular molecules,
one of them being synectin. Since synectin knockdown reduced, but not to a signicant
level, the level of HCASMC migration, other NRP1 intracellular domain binding partners
must contribute to PDGF-induced migration.
As observed in endothelial cells (this thesis) and in cancer cells (Frankel et al., 2008),
p130Cas Tyrosine phosphorylation is stimulated via NRP1 in VSMC. In this study, I have
shown that both PDGF-AA and PDGF-BB are able to stimulate p130Cas activation and
that this response is partially inhibited by NRP1 knockdown and by the expression of
the NRP1 C mutant in HCASMC. In contrast, other intracellular signalling molecules
involved in survival and proliferation such as FAK, Akt, or ERK were not signicantly
aected by the lack of NRP1 at the cell surface. It is surprising that FAK activity was
not altered as p130Cas is known to both associate with FAK and to be a substrate for
FAK-directed phosphorylation (Delippi et al., 2006). Nevertheless, as I probed only one
major site of phosphorylation, I cannot exclude the possibility that NRP1 activates other
FAK phosphorylation sites that might be more important for the mediation of p130Cas
activation. Little work has been done on the role of p130Cas in PDGF-dependent sig-
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factor-dependent recruitment of adaptors and eectors that activate downstream path-
ways, resulting in cell survival and increased cell motility (Delippi et al., 2006). In
support of a role for p130Cas in VSMC migration, I further demonstrated that p130Cas
is essential for the PDGF-AA and PDGF-BB migratory response using siRNA-mediated
knockdown. The identity of the kinase directly responsible for PDGF-stimulated p130Cas
Tyrosine phosphorylation in VSMC and EC is unknown, though as discussed above, FAK
is an obvious candidate. Another candidate is the FAK related kinase, Pyk2. Recent nd-
ings from this laboratory show that NRP1 is required for VEGF-induced Pyk2 activation
in HUVECs and that Pyk2 mediates VEGF-stimulated p130Cas Tyrosine phosphorylation
(Evans et al., MS submitted). Moreover, Pyk2 can associate with p130Cas (Kuwabara
et al., 2004). In future work, I would examine the role of Pyk2 in PDGF-induced p130Cas
phosphorylation in VSMC.
I hypothesised that, similar to EC where NRP1 modulates VEGF signalling through its
association with VEGFR2/KDR, NRP1 might form a complex with PDGFRs in order
to modulate PDGF signalling. Although one study by Banerjee et al. (2006) reported
the physical interaction between NRP1 and PDGF-BB, I could not reproduce these nd-
ings. However, I showed that NRP1 co-immunoprecipitates with PDGFR in HCASMC.
My results indicated that PDGF treatment did not signicantly alter the extent of co-
immunoprecipitation of PDGFR and NRP1. This appears to dier from the situa-
tion in endothelial cells in which VEGF stimulates VEGFR2 complex formation with
NRP1. However, it is important to note that studies of VEGFR2/NRP1 complexation
have produced conicting results. Thus, some groups have concluded that VEGF is re-
quired to promote NRP1 association with VEGFR2 (Pan et al., 2007a; Soker et al., 2002),
whereas others have reported that NRP1/VEGFR2 association occurs constitutively and
is largely independent of ligand stimulation (Shraga-Heled et al., 2007; Whitaker et al.,
2001). Therefore, it remains controversial whether VEGFR2/NRP1 complex formation
is constitutive or ligand-dependent, or a combination of the two. Further work is re-
quired to establish whether the association between PDGFR and NRP1 in VSMC is
regulated by PDGFs, and the role this association plays in VSMC function. However,
there was apparently no similar complex formation between PDGFR and NRP1, indi-
cating that NRP1 may associate preferentially with PDGFR. Since PDGFR is able
to bind both PDGF-AA and PDGF-BB homodimers as well as AB heterodimers, the
interaction between NRP1 and PDGFR suggests a possible mechanism in which both
215growth factors act through PDGFR/NRP1 complexes resulting in optimal chemotactic
signalling. Interestingly, PDGFR activation in response to PDGF-AA and PDGF-BB
was reduced in HCASMC depleted of NRP1 via siRNA-mediated knockdown. In con-
trast, NRP1 knockdown had no detectable eect on PDGF-BB induction of PDGFR
activity, possibly reecting on the absence of interaction of NRP1 with the  receptor. It
was also noteworthy that the inhibitory eect of NRP1 knockdown on PDGF-BB-induced
PDGFR activation was modest. These results suggest that the activation of PDGFR
by PDGF-AA and PDGF-BB is dierentially dependent upon NRP1. This might reect
the ability of PDGF-BB to bind and activate PDGFR heterodimers, which might be
less susceptible to inhibitory eect of NRP1 siRNA, whereas PDGF-AA activate only
PDGFR heterodimers. However, due to assay limitations, it is unclear whether the
assay of PDGFR can detect phosphorylation in heterodimers. Interestingly, a study
by Rolny et al. (2002) showed that PDGF-BB can specically aect phosphorylation of
PDGFR and dowstream signalling without aecting PDGFR activation. These inves-
tigators used exogenous heparin to potentiate PDGF-BB-induced PDGFR phosphoryla-
tion without altering the phosphorylation state of PDGFR in heparan sulphate decient
Chinese hamster ovary (CHO) 677 cells. Moreover, the potentiation of PDGFR sig-
nalling by heparin was not induced by PDGF-AA. These ndings suggest that PDGF-AA
and PDGF-BB can dierentially aect activity of the same receptor. Such a dierential
mode of action of PDGFs on PDGFR could be applied to explain the greater inhibitory
eect of NRP1 knockdown on PDGF-AA-induced, as compared to PDGF-BB-induced,
PDGFR activity.
In future work I would like to investigate in much greater detail the role of NRP1 in
PDGFR activation. These studies would include examination of NRP1 association with
PDGFRs using FRET analysis, and investigation of PDGFR activation in heterologous
cells expressing dierent combination of NRP1, PDGFR and PDGFR, in order to clarify
NRP1-dependent regulation of , and  receptors dimers. I will also investigate the
role of the NRP1 GAG-modication in complex formation between NRP1 and PDGFR
using adenoviral over-expression of the S612A construct in HCASMC.
Given the importance of PDGF and VSMC migration for neointima formation, those
ndings suggest a potential role of NRP1 in abberant VSMC migration in cardiovascular
proliferative disorders, including restenosis, graft failure and atherosclerosis. One of my
principal future aim would be to characterise the expression of NRP1 in arteries in vivo,
216particularly in the rat carotid balloon injury model and to analyse the role of NRP1 in
the migration of the VSMC into the neointima. Decreasing the expression of NRP1 in
these cells via adenoviral delivery, could potentially result in the decrease of the neointimal
lesion in the lumen following the injury. Also I will try to characterise the importance of
NRP1 and its GAG post-translationnal modication in the interaction between endothelial
cells and smooth muscle by generating spheroids which consist of a sphere formed by a
single layer of EC covered by a layer of SMC (Kor et al., 2001). I would expect a
disruption between the two layers when cells are depleted of NRP1 and/or lacking the
GAG-modication, since NRP1 is important for cell adhesion and the GAG-modication
might play a role in the trans interaction of receptors between the two cell types. It will
also be of interest to examine the role of NRP1 in VSMC by generating VSMC-specic
NRP1-decient mice, possibly by crossing oxed NRP1 mice with mice expressing Cre
under the control of a VSMC dominant promoter, such as the smooth muscle cell-specic
myosin heavy chain. Future studies might also examine the role of NRP1 in atherosclerotic
plaque formation by generating mice doubly decient in NRP1 in VSMC (if these mice
were viable) and ApoE mice.
In conclusion, the investigation of NRP1 in vascular cells led me to the discovery of a
dierent expression pattern in VSMC an EC, with the expression of a single 130 kDa
species in EC and the additional expression of a form of >250 kDa in VSMC. This novel
high molecular weight species observed in VSMC corresponds to a CS- and HS-GAG
modied species. I discovered a role for NRPs in PDGF-stimulated migration of SMC and
shown the colocalisation of NRP1 with PDGFR. I also shown that NRP1 could regulate
PDGFR in VSMC, further reinforcing the role of NRP1 in PDGF-mediated signalling
in these cells, probably via the formation of a NRP1/PDGF/PDGVFR receptor complex.
Finally, investigations of the possible mechanisms responsible for NRP1 role in VSMC
led to the discovery of the role of the docking protein, p130Cas, in mediating NRP1
cytoplasmic domain downstream signalling in EC and VSMC.
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248Appendix A
Figure A.1: NRP1 amino acid sequence from the Protein FASTA database
(NCBI)
249>gi|66912183|ref|NM_003873.3| Homo sapiens neuropilin 1 (NRP1), 
transcript variant 1, mRNA
ATGGAGAGGGGGCTGCCGCTCCTCTGCGCCGTGCTCGCCCTCGTCCTCGCCCCGGCCGGCGCTTTTCGCAAC
GATAAATGTGGCGATACTATAAAAATTGAAAGCCCCGGGTACCTTACATCTCCTGGTTATCCTCATTCTTAT
CACCCAAGTGAAAAATGCGAATGGCTGATTCAGGCTCCGGACCCATACCAGAGAATTATGATCAACTTCAAC
CCTCACTTCGATTTGGAGGACAGAGACTGCAAGTATGACTACGTGGAAGTCTTCGATGGAGAAAATGAAAAT
GGACATTTTAGGGGAAAGTTCTGTGGAAAGATAGCCCCTCCTCCTGTTGTGTCTTCAGGGCCATTTCTTTTT
ATCAAATTTGTCTCTGACTACGAAACACATGGTGCAGGATTTTCCATACGTTATGAAGTTTTCAAGAGAGGT
CCTGAATGTTCCCAGAACTACACAACACCTAGTGGAGTGATAAAGTCCCCCGGATTCCCTGAAAAATATCCC
AACAGCCTTGAATGCACTTATATTGTCTTTGCGCCAAAGATGTCAGAGATTATCCTGGAATTTGAAAGCTTT
GACCTGGAGCCTGACTCAAATCCTCCAGGGGGGATGTTCTGTCGCTACGACCGGCTAGAAATCTGGGATGGA
TTCCCTGATGTTGGCCCTCACATTGGGCGTTACTGTGGACAGAAAACACCAGGTCGAATCCGATCCTCATCG
GGCATTCTCTCCATGGTTTTTTACACCGACAGCGCGATAGCAAAAGAAGGTTTCTCAGCAAACTACAGTGTC
TTGCAGAGCAGTGTCTCAGAAGATTTCAAATGTATGGAAGCTCTGGGCATGGAATCAGGAGAAATTCATTCT
GACCAGATCACAGCTTCTTCCCAGTATAGCACCAACTGGTCTGCAGAGCGCTCCCGCCTGAACTACCCTGAG
AATGGGTGGACTCCCGGAGAGGATTCCTACCGAGAGTGGATACAGGTAGACTTGGGCCTTCTGCGCTTTGTC
ACGGCTGTCGGGACACAGGGCGCCATTTCAAAAGAAACCAAGAAGAAATATTATGTCAAGACTTACAAGATC
GACGTTAGCTCCAACGGGGAAGACTGGATCACCATAAAAGAAGGAAACAAACCTGTTCTCTTTCAGGGAAAC
ACCAACCCCACAGATGTTGTGGTTGCAGTATTCCCCAAACCACTGATAACTCGATTTGTCCGAATCAAGCCT
GCAACTTGGGAAACTGGCATATCTATGAGATTTGAAGTATACGGTTGCAAGATAACAGATTATCCTCGCTCT
GGAATGTTGGGTATGGTGTCTGGACTTATTTCTGACTCCCAGATCACATCATCCAACCAAGGGGACAGAAAC
TGGATGCCTGAAAACATCCGCCTGGTAACCAGTCGCTCTGGCTGGGCACTTCCACCCGCACCTCATTCCTAC
ATCAATGAGTGGCTCCAAATAGACCTGGGGGAGGAGAAGATCGTGAGGGGCATCATCATTCAGGGTGGGAAG
CACCGAGAGAACAAGGTGTTCATGAGGAAGTTCAAGATCGGGTACAGCAACAACGGCTCGGACTGGAAGATG
ATCATGGATGACAGCAAACGCAAGGCGAAGTCTTTTGAGGGCAACAACAACTATGATACACCTGAGCTGCGG
ACTTTTCCAGCTCTCTCCACGCGATTCATCAGGATCTACCCCGAGAGAGCCACTCATGGCGGACTGGGGCTC
AGAATGGAGCTGCTGGGCTGTGAAGTGGAAGCCCCTACAGCTGGACCGACCACTCCCAACGGGAACTTGGTG
GATGAATGTGATGACGACCAGGCCAACTGCCACAGTGGAACAGGTGATGACTTCCAGCTCGCAGGTGGCACC
ACTGTGCTGGCCACAGAAAAGCCCACGGTCATAGACAGCACCATACAATCAGAGTTTCCAACATATGGTTTT
AACTGTGAATTTGGCTGGGGCTCTCACAAGACCTTCTGCCACTGGGAACATGACAATCACGTGCAGCTCAAG
TGGAGTGTGTTGACCAGCAAGACGGGACCCATTCAGGATCACACAGGAGATGGCAACTTCATCTATTCCCAA
GCTGACGAAAATCAGAAGGGCAAAGTGGCTCGCCTGGTGAGCCCTGTGGTTTATTCCCAGAACTCTGCCCAC
TGCATGACCTTCTGGTATCACATGTCTGGGTCCCACGTCGGCACACTCAGGGTCAAACTGCGCTACCAGAAG
CCAGAGGAGTACGATCAGCTGGTCTGGATGGCCATTGGACACCAAGGTGACCACTGGAAGGAAGGGCGTGTC
TTGCTCCACAAGTCTCTGAAACTTTATCAGGTGATTTTCGAGGGCGAAATCGGAAAAGGAAACCTTGGTGGG
ATTGCTGTGGATGACATTAGTATTAATAACCACATTTCACAAGAAGATTGTGCAAAACCAGCAGACCTGGAT
AAAAAGAACCCAGAAATTAAAATTGATGAAACAGGGAGCGCGCCAGGATACGAAGGTGAAGGAGAAGGTGAC
AAGAACATCTCCAGGAAGCCAGGCAATGTGTTGAAGACCTTAGACCCCATCCTCATCACCATCATAGCCATG
AGTGCCCTGGGGGTCCTCCTGGGGGCTGTCTGTGGGGTCGTGCTGTACTGTGCCTGTTGGCATAATGGGATG
TCAGAAAGAAACTTGTCTGCCCTGGAGAACTATAACTTTGAACTTGTGGATGGTGTGAAGTTGAAAAAAGAC
AAACTGAATACACAGAGTACTTATTCGGAGGCATGA
Figure A.2: NRP1 mRNA sequence from the Gene database (NCBI)
250Figure A.3: NRP1 protein expression in tumour cells
The high molecular weight NRP1 species is expressed in several human tumour cell lines:
ACHN (renal carcinoma cell line), Skov-3 (ovarian carcinoma cell line), MDA-MB-231
(breast adenocarcinoma cell line), U78 MG (glioblastoma cell line), A549 (pulmonary
carcinoma cell), from Frankel et al. (2008).
Figure A.4: NRP1 protein expression in SMC in neointimal hyperplasia
3D reconstruction of the rat carotid artery 14 days after balloon injury using the volocity
software (document kindly provided by Dr. Manfred Junemann-Ramirez). The smooth
muscle cell of the neointimal hyperplasia (with blue nuclei stained with DAPI), on top
of the internal elastic lamina (on the green channel), strongly express NRP1 (on the red
channel).
251Figure A.5: NRP1 mRNA expression in SMC in neointimal hyperplasia
NRP1 is upregulated by the rat carotid artery smooth muscle cells after ballon injury,
with a peak at 14 days after the surgery (data obtained from Dr. David Sanz-Rosa).
Figure A.6: Cell free competitive binding assay for VEGF to NRP1
Increasing concentrations of PDGF-BB were left to compete for 2 hours with biotinylated
VEGF (btVEGF), there was no dose-response observed with the increasing amount of
VEGF suggesting that they do not compete for the same binding site on NRP1 (data
obtained from Dr. Malini Menon).
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